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SUMMARY
A brief review of narcotic analgesics, with particular 
attention to the 4-arylpiperidine class, is presented in Chapter 1.
Isomeric reversed esters of pethidine bearing 3-methyl substituents, 
together with the 4-alkyl-4-arylpiperidines, have been discussed 
from both a stereochemical and structure-activity point of view, 
and aspects of this are presented.
A brief general introduction to phencyclidine (PCP) is also presented, 
with particular reference to new analgesics derived from phencyclidine 
by introduction of a phenyl and hydroxyl moiety at position 4 of the 
piperidine ring of this agent.
In Chapter 2, the synthesis and characterisation of a novel 
series of potential analgesics based on 3-methyl substitution in 
the piperidine ring of this series of PCP analgesics is reported. This 
study was encouraged by the observation that such methyl substitution 
in the pethidine reversed ester significantly enhanced analgesic 
potency. The a-isomer of 4-hydroxy-3-methyl-4-phenyl-l-(1-phenyl- 
cyclohexyl)piperidine had a particularly interesting pharmacological 
profile, and therefore resolution of this compound was undertaken.
The details of this resolution are reported.
The synthesis and characterisation of a series of 4-alkyl-4-
arylpiperidines and their 3-methyl analogues is also described in
1 13
Chapter 2. Extensive use of high field H and C NMR has been made 
in the conformational and, in appropriate cases, configurational 
analysis of the prepared compounds, and the data secured are 
discussed in detail.
Finally, those pharmacological results available at the time of 
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Pain is a universal syndrome with which everyone has had 
some personal experience. The earliest use of drugs for the relief 
of pain cannot be easily identified; nevertheless, opium is thought 
to have been used as a drug since ancient Greek times.
Alcohols, plants and their extracts were known in antiquity. 
However, it is probably the case that opium represented the best 
first line of therapy in this regard.
The Sumerians were believed to have used crude opium as 
early as 4,000 BC for its ability to relieve pain and produce a 
state of euphoria. However, despite the long history behind opium, 
it was not until 1803 that a German pharmacist isolated an alkaloid 
from opium which he called morphine (1). By the middle of the 19th 
century the use of pure morphine, rather than the crude opium 
preparations, had spread widely. Unfortunately, analgesia is not 
the sole pharmacological effect of morphine. Other undesired side 
effects, such as gastrointestinal disturbances, nausea, vomitting, 
and respiratory depression, are produced by affecting many of the 
vital centres in the brain. The most undesirable side effect of 
morphine is the development of rapid tolerance with repeated use, 
so that the user becomes addicted to the drug. The widespread use 
of morphine has resulted in a dramatic increase in addiction, so 
that it now presents itself as a significant social problem. This 
prompted the search for non-addictive synthetic opiates lacking the 
undesirable side effects of morphine, while maintaining the pain 
relieving property of the drug.
2.
1.2 MORPHINE AND ITS DERIVATIVES
In 1952, Gates and Tschudi1 confirmed the morphine structure
as (1), and this was consistent with that originally suggested by
2
Gulland and Robinson in 1923. The addiction liability, and 
numerous undesirable side effects of morphine, have led to much 
modification of this molecule in an effort to produce the ideal 
centrally-acting analgesic.
i « / N
Me
(i)
Early modification of morphine, in an attempt to produce 
analgesics superior to morphine, involved derivatisation of the 3- 
and 6-hydroxy groups. Diacetylmorphine (Heroin; 2) is one of the 
earlier known examples, and this substance has a greater analgesic 
activity than morphine, and intense dependence liability. On the 
other hand, etherification of the phenolic hydroxyl group decreased 
the analgesic potency, as illustrated by codeine (3) and peronine 
(4).
(2) R  =  R’s  COCH,
(3)R=M«; R = H
Other modifications involved chemical transformations within 
ring C of morphine which generated several drugs having 
morphine-like activities. However, these derivatives offer no real 
advantage over morphine because of their severe addictive 
liability. One example is dihydromorphinone (5).
H C
(5)
Substitution of morphine N-Me by certain other groups has
led to the production of several compounds which antagonise a wide
spectrum of morphine activities, with little or no analgesic
3
potency in laboratory animals. Thus, N-substituents such as allyl,
dimethylallyl and cyclopropylmethyl (CPM) generally impart
antagonist action in morphine and related substances. The N-allyl
compound (Nalorphine, 6) was one of the first compounds recognised
4
as a narcotic antagonist, and has been used as an antidote in
3
morphine poisoning. Unfortunately, nalorphine has psychotomimetic 
effects which prevent its clinical use as an analgesic. This 
observation has led to the development of several clinically useful
5




Naloxone, (7),the N-allylanalogue of oxymorphine,is a potent 
antagonist. It has seven times the potency of nalorphine in
antagonising morphine, and is considered to be an almost pure 
antagonist, as it does not exhibit any analgesic activity.
H O
(7)
Utilization of the medically useless alkaloid thebaine (8) 
by Bentley and co-workers has produced a series of morphine
7
analogues called the oripavines. Thus, exploitation of the diene 
component of thebain via Diels Alder condensation with a variety 
of dienophiles, gave rise to ketonic adducts with activities 
comparable to those of morphine, while certain tertiary alcohols 
derived from Grignard reactions on these ketonic adducts were known 
to have very high levels of activity. One such compound, etorphine 
(9), has an activity 1,000-10,000 times that of morphine in a
Q
variety of animal species, and has been used to capture large wild 










1.3 SYNTHETIC CENTRALLY-ACTING ANALGESICS
Research workers in the field of synthetic centrally-acting 
analgesics have concentrated on modification of the morphine 
structure in an effort to extract the pharmacophore necessary for 
activity. Although not in historical order of development, the 
following sections attempt to illustrate how a continual reduction 
in the size of the morphine structure has produced several groups 
of drugs with analgesic properties. Though these analgesics differ 
in structural characteristics, they can all be related to the 
standard morphine (see Fig. 1).
7.
1.3.1 The Norphinans
The synthesis of the morphinan ring structure showed that
the entire morphine nucleus is not essential for analgesic 
9 ,activity (see Fig. la). Among the various derivatives within this 
group, racemorphan (10) was the first clinically valuable agent, 
with twice the activity of morphine,^ and most of its activity 
resides in the levo-isomer, levorphanol.**
Fig. 1 . Structural elements of (a) the morphinans, (b) the benzomorphans, 
(c) the phenylpiperidines and (d) the diphenylpropyl.amines as 
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As with morphine, it has been found that methylation of the
phenolic hydroxyl results in a significant decrease in potency,
while replacement of the N-methyl group by N-allyl gives the potent
morphine antagonist levallorphan (11), with about five times the
12
potency of nalorphine. Dextromethorphan (12), the O-methylether 
of the dextroisomer of racemorphan has found extensive use as a 
non-addictive antitussive agent.
R O (11) R = H;R = CHtCH=CH, 
(12) R = R'sCH,
1.3.2 The 6,7-Benzomorphans
The synthesis of 6,7-benzomorphans of the type (13) was
13first carried out by May and Murphy in 1954. In these compounds,
the (C) ring has been replaced by methyl and other alkyl
substituents at C-5 and C-9, a modification which confers
additional cis/trans geometric isomerism on the derivative (see
1 2
Fig. lb). The isomer with the configuration in which (R ) and (R ) 
are cis in relation to ring (B) is designated the alpha (a_-) 
isomer, while the trans orientation is the beta (0-) isomer. It has
been found that greater analgesic activity, dependence liability 
and toxicity is associated with the g-series, and, additionally, 
agonist activity resides mainly in the levo-isomer.*4
(13)
Clinically important 6 ,7-benzomorphan derivatives include
phenazocine (14; N-phenethylnorbenzomorphan), with 3-5 times the
15
activity of morphine in man but a lower dependence liability, and
pentazocine (15), the N-dimethylallylnorbenzomorphan 
16 17
derivative. ’ Although a weak antagonist of morphine, 
pentazocine is an effective analgesic in man and it is marketed as 
an analgesic with low addictive liability (as "Fortral"), but 
clinical experience has disproved this latter aspect. It is now 
classified as a controlled drug.
11.
(14) R=CH,CHtPh 
(15) R = CH,CH=C(Mo)
1.3.3 The 4-Phenylpiperidines
Pethidine (16), the parent compound of the 4-phenyl-
piperidine analgesics, was originally synthesised as a potential
antispasmodic agent. Its analgesic properties were observed in the
18
course of clinical trials. After its analgesic properties became 
known, pethidine was recognised as bearing a similarity to part of 
the morphine molecule (see Fig. lc). A full consideration of the 
chemistry and stereochemistry of the 4-phenylpiperidines and 
related compounds is given in Section 1.4.1.







Analgesics of this class have an open chain structure. The
best known example employed in clinical practice is methadone 
19 20(17) ' This acyclic analgesic, a 3,3-diphenylpropylamine
derivative, was one of the early non-fused ring analgesics 
recognised. A possible conformational relationship of methadone to 






Advantages of methadone over morphine are that it sustains 
addiction at one quarter the dose of morphine, and withdrawal 
effects, both physical and emotional, are less severe.
Variations about the nitrogen atom of methadone produced
other clinically used analgesics, such as the piperidino (19,




C»H.— C — C— CH.—CH—R
II I J.O Ph Me
(is) r=  o
(19) R■-o
Many other analogues based on variation of the methadone 
structure have been prepared, some of which are used clinically, 
but none offers any real advantage over methadone itself.
1.4 ARYLPIPERIDINES
1.4.1 4-Phenylpiperidine Analgesics and Related Compounds
1.4.1.1 Introduction
The 4-phenylpiperidine type of analgesics is historically
the oldest synthetic group (reports appeared in 1939). It has
probably attracted the greatest amount of research towards related
compounds of any of the synthetic analgesic classes. It is
estimated that about 4,000 analogues of this type had been prepared 
23
by 1965. Publications subsequent to that date suggest that 
phenylpiperidines are still not a dead issue, and the field 
continues to expand even today.
18
In 1939, Eisleb and Schaumann prepared a large number of
piperidine derivatives as potential antispasmotic agents on the
basis of their chemical relationships to atropine. However, several
of these compounds exhibited marked analgesic activity during the
general screening tests. Pethidine (meperidine, 16) was the first
clinically valuable derivative of this series, and it is remarkable
how pethidine, the original nonopioid-derived analgesic, has
maintained its popularity in the face of competition from other
synthetic analgesics marketed over the past 47 years.
Pethidine has one fifth to one tenth the potency of morphine 
24
in man, and is one of the most widely accepted substituents for 
morphine. It is useful for the suppression of mild to moderate 
pain, especially in patients intolerant to opioids. It has a lower 
level of toxicity and a shorter duration of action compared with 
morphine. Tolerance to pethidine develops slowly, and its 
dependence liability is lower than that of morphine in equivalent
dosage. As with morphine, pethidine produces respiratory
depression, nausea and vomiting. It is extensively used for the
25 26
relief of labour pain, where it has attracted some criticism.
Extensive research into synthetic modifications of pethidine
has been undertaken with the aim of producing an ideal analgesic,
and also to investigate the structure-activity relationships that
apply among the 4-phenylpiperidines.
1.4.1.2 Synthetic Modifications of Pethidine
a. Variation of the Nitrogen Substituent
It has been found that the potency of analgesics in the 
4-phenylpiperidine series depends critically on the nature of the 
substituent on the nitrogen, and substitution of pethidine N-methyl 
has led to the production of several compounds with greater potency 
than the parent drug, but it has also been found that the side 
effects, including addiction liability, have increased with the 
analgesic potency.
27Perrine and Eddy altered the character of the nitrogen
substituent and related the length of the alkyl chain to potency.
They found that N-phenethylnorpethidine (pheneridine, 20) had a
27potency twice that of pethidine in mice, and they also found that
the activity rises from N-benzyl (0.25 x pethidine) to N-phenyl-
propylnorpethidine (13 x pethidine), and decreases on further
28extension of the alkyl chain. Replacement of the side chain aryl
29by pyridyl enhances activity, whilst the dioxolane group in that
position gives a compound with the same potency as the parent 
30
ester. Substituents in the benzene ring of pheneridine, such as
amino, nitro, methoxy and ring nitrogen (4-pyridyl), enhance
activity in the N-phenethyl compounds but not always in other
series. Chain branching severely reduces the potency.
N-substituted analogues of pethidine in clinical use include 
26phenoperidine (Operidine, 21), the secondary alcohol derived from
the reduction of the Mannich base derived from norpethidine and
31 32acetophenone, with 150 times the potency of pethidine 1 ,
anileridine (Leritine, 23) the N-para ami nophenethy1 analogue of
33 34pethidine, with 2-3 times the potency of pethidine ' , and
piminodine (Alvodine, 22), which bears an N-substituent containing
a secondary amino group between the alkyl and aryl function, is 100
times more potent than pethidine, and has been marketed in the 
35
United States.
A variety of pethidine analogues with oxygen-containing
N-substituents have been investigated by Janssen and co-workers,
who reported that the highest activity was found in the
propiophenone derivative (24), which was about 60 and 200 times
31 32more active than pethidine in mice and rats, respectively. '
(20) R.CH,CH,Ph
(21) R * C H jC H2CHOHPh
(22) R*CH,CH,CH,-NH-Ph
(23) RsCH,CH • " O '  NH, 
(2-») RsCH2CH,COPh
Unlike the morphine and benzomorhan series, attempts to
prepare antagonists in the 4-phenylpiperidine series by Introducing
appropriate N-substituents (such as allyl and CPM groups) was
unsuccessful. Examples include the N-allyl derivative (25) of
norpethidine, which is agonist with no power to block the opiate 
36
receptor. However, a notable exception to this observation is 





third the activity of nalorphine against morphine.
(26)
Ph :0,Et
b. Variation of the C4-0xygen Function
This was the second modification to the basic structure of
pethidine, which was investigated soon after the drug was
introduced into clinical practice. The carbethoxy group (CO^Et) is
38
considered to be of optimal size for analgesic activity, and its
39replacement by carbomethoxy, or a bulky ester function, decreases
31 32activity. ’ However, in 1943 it was reported that the
replacement of 4-carbethoxy by 4-propionyloxy (OCOEt) enhanced
39 40potency by a factor of 20. * This group of analgesics, the
so-called reversed esters of pethidine, showed high levels of
39potency, regardless of the nature of the N-substituent. In 1960,
Janssen and Eddy reported that remarkably potent 4-phenylpiperidine
analgesics may be obtained by choosing the appropriate 
39N-substituent, and they also found that the reversed ester 
analogue of phenoperidine (27) is over 3000 times as active as
pethidine in rats, while the precursor Mannich base (28) is about
The replacement of the carbethoxy (CO^Et) group of pethidine
with a ketone moiety gave the bemidone series. The best known
example in this series is ketobemidone (29; R = H), made from the
4-cyano intermediate (30), which possesses a 4-propionyl group
together with a 4-m-hydroxyphenyl group. It has 10 times the
42activity of pethidine, with similar activity to a-prodine and
morphine. It shows high PDC (physical dependence capacity) in
33 43monkeys and is at least as addictive as morphine in man. *
The 4-ethoxy-4-(2'-furyl) analogue (31) of pethidine has 2.5
44times the activity of the parent.
half as active as the secondary alcohol.
41
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Since the replacement of C4-oxygen by various C-alkyl 
substituents is relevant to the present work, it will be discussed 
in more detail in section 1.4.2.
c. Variation of the 4-Aryl Group
Most data concerning the effect of variation of 4-phenyl on
potency in 4-arylpiperidine analgesics relate to reversed esters as
a result of the versatility of 4-aryl-4-piperidinol syntheses. Bulk
increase in the size of the aryl group, as in naphthyl derivatives,
led to inactive compounds, while 4-tolyl analogues were reported to
45be less active than the parent compound. Isosteric replacement of
phenyl by other groups such as furyl, thienyl and pyridyl is also
44 45 46disadvantageous in terms of potency (see 32) * * , while its
replacement by groups capable of donating t electrons, such as













Complete removal of the 4-phenyl results in a severe fall in
. . . 47,48potency (see 33).
H ^ O C O E to
Me
(33)
(33): EDggi 20.2 mg/kg SC (MHP) 
CODEINE ED^: 7.5 mg/kg SC (MHP)
No consistent relationship between potency 
and position of substitution in the phenyl ring can 
be observed; however p-substitution usually
results in the greatest, and ortho the least, fall in activity. The 
introduction of substituents into the aromatic ring, such as methyl
(34) and methoxy (35) have been reported, although in most cases 























In analgesics with a rigid skeleton like morphine and
levorphanol, the presence of a free phenolic group is a
52prerequisite for high potency. Such is not the case for most 
4-arylpiperidines, although the introduction of a met a phenolic 







On the other hand, m-phenolic analogues (37), (38) and
(39) of the reversed ester of pethidine, g- and fc-prodine, 
and o- and £-allylprodine (see page 28) respectively, have been shown to 






d. Alkylation of the Piperidine Ring
The effect of alkyl substitution in the piperidine ring of
4-phenylpiperidine analgesics has attracted much interest since the
3-methyl analogues of the reversed ester of pethidine were
55
described by Roche workers in the late 1940s. The ease of
synthesis and high levels of activity associated with the reversed
esters are probable reasons why most of the investigations have
been associated with derivatives of the reversed ester of
pethidine, rather than pethidine itself.
It has been found that further alkylation of the piperidine
carbon atoms has a marked effect on the potency of the reversed
ester of pethidine, and the potency of these derivatives depends
not only on the nature of the C-alkyl substituent, but also on the
49
stereochemical features associated with the molecules.
The 3-alkyl analogues of the reversed ester of pethidine, 
particularly the 3-methyl (a- and 0-prodine) derivatives will be 
described in more detail in the following section. The mono and 
di-C-methyl analogues of the reversed ester of pethidine have been 
reviewed elsewhere.^
The isomeric 3-alkyl analogues of the reversed ester of 
pethidine
The 4-phenyl-4-acyloxy piperidines are "reversed ester"
analogues of the pethidine series. This type of compound was first
40
described in 1943 by Jensen et al. who found that reversal of the 
ester function is generally correlated with increased analgesic 
potency. Extensive study of the isomeric nature of the 3-methyl
57
derivative (and other alkyl derivatives) by Ziering et al. has
led to the synthesis of the isomeric derivative a_-prodine (40) and
B-prodine (41). The a-isomer was found to be the major synthetic
product, with a potency equivalent to morphine. g^-Prodine, the
minor component, has been shown to have five times the activity of








EDgQ mg/kg 0.92 0.18 0.85
Definite stereochemical assignments of the prodines was a
controversial area for some years until the relative configurations
59were established by X-ray crystallographic studies, and
1 13 60 61substantiated by H and C NMR studies. ' The assignments are
trans 3-Me/4-Ph for a-prodine and cis 3-Me/4-Ph for jj-prodine. The
corresponding IUPAC nomenclature is a : c-3-Me; r-4-0C0Et;
jj: t-3-Me; r-4-0C0Et. It will be recalled that greater potency
resides with the B-isomer. Both diastereoisomers are considered to
exist in the equatorial 4-phenyl chair conformation.
However, it is now accepted that the case of the 3-methyl
substituent is unique and in pairs with larger alkyl substituents,
62
the a-isomer (trans 3-R/4-Ph) is more potent (see Table 1).
Hence, taking the unsubstituted ester (42) propionoxy and acetoxy
as standards, the drug receptor interaction appears to be enhanced
by a-ethyl and impeded by a-n-propyl (moderately) and a-n-butyl
(severely), while all 0-substituents except methyl have detrimental
influences (see Table 1; the case of 3-allyl will be discussed
later). Receptor affinities measured by determining the
concentration of the 3-alkylated ester to displace 50% of specially 
3
bound [ H ]dihydromorphine from rat brain homogenates have
confirmed the higher affinity of £- over a- (43; R = Me, Table 1)
and a- over B_- (43; R = Et, allyl and n-hexyl), and the results
63
were found to be well correlated with analgesic potencies.
Pharmacodynamic studies of 3-alkyl substituted reversed
esters of pethidine, using analogues labelled with tritium in the
64
aromatic moiety of the molecule, have shown that the differences 
in the analgesic potency between the prodine isomers is also partly 
due to differences in brain level concentration, rather than other 
factors such as metabolism, distribution or plasma binding.
The influence of a jj-3-methyl may be achieved directly 
through interaction with a binding site on the receptor specific 
for axial methyl. However, longer hydrocarbon groups of the same 
axial orientation are not accommodated at this site and act against
Table 1. Analgesic Activity (Hot Plate ED__ «g/kg SC in Nice)
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a. Acetate data in parentheses, pethidine reverse ester 0.85 (3.62)
drug-receptor association. An alternative explanation, however, is
that a JJ-3-methyl group has an indirect influence on ligand-
receptor association by facilitating a rise in the population of
reversed ester conformations that bind more effectively than the
equatorial 4-phenyl chairs favoured for unsubstituted and
3 o-substituted derivatives.
Stereochemical studies of 3-allyl prodines been
65 66clarified by simultaneous results from two groups. * The
configurations were established by *H NMR and X-ray
crystallographic studies as trans 3-allyl/4-Ph for the a-isomer and
cis 3-allyl/4-Ph for the B^-isomer. a-Allyl prodine is about 13
times as active as morphine and the B_-isomer about one-tenth as
active as morphine, results which confirm the superiority of the
a-form as an analgesic but give the B_-compound a much lower potency
67 68than that originally reported. *
Comprehensive study of stereochemical structure-activity
relationship of 4-phenylpiperidine analgesics has been carried out
69
by Portoghese and co-workers, who separated the two chiral dia-
stereoisomers into antipodal forms, established the absolute
configuration of each enantiomer, and determined each enantiomer’s
analgesic potency.
Considering the 4-phenylpiperidine reversed esters to exist
in favourable 4-phenyl chair conformations, Portoghese and his
70workers used biochemical nomenclature to differentiate between 
the two sides of the piperidine molecule. One side was termed 
pro-chiral-4S (Pro-4S) and the other pro-chiral-4R (Pro-4R; see 
44). In the unsubstituted standard ester (42) C-4 is symmetrical,
29
and insertion of an alkyl group on the Pro-4S side gives C-4 an S
configuration by application of the Cahn Ingold-Prelog 
71








It has been found that greater activity resides in the 3R,4S
enantiomer of a_-prodine (40a) than the corresponding 3S,4R 
69enantiomer (40b).
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These results raised the question of whether the opiate 
receptor discriminates against the Pro-4S side of the molecule. 
Thus, if the Pro-4R side of the moledule is submitted to the opiate 
receptor, equatorial 3-Me substituents situated on this side hinder 
drug receptor binding, while equatorial 3-methyl groups on the 
Pro-4S side do not affect this binding.
This study has been proved by further investigations on 
other antipodal forms of 3-a-alkyl analogues. One example to 
demonstrate this is the 3-oi-allyl derivative of the reversed ester 
of pethidine; the 3R,4S enantiomer (ED__ = 0.03 mg/kg) has a higher
DU
level of potency than the corresponding 3S,4R podal form (ED-.- =
50
72 73
25.2 mg/kg) in mice (hot-plate test). *
A similar study of the two antipodal forms of g_-prodine
(41), in which the 3-methyl substituent has an axial orientation,
revealed that greater analgesic potency resided with the 3S,4:S
69
antipode (41a) compared to the 3R,4R isomer (41b).
Ph*. ^OCOEt













ED50 mg/kg 0.25 3.3
Hence, with an equatorial 4-phenyl chair conformation, an 
axial 3-methyl substituent on the Pro-4S side is preferential for 
high levels of activity and, in addition, such axial 3-methyl 
substitution has an active role to play in opiate receptor 
interaction. This is illustrated by comparison of the analgesic 
activities of 3R,4S-o-3-methyl and 3S,4S-B-3-methyl analogues of the 
reversed ester of pethidine.
1.4.2 3-Arylpiperidines
In 1965, certain 3-arylpiperidines with moderate analgesic
activities were reported. Derivatives of this class are believed to
be closely related to the 4,4-disubstituted piperidines, and also
resemble morphine in their associations with opiate receptors.
N-methyl derivatives of this class are relatively weak
analgesics, but high level of potency has been obtained by
replacing the N-methyl by N-arylalkyl substituents. Examples
include (45; R1 = H; R = CH2C0Ph), which was reported to have a
74




Insertion of a methyl substituent at C-2 of the piperidine 
ring has led to the production of compounds with higher potency, 
and a potency difference between the two diastereoisomers (examined 
as racemates) was reported. Stereochemical studies of this class 
have shown that single isomeric forms of the derivatives (45; R* = 
Me; R = CH^CF^Ph and -CHgCOPh) were about half as active as 
morphine in mice by the hot-plate test, while the corresponding
N-allyl derivative antagonises the analgesic effect of morphine in 
75 76
the same animal. ' This contrasts with the action of
4-arylpiperidines bearing N-allyl functionalities (see page 17).
Stereochemical studies on 2 ,3-dimethyl-3-arylpiperidines
77
have been clarified by further work, which also provided
pharmacological data that confirms the previous reports. Both
isomeric forms of the parent secondary amine (46) were obtained by
hydrogenation of the tetrahydropyridine (47), and then converted to
77








The configurations, termed c-2-Me, r-3-Ar for the a_-isomer
(48) and t-2-Me, r-3-Ar for the B-isomer (49), were established by
analysis of differences in the 1H NMR spectra of the N-benzyl and
13 77






The N-methyl, N-allyl and N-CPM derivatives were found to be 
very weak or inactive as analgesics in mice, while the N-phenethyl 
isomers were active by tests on the guinea-pig ileum (a^ : 0.7; B :
were found to antagonise fentanyl-induced effects. The B_-isomer was 
twice as active as nalorphine, and four times more effective than 
the a_-isomer in both cases. Again, by comparing these results with 
the pharmacological properties of N-allyl and N-CPM derivatives of
4-phenylpiperidines, it seems likely that 3-arylpiperidines 
interact with the opiate receptor in a morphine-like manner.
All active analogues of this class are phenols; the 
£-hydroxyphenyl derivatives [45; R1 * Me; R * CH^CHsCH^, CPM and 
CH^-CHssCfMe^) ] are much less potent antagonists than the 
corresponding m-hydroxyaryl isomers, a result which emphasises the 
importance of the m-hydroxyaryl moiety in binding with opiate 
receptors.
0.3-0.4 x pethidine). 78 In rats the N-allyl and N-CPM derivatives
35.
The original assignments of 2,3-dimethyl-3-arylpiperidines
13 79
were later confirmed by C NMR studies.
1 13
H and C NMR studies of the o_-N-benzyl derivative (50, Ar
80
= m.OH.C-H.) as the hydrochloride by Casy et al. have shown that 
— 6 4 -- --
the preferred solute conformation is (52), and not the previously
77
suggested one (51). They also synthesised the 3,5- and
3,6-dimethyl derivatives and studied their stereochemical features, 











Analgesically-active derivatives of 3-arylpyrrolidines (53;
e.g. R = Me) were prepared, and converted to morphine antagonists
81—S3
by replacing N-Me by N-allyl or N-CPM.
Profadol (53; R = n-Pr) was the first notable compound of 
this type. It shows twice the activity of codeine in rats by
antinociceptive tests, and its action was antagonised by




Replacement of the 3-alkyl substituent by CO^Et or COEt
results in a severe fall of potency. Derivatives with various
81 823-alkyl substituents have been reported. * Compound [53; R ■ 
CH^CHtMe)^] was found to be 2.7 times as active as codeine, while 
the corresponding N-CPM derivative was reported to have 3.5 times 
the activity of pentazocine against morphine.
1.4.3 4-Alkyl-4-ArylPiperidines
1.4.3.1 Introduction
The synthesis of these compounds was first described by
86
McElvain and Clemens in 1958. In these compounds, the C4-oxygen
function has been replaced by various alkyl substituents, a
modification which was initially intended to determine whether such
a polar substituent as the former is essential for the analgesic
activities of such compounds, or whether a non-polar alkyl
substituent would be satisfactory.
To reiterate, narcotic antagonistic activity in morphine,
6 ,7-benzomorphans and the morphinans is usually associated with
replacement of the N-Me by N-CPM, N-allyl (as in, for example,
5 87
Naloxone) or other related groups. * On the other hand, such
replacement in the 4-phenylpiperidine series has not produced
36
narcotic antagonists. Nevertheless, there are exceptions to this;
levo-metazocine and profadol, both N-methyl compounds with agonist
properties, show some antagonist activities, although this is
relatively weak.
However, during pharmacological investigation of a series of
88
l,3,4-trialkyl-4-arylpiperidines (54), Zimmerman et al. 
discovered that the presence of 3-methyl cis to 4-aryl, for example 
(54a; Table 3; p.41 ) resulted in analgesic-antagonist properties.
Thus, they concluded that position 3 of the piperidine ring, rather 
than substitution at the nitrogen, is the area critical for 
determining antagonist activity in these compounds.
The following section attempts to illustrate the chemical 
and pharmacological aspects of this new series of 
phenylpiperidines.
1.4.3.2 Chemical and Pharmacological Aspects of 4-Aryl-4-alkyl- 
piperidines and Related Compounds
Strueture-activity relationships of the 1,4-dialkyl 
86
derivatives (55; see Table 2) have shown that the free m-phenolic 
hydroxyl is an essential feature of all active compounds, since 
introduction of a hydroxyl or a methoxyl substituent in the o- (see 
55d and 55e) or p-position (see 55k) results in complete loss of 
analgesic activity.
Increasing the size of the C4-methyl substituent of (55h) to 
n-propyl (55i.) enhanced potency by a factor of 10-40, while its 
replacement by hydrogen results in compounds without any 
significant analgesic activity (for example, 55t).
Other changes include substitution of the N-methyl group in 
(55a) by N-butyl (as in 55r), which results in no significant 
change in analgesic properties, while its replacement by N-ethyl or 
N-propyl (as in 55m and 55n respectively) results in inactive 
compounds. Some activity returns when the N-substituent is 
isopropyl (as in 55p), but none of these compounds display any 
marked analgesic action.
No pharmacological data concerning compounds with a 3-methyl 
substituent have been presented in the series investigated by 
McElvain and Clemens.
Table 2. Analgesic Potencies of Some l,4-Dialkyl-4-arylpiperidines
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Demerol 5 and 10-20 C and D-l
Morphine 1 and 2-40 C and D-]
A. No analgesia C. Moderate
B. Trace D. Marked
E. Profound
Interest in this series was revived in 1978 by a paper by 
88
Zimmerman et al., which confirmed the original structure-activity 
relationships, and also provided pharmacological data of some
1,4-dialkyl compounds and, of more interest, their corresponding
3-methyl derivatives. It has been found that the 3_-isomer (54a) is 
either half or twice as acive as nalorphine (depending on rodent 
species), and lacked agonist activity. The corresponding a-isomer 
(54b) was found to behave as a partial agonist.
Further investigation into the 4-propyldiastereoisomers gave 
less precise SAR data; the a-isomer (54d) was essentially sin 
agonist, with less potency than the corresponding 3-desmethyl 
derivative, while the B-isomer (54c) was a significsint sintagonist 
in rats, and a weak agonist in mice.
It also has been found that replacement of the N-methyl of 
(54a) by N-allyl and N-CPM (substituents which produce antagonists 
in the morphine, morphinans and 6,7-benzomorphsin series) resulted 
in a significant decrease in antagonist potency in rats, while its 
replacement by N-2-phenethyl (as in 54g) sind N-2-benzoylethyl 
(54h), (substituents that usually increase agonist activity in the 
pethidine series), raised potency to the level of naloxone in the 
latter example. Resolution of (54h) into its antipodal forms 
provided only partial separating of activity, as both antipodes 
were antagonists, with the dextro-isomer being 2-6 times more 
potent than the levo-isomer in mice (see Table 3).
Antagonist properties were also alleged for 8-3-methylketo- 
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R R1 Isomer Rats Mice Rats Mice
(ED2 5 )B (ED50)C
Me Me 0 0.24 1.0 50 50
Me Me a 13.0 45.0 33.0 15.0
Me Pr 0 4.6 43.0 50 13.0
Me Pr a Addictive 45.0 2.0 2.4
C3H5
Me 0 0.47 0.98 - -
CPM Me 0 0.72 0.72 - -
(CH2 )2Ph Me 0 0.11 0.14 - -
(CH ) COPh Me £-(*)- 0.056 0.049 — —
*-<->- 0.05 0.14 - —
?-<♦>- 0.023 0.025 — - ^
20.0 14 — »-*
0.45 0.045 — _
0.022 0.079 - —
- - 1.8 0.97
Addictive - 0.89 0.85
0 21 38 — _
0 6.2 9.9 — _
Footnotes to Table 3.
A. Dose (mg/kg, S.C.) required for a 50% reduction in the response 
to morphine in rats (tail heat) and mice (Straub tail and 
locomotion).
B. Dose required for a 2 second increase in reaction time in rat 
tail heat test.
C. Dose required for 50% reduction in the frequency of writhing.
Separation of the two optical forms of the a-4-n-propyl
derivative (54d; Picenadrol) and subsequent analgesic testing
indicated that most of the activity resided in the dextro-isomer,
while the levo-isomer, which is a weak agonist in mice, exhibited
marked antagonist properties in rats (tail flick test), with a
89-91
pottency between that of nalorphine and pentazocine. Since all
4-propyl derivatives differed little in their binding values,
their different pharmacological profiles were accredited to changes
in intrinsic activity rather than receptor affinity.
The view that the ^-derivatives of this series were pure
antagonists was backed by the following test; they were without
measurable agonist activity at 100 mg/kg, SC in the mouse writhing
analgesic test, a test procedure in which compounds with mixed
agonist-antagonist activity (such as nalorphine) exhibit analgesic
92
effects, and this was supported by in vitro tests.
In an attempt to determine the active conformational mode of
(54; axial or equatorial-4-chair), some 3,6-dimethyl analogues were
synthesised and tested, and evidence that the social 4-aryl
conformation leads to an agonist response, while equatorial 4-aryl
89—91conformation causes receptor blockade, was obtained. Thus,
the trans-3,6-dimethyl isomer (56) was an agonist with a potency 
half that of morphine, while the cis isomer (57) was an antagonist, 






These ideas require that the agonist (55fc, Table 2;p.39)binds in the
axial 4-aryl conformation, and there is computational evidence that
93such a conformer is preferred in this derivative.
If axial 4-arylpiperidine chairs are in fact the active 
conformational species in those members of this series with agonist 
properties, then the close relationship of their binding mode to 
that of morphine becomes an attractive possibility and accounts for 
their need of a phenolic substituent.
1.5 PHENCYCLIDINE
1.5.1 Introduction
Phencyclidine (58a; PCP) was initially introduced as a
94
surgical anaesthetic in 1958, but a few years later emerged as a 
drug of abuse in street use. Adverse psychotic reactions, such as 
agitation, disorientation, delirium, hallucination and many other 
undesired side effects, developed in many post surgical patients 
and it was later abandoned, though it is still used legally in 
veterinary medicine. The remarkably high potency of PCP, and its 
ease of synthesis, made it one of the widely abused psychotomimetic 
drugs.
The precise classification of PCP is presently unsettled.
95 96 97
PCP has stimulant, depressant, hallucinogenic, and analgesic
98
properties, some of which are dose-dependent.
In all actuality, PCP probably falls into a class of its
own, given the unique spectrum of properties that it displays.
However, a report suggested that PCP, and a variety of its
99
analogues, interfere with cholinergic processes.
Evidence on whether or not the analgesic property of PCP is
mediated through the a-receptor, which is known to be the third of
the original three sub-species of opioid r e c e p t o r , w a s  first
obtained by Vaupel and Jasinski.^^ They reported that N-allyl-
normetazocine, already known to bind with the a-receptor, and
PCP have similar effects on the dog with transected spinal cord, a
result which suggests that a common receptor is involved in their
102 103actions, and this was later supported by further tests. *
46.
1.5.2 Some Derivatives of Phencyclidine
Variation of the PCP structure in an attempt to produce a
safe general anaesthetic has led to the production of several
analogues (see Table 4)f some of which have similar psychic
effects. Compounds 58e-58p represent the most active members of the 
104
series.
Variations in the amine and aromatic functional moieties of
PCP produced other active compounds (Table 5), but none offers any
105
real advantage over PCP.
NMR and X-ray crystallographic studies10^ * o f  PCP 
hydrochloride have established that the preferred solute 
conformation of PCP hydrochloride is (60) in which both the 
cyclohexane and piperidine rings are in the chair form, and the 
phenyl ring assumes an axial position relative to the cyclohexyl 
and piperidine rings. This was later confirmed by variable
temperature NMR, X-ray crystallographic and molecular mechanics
* 108 studies.
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48.
Table 5. Relative Systemic Potencies of PCP Derivatives as the
105Hydrochlorides in Nice, as Measured by the Rotarod Test
R
(59)
Compound R X ED50 m^/kg
a H -n h 2 9.50
b H
CH3NC5H10‘r not active up to 6.5 mg/kg
c OH
NC5H10 1.24
d NH_ NC_H.. 9.82 5 10
e n o 2




1.5.3 New Analgesic Drugs Derived From PCP
Despite its undesirable side effects, PCP is unique in its
94 109
lack of depressant effect on the heart and respiration. * PCP
has been accredited with the exertion of a n a l g e s i a , b u t  no
precise data are available. It has thus been assumed that a proper
manipulation of the PGP structure might change the balance between
its antinociceptive and psychotomimetic properties in favour of the
former. This is not unreasonable in view of the successful
precedence offered by ketamine (61), which has retained the




The introduction of new substituents at position 4 of the 
piperidine ring of PCP has led to the production of several 
compounds which are structurally similar to the well known 
4-phenylpiperidine narcotic analgesics, some of which were reported 
to possess analgesic properties in the usual animal tests (see 
Table 6).113,114
50,




















































A. Tested as water soluble hydrochloride salts
B. Not active up to 9 mg/kg SC; higher doses produced ataxia
C. Not active up to 25 mg/kg SC? higher doses produced ataxia.
It has been presumed that different mechanisms are involved 
in the antinociceptive effect of PCP and the new compounds, 
particularly (62g), (62h) and (62k); (Table 6) . The fact that 
there is a good correlation between the relative potencies found in 
the hot-plate test and the mouse vas-deferens bioassay, that the 
effects are reversed by naloxone, and that the new compounds are 
structurally similar to the 4-phenylpiperidine analgesics, imply 
that the analgesic effect is mediated by the opiate receptors. This
view is supported by preliminary results of the radioreceptor
r3ul . . 104
assay using [ HJmorphine.
So, the introduction of a second phenyl moiety at position
4- of the piperidine ring of PCP (Table 6) significantly enhanced 
the affinity of these molecules to specific opiate receptors, both 
in vivo and in vitro. In contrast, PCP-4-0H (no. 62a, which lacks 
the additional phenyl moiety) is devoid of any opiate-like activity 
and is about 50-70 times less active than PCP-4-Ph-4-0H (62g). Also, 
esterification (i.e. PCP-4-Ph-4-0C0Et)of the alcohol (as in compound 
62h) significantly reduced the potency of the substance.
In summary, the structural modification of the PCP
"skeleton” gives rise to two different analgesic groups. It is 
113
proposed that certain substituents direct the molecule 
preferably towards the y-receptor of morphine, but other substances 




As pointed out in the introduction of this thesis, early
modification of phencyclidine (58a; PCP or "Angel dust"), in an
effort to produce a safer general anaesthetic and analgesic, devoid
104 105
of hallucinogenic effects, was unsuccessful. '
However, recent structural modification of PCP which
borrowed elements from the well known 4-phenylpiperidine analgesics
113,114
proved more successful. Thus, introduction of a phenyl and
hydroxyl moiety at position 4 of the piperidine ring of PCP 
significantly enhanced the affinity of this molecule (62g) towards 





Following the successful chemical manipulation of the PCP
structure, which altered the balance between its antinociceptive
and psychotomimetic properties in favour of the former, it was
considered of interest to study the effect of 3-methyl substitution
in the piperidine ring since such substitution in piperidine
55 57reverse ester significantly enhances analgesic potency. * Thus, 
a portion of the research undertaken by the author involved the 
synthesis of the a- and 0- forms of compound (70), and, because of 
interesting pharmacological data, the resolution of the a- isomer 
(which is much more readily available) into its antipodal species.
One other major aim of the present work is to re-examine the 
stereochemical structure-activity relationships that apply among 
the 4-alkyl-4-aryl-3-methylpiperidines and their corresponding
(70)
3-desmethyl analogues, with a view to establishing the relative 
configuration and the preferred solute conformation of the isomers. 
The detailed aims and objectives of this thesis thus entail:
1. The synthesis of required compounds.
2. Separation of isomers.
3. Resolution of a-prodinol.
4. Configurational and conformational assignments using 
spectroscopic techniques (particularly high field and 
13C NMR).
5. Pharmacological evaluation.
2.2 PHENCYCLIDINE DERIVATIVES DERIVED FROM o-and B-PRODINE
The proposed route of synthesis for these analogues is as 
outlined in Schemes 1, 2, 3, 4 and 7.
2.2.1 Synthesis and Separation of o- and 6-Prodine
i 1,3-Dimethyl -4-piperidone (63; Scheme 1), the key
intermediate in the synthesis of o- and £-prodine, (40) and (41)
respectively, was prepared as outlined in Scheme 1.
The synthesis of this compound (63) involved the stepwise
Michael condensation115”117 of methylmethacrylate with methylamine,
then the addition of the resulting secondary amino ester (64) to
ethylacrylate, to yield the diester (65).
118Dieckmann cyclization of the diester using the shot-bird 
sodium method yielded compound (67). Hydrolysis followed by 
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Reaction of phenyl lithium with the ketone (63), afforded a
mixture of ri-and £-prodinol in the approximate ratio 9:1 as judged
by N- and C3-methyl NMR signals. Separation of the a-isomer was
achieved by fractional crystallisation of the free base, while the
8-isomer was separated as the hydrochloride salt of the
corresponding propionate ester after most of the a-isomer had been
collected (see Scheme 2).
Acylation of a-prodinol with propionyl chloride afforded
(40) as the hydrochloride salt. The IR spectrum of this compound
displayed a strong absorption at 1750 cm \  characteristic of ester
carbonyl. Propionoxy carbonyl was also observed at 171.34 ppm in 
13
the C NMR spectrum. Another important feature confirming
esterification was the downfield chemical shift (approximately 9-10
13ppm) of the C-4 quaternary carbon in the C NMR spectrum, due to a 
stronger deshielding effect of 0C0 group over the OH group of the 















fractional crystallisation of 
the free base
pure
mixture of a 
and B approximate 
ratio 1:1.2
pure a-prodinol (68) a-prodinol + jB-prodinol
propionylchloride











pure £-prodine (41) 
HC1
Scheme 2
13 ATable 7. C Chemical shifts of bom «- and 0- Diastereoisomeric Analogues of Piperidine
P h ^ O R 1
Cr1
Compound R
13C Chemical shifts (ppm, TMS as internal standard)
Isomer _ _






69a, in C0C.H_ H 
DMS0-d_




58.26 41.91 11.69 82.16 31.77 50.38 141.02
57.60 40.07 14.68 82.20 25.41 51.35 143.04
47.56 40.05 12.18 74.71 40.14 41.24 148.31
(43.75)® (12.03) (39.41)(37.44)
48.71 41.84 15.02 74.40 31.14 43.3 148.25
(44.86) (42.04) (14.95) (32.1) (39.27)
49.30 39.89 12.65 74.12 39.70 42.29 148.31
48.01 39.51 14.83 73.40 31.89 41.88 147.73
N-£h3; 45.15; CO: 171.31; CHgi 27.68;
CH3: 8.58; Ar-C: 124.15-127.01
N-CH3: 46.14; CO: 172.10; CHg-ester 28.27;
CH3: 8.85; Ar-C: 124.57-127.88
CO: 174.58; CH2: 25.73; CH3: 9.68
Ar-C: 125.20-127.88
CO: 175.60; CHg: 27.28 (27.60); CH3: 10.51 







49.65 39.54 12.36 73.33 40.59 42.59 146.74
48.66 39.48 15.89 73.01 31.40 40.19 146.53
60.01 CN: 119.35, cyclohexyl-C: C-2/6: 33.96;
C-3/5:22.24; C-4: 24.86? Ar-C: 124.66-128.05
60.17 £N: 119.61; cyclohexyl-C: C-2/6: 33.86;
C-3/5: 21.73; C-4:24.91? Ar-C: 124.61-128.01
Table 7. Continued
0
13 Chealcal shifts (ppa, TMS as internal standard)
Coapound R R1 Iaoner
daalgn. C-2 C-3 C3-Na C-4 C-5 C-6 4Ph-Cq Cq-1° Cq-1,D Other carbons
3<r*
«9g r  
*
; H a 48.52 40.22 12.45 74.09 40.25 41.58 147.20 139.91 60.04 Cyclohexyl-C: C-2/6: 33.64; C-3/5: 22.64; C-4: 24.56;~Ar-C: 124.73-128.04
09h f ) H $ 47.71 40.91 16.38 73.88 33.44 41.45 147.26 141.45 60.65 Cyclohexyl-C: C-2/6: 33.60; C-3/5: 22.28; C-4: 26.8; Ar-C: 124.88-127.96
69J ^ 5 -OOCHg a 48.38 42.61 12.81 84.00 33.51 40.81 142.00 138.1 61.21 CO: 169.10; CH3: 21.58; Cyclohexyl-C:C-2/6: 33.32; C-3/5: 22.48; C-4: 26.31; 
Ar-C: 124.80-127.87
A. SpMtrt recorded aa baaa in CDCl^. unlaaa othtrwlat stated. B. Dstsi in psrsnthcsss refer to distinct spectra resonances noted from
the other form.
C. Tha quaternary carbon of tha phenyl group attachad to cyclohexsne.
D. Tha quaternary carbon of cyclohexane.
Table 8. Si M R  ( 8 scale) Characteristics of Soae a- and 0- Dlastereolsoaerlc Analogues of Piperidine*
PH.O R
(69)










C3-H C3-Me Other protons
40 Me coc2h5 a 2.52dd 2.58brt 2.01brt 2.88brd 1.74brt 2.22d 1.78m 0.54d Ar-H: 7.01-7.34m; N-CH3: 2.13s 
CH3 (Ester): 1.04t; OCHgt 2.28q
41 Me C0C2h5 £ 2.78m 2.52brd 2.57dt 2.88brd 2.13dt 2.32m 2.15brq 0.73d Ar-H: 7.19-7.30m; N-CH3: 2.26s
CH3 (ester): 1.08t; 0CH2: 2.30q
69a, in 
DMSO-dg






















1.72brt F 2.02m 0.59dd Ar-H: 7.22-7.47; )CH : F 
CH3”(amide): 1.14dt
69c H H o 2.90m 3.05m 2.52m 3.10brd 1.68dt 2.75m 1.95m 0.60d Ar-H: 7.21-7.47m; N-H: 2.3®
69d H
^ 5 N
H 1 3.33dd 3.0m 2.54brt 2.85brd 1.53dt 2.31m 2.22m 0.64d Ar-H: 7.21-7.43m; N-H: 2.32°
69e f H a 2.62m 2.85brd 2.38t 3.15brd 1.38m 1.84® 1.84® 0.65d Ar-H: 7.23-7.48m; cycl. H®: 1.74°
Table 8 (continued)
Compound R R* Isomeric C2-H C6-H CS-H C3-H 63-Me Other protons
designation ax eq cue eq ax eq
69f H jj 3.12m 2.94dd 2.62® 2.64® 1.35m 2.10® 2.15m 0.73d Ar-H: 7.25-7.45; cycl. H: 1.65
69g H ~ 2.18m 2.88° 2.08m 2.88° 1.60m 1.32m 1.76° 0.52d Ar-H: 7.11-7.31m; cycl. H: 1.76
^ P h
69h H £ 2.89m 2.58brd 2.37° 2.76m 1.42m 2.12° 2.08° 0.68d Ar-H: 7.13-7.43m; cycl. H: 1.77
Ph
69j i ^ S  C0CH3 a 2.27° 2.88® 2.27® 2.88® 1.36 2.10® 1.78m 0.58d Ar-H: 7.10-7.37m; cycl. H: 1.64
I \ CHgTester): 1.81s
A. Spectra recorded as base in CDC13 with TMS as internal standard. Values refer to centres of resonance signal and hence represent 
only approximate chemical shift in most cases.
B. Overlapping multiplet (4H) C. Overlapping multlplet (8H)
D. Overlapping multiplet (10H) E. Cyclohexane ring protons
Overlapping multiplet 2.28-2.61 (3H) G. Data in parenthesis refer to distinct spectra resonances noted from the other form.
Spectral data obtained for B-prodine were consistent with
the assigned structure (41). The stereochemistry of and
^8-prodine has been the subject of previous investigation and is 
59 60 61 78
well established. * * * Present assignments of the isomeric
esters correlated well with the stereochemical assignments made.
13
Analysis of C NMR spectra provides two characteristic 
features that can be used to distinguish the two isomers. Firstly, 
the C3-methyl chemical shift (at 11.69 and 14.68 ppm) is assigned 
respectively as equatorial C3-methyl for the o-isomer and axial 
C3-methyl for the ^-isomer. Secondly, the high field chemical shift 
of the C-5 ( 25.41 ppm) of the B-isomer, compared with C-5 of the 
a-isomer ( 31.77 ppm), is due to the y-gauche effect of the axial 
C3-methyl causing steric compression on C-5. This y-effect is of 
particular stereochemical significance in conformational studies of 
6-membered alicyclic compounds. It is based on the fact that 
insertion of an equatorial substituent such as methyl in position 3 
of compound (42), for example, causes very little change about 
(0.5 ppm) in the chemical shift of C-5, while insertion of an axial 
C3-methyl in the same compound resulted in large upfield shift 










2.2.2 The Synthesis of a-4-hydroxy-3-methyl-4-phenylpiperidine 
(69c; Scheme 3) by N-demethylation of a-prodine
The synthesis of this compound was effected by
N-demethylation of a-prodine (40) with 2,2,2-trichloroethylchloro- 
121
formate via the intermediate carbamate (69m; Scheme 4). 
Ordinarily such carbamates are hydrolysed to secondary amines using 
Zn and acetic acid. However, hydrolysis of the carbamate (69m) with 
zinc and glacial acetic acid in an effort to secure the secondary
65.
amine (69c) afforded the amide (69a) instead. Formation of this
compound is believed to proceed as outlined in Scheme 4.
Characterisation of this amide was based on the spectral
data obtained. The IR spectrum displayed a strong carbonyl
absorption at 1640 cm \  characteristic of amide carbonyl
13
functionality. The C NMR spectrum was consistent with the 
assigned structure (69a), with characteristic amide carbonyl carbon 
resonance (at 174.88 ppm). Additonally, NMR signals for C-2; 
C3-CH^; C-5 and C-6 of the piperidine ring were duplicated, in 
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Duplication of signals observed in the C and H NMR 
spectra is thought to be the result of a cis/trans relation between 








/ C ^ E t
Scheme 5
1 13H and C NMR analysis of the 6-amide (69b) also indicated 
duplication of resonances, and it was noticeably more pronounced 
for the C3-CH3(dd) and OCH^CH^ (dt), presumably due to a
1,3-interaction involving axially placed methyl (see Fig. 3; p.71). 
Duplicated signal chemical shift differences for the piperidine 
ring protons, particularly C2-H and C6-H, were narrower compared 
with those in the a-isomer (69a).
This compound (69a) was analysed by mass spectroscopy, and 
the possible routes of fragmentations are shown in Scheme 6.
69.
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1H NMR spectrum of o-4-hydroxy-3-methyl-4-phenyl-1-propanoylpiperidine, recorded at 270 MHz in DMSO-dg 
to illustrate duplication of signals.
C H 3 (amide)
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Fig. 3. H NMR spectrum of B-4-hydroxy-3-methy]-4-phenyl-1-propanoylpiperidine, recorded at 270 MHz in CD OD to
o
illustrate duplication of signals.
Alkaline hydrolysis of this amide (69a) with KOH pellets in 
isopropanol afforded the secondary amine (69c)f as outlined 














13The C NMR and IR spectra of the secondary amine were
consistent with the assigned structure (69c)f a notable feature in
O
II
both spectra being the disappearance of -C- resonance.
2.2.3 The Synthesis of a-l-(l-cyanocyclohexyl)-4-hydroxy-3-methyl- 
4-phenylpiperidine via the Strecker reaction (Scheme 3)•
122
The Strecker reaction is a well-known classical 
procedure, including its modifications, for the preparation of
aminonitriles
123,124
from aldehydes and ketones. In general, the
procedure involves reaction of equimolar proportions of an amine 
salt and an aldehyde or ketone with alkali cyanide in aqueous or 
alcoholic solution. The mechanism for this reaction has not been 
fully explained, but three possible mechanisms have been 
postulated.
Firstly, the reaction may proceed, particularly in the case 
of primary amines and aldehydes, via formation of a Schiff base 
(70), followed by nucleophilic attack by cyanide ion, as outlined 
in Scheme 8.
Alternatively, the nucleophilic addition of cyanide ion to 
the carbonyl group leads to the formation of a cyanohydrin followed 
by subsequent nucleophilic displacement of the hydroxyl group by 
the amine (see Scheme 10).
H
l





Another possibility is the formation of an amino alcohol 
intermediate, which could undergo nucleophilic attack by cyanide 
ion, as shown in Scheme 9 .
R,-c  =To* H*




R1 / N 





R \ y  Y ~ *C L. OH
rvt, -NH H R1
Scheme 10
However, it is possible that formation of amino nitriles may
well be due to a combination of all three mechanisms.
This general synthetic reaction was successfully employed in
the present work for the synthesis of (69e)t using the secondary
amine (69c) as the hydrochloride salt, cyclohexanone and potassium
cyanide in aqueous solution, as shown in Scheme 3.
13The C NMR spectrum of this compound was consistent with 
the assigned structure (69e), with characteristic CsN resonance (at 
119.35 ppm). Also, the spectrum displayed six -CHg lines in 
addition to two quaternary carbons in the aliphatic region,
compared with only three -CH^ lines and one quaternary carbon in 
the starting material, due to C-l (quaternary); C-3/5; C-2/6 and 




2.2.4 The Synthesis of o-4-hydroxy-3-methyl-4-phenyl-l-(l-phenyl-
cyclohexyl)piperidine and the corresponding acetoxy ester*
The synthesis of (69g; Scheme 3), one of the main aims of 
the present work, was achieved by reaction of (69e) with phenyl 
magnesium bromide.
The spectral data obtained for this compound were consistent
13
with its assigned structure. Thus, the C NMR spectrum showed 
absence of C=N resonance (characteristic of starting material). The 
spectrum also displayed the appropriate aromatic signals in accord 
with the assigned structure.
This compound was analysed by mass spectroscopy, and the 
possible routes of fragmentation are shown in Scheme 11.
77.
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Esterification of (69g) with acetyl chloride afforded 69j;
see Scheme 3) as the hydrochloride salt.
The IR spectrum of this compound displayed a strong
absorption at 1760 cm”1, characteristic of an ester carbonyl group.
The characteristic feature of the NMR spectrum was the methyl
ester protons, which appeared as a singlet at 1.81 ppm. Acetoxy
carbonyl carbon chemical shift (at 169.10 ppm) was observed in the 
13C NMR spectrum. Another important feature confirming 
esterification was the down field chemical shift of the 
C4-quaternary (at 84.00 ppm).
Ph I Ph
(69g) (69j)
2.2.5 The Synthesis of 6-4-hydroxy-3-methyl-4-phenyl-l-( 1-phenyl- 
cyclohexyl )piperldine
_B-Prodine was subjected to the same synthetic procedures 
previously described in Schemes 3, 4 and 7 for the synthesis of the
a-isomeric analogue (69g)t in order to secure the £-isomeric
analogue (69h).
There were no distinctive differences in the experimental
results obtained for the o- and £-isomers. However, for full
details of the experimental results see Table 25, p. 216. For *H NMR
13
results, see Table 8, p. 61 and for C NMR results, see Table 7,
p. 59 .
Phx?H




Pharmacological evaluation of compound (69g) showed that it 
had about 3 times the activity of morphine (see p. 199 for 
pharmacological results). Thus, resolution of a-prodinol was 
undertaken to establish the analgesic activity of the two optical 
forms of compound (69g).
The term resolution is generally defined as a procedure 
through which both optical isomers (enantiomers) are separated in 
the purified state from a racemic mixture.
Resolution of o-prodine was achieved by diastereoisomeric 
125
salt formation. This general procedure involves the interaction 
of racemic bases (B) with optically active acids (A) or racemic 
acids with optically active bases. Thus, enantiomers are 
transformed to diastereoisomeric salts which may then be separated 
by differential solubility (Scheme 12)
(+) A + (±) B (+) A ( + ) B + ( + ) A (-) B
(+) B + (±) A ( + ) B ( + ) A + (+) B (-) A
Scheme 12
The diastereoisomeric salts cropped after fractional 
crystallisation can then be hydrolysed with inorganic alkalis or 
acids to give the enantiomers. This procedure usually involves many 
recrystallisations, monitored by polarimetry.
Common optically active acids used for the resolution of 
racemic bases include tartaric acid, mandelic acid, camphoric acid 
ani camphor-10-sulphonic acid. Optically active bases such as
morphine, ephedrine and manthylamine are used for resolving racemic 
acids. The conditions necessary to effect resolution cannot be 
generalised, although the choice of optically active resolving 
agent and the solvent are important considerations.
employed fractional crystallisation of the tartarate salts. 
Basification of the two salts generated (+)-a- and (-)-a-4-hydroxy-
l,3-dimethyl-4-phenylpiperidine (see Table 26#  ^ p.217 for specific 
optical rotation results).
Esterification of (+)- and (-)-a-4-hydroxy-l,3-dimethyl-4- 
phenylpiperidine with propionyl chloride afforded the corresponding 
(+)- and (-)-a-l,3-dimethyl-4-phenyl-4-propionoxypiperidine 
respectively, as the hydrochloride salts (see Scheme 13).
Optical resolution of (±)-a-prodinol was achieved by
69












2.2.6 .2 Qualitative determination of enantiomeric purity of
resolved a-prodinol by ~*~H NMR using B-cyclodextrin
Optical purity of (+)-a -prodine was judged by the
application of the NMR spectroscopic technique described by Casy 
126
and Mercer. This procedure involves the use of 0_-cyclodextrin 
which has been reported to form inclusion complexes with chiral 
medicinal agents (chiefly antihistamines and central analgesics to 
date).
The NMR spectrum of a 1:1 mixture of( t ) a-prodine and 
jj-cyclodextrin has indicated the formation of an inclusion complex 
between the two compounds. Thus, analysis of this spectrum 
indicated duplication of ligand resonances, which was clear for the 
3-methyl (doublet becomes a triplet) and ester (methyl triplet 
becomes a double triplet) signals (see Fig. 4). On the other hand, 
the symmetrical appearance of the 3-methyl doublet signal of 
(+)-a-prodine (see Fig. 4.) in the presence of B-cyclodextrin is 
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Fig. 4. Partial *H NMR spectra (at 400 MHz, in D O )  of: a) A 1:1 mixture of (±)-o-prodine hydrochloride and B_-cyclodextrin, 
which clearly illustrates duplication of C3-CH3 and CHg (ester) signals; b) A 1:1 mixture of 
(+ )_a-prodine hydrochloride and IB-cyclodextrin, which shows the symmetrical appearance of both signals.
oo
co
2.2.6 .3 Synthesis of (-)- and (+)-a-4-hydroxy-3-methyl-4-phenyl- 
1-(1-phenylcyclohexyl)piperidine
The synthesis of the two optical forms of (69g) was carried 
out by the same synthetic procedures previously described for the 
synthesis of the racemate (69g; Schemes 3, 4 and 7), by using the 
appropriate resolved a-prodinol. For experimental results see 
Tables 27, 28, p. 218-219.
Attention will now be given to the stereochemical features 
associated with (69g) and (69h).
13
Stereochemical assignments of both isomers were based on C
NMR chemical shift parameters following similar assignments of a-
and _3- prodinol and phencyclidine, compounds of established
stereochemistry, and evidence supporting the relative configuration
trans 3-Me/4-Ph for (69g) and cis 3-Me/4-Ph for (69h) with an
axially oriented phenyl chain [of l-(l-phenylcyclohexyl ] in both
isomers was obtained. Thus, the two isomers have retained the
original stereochemistry of a- and J-prodinol, and phencyclidine.
13
C NMR data of the a-isomer (69g) indicated that both C3-Me
( 12.45 ppm) and C4-Ph (Cq at 147.20 ppm) have an equatorial
orientation. The C-5 chemical shift at 40.25 ppm (similar to that
of the des 3-Me analogue) is further evidence that the C3-Me has an
119 120
equatorial orientation. * The upfield chemical shift of Ar-Cq 
(of the phenyl attached to cyclohexyl) relative to Ar-Cq of the 
piperidine moiety suggests the preferred axial phenyl-chair 
conformation of the cyclohexyl moiety.
On the other hand, the downfield chemical shift of C3-CH of
O
(69h, at 16.38 ppm), characteristic of axial C3-Me, with a
corresponding upfield chemical shift of the C-5 by about 7 ppm, due
to the steric compression produced by the axial C3-Me,is evidence
that the compound retains the stereochemistry of ji-prodinol.
C4-Ar-Cq and Ar-Cq (of the phenyl attached to cyclohexyl) chemical
shifts at 147.26 ppm and 141.45 ppm (at higher field because it
119 120subjects to greater steric polarization at Cq), * 
respectively, suggested that the C4-Ar has an equatorial
orientation, while the second phenyl is axially orientated.
In the case of phencyclidine, the adamantyl analogue (PAP)
13provides a good model for the Cq-11 C chemical shift of an
108axially placed phenyl substituent. The conformation of the PAP
of the rigid adamantyl derivative has been established
108
unequivocally by X-ray analysis.
64.4 ppm ^"■*.137.60 ppM70.77 ppm ^-^130.11 ppm
H Cf
(PCP in D20) (PAP in CDC13)








(69g in CDC13) (69h in CDClj)
2.3 THE 4-ALKYL-4-ARYLPIPERIDINES
2.3.1 Introduction
The marked mixed agonist/antagonist activity of some 
analogues in the 4-alkyl-4-aryl series has resulted in intensive 
investigation of the chemical and stereochemical aspects of these 
analogues.
A brief discussion is presented here on some of the
synthetic procedures employed to secure these analogues.
86
The original 4-alkyl-4-arylpiperidines (Table 2, p. 39)
were prepared by cyclization of 3-alkyl-3-arylpentane-l,5-diol (86;
Scheme 14) with the appropriate primary amine, in the presence of
hydrogen at 250°C and 4400 p.s.i. On the other hand, 2-hydroxy-
methylpentane-3-(o-methoxyphenyl)-3-methyl-l,5-diols and methylamine
(87; Scheme 15), under similar conditions, was utilised to secure
86
the 1,3,4-trimethyl analogues.
However, this procedure required a multistep reaction scheme 
with vigorous reaction conditions at certain stages.
Ar.
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Compounds of this type were later prepared by ring expansion
127of 3-arylpyrrolinium iodide using diazomethane (88; Scheme 16),
a method which demands great caution. The relevant patent relating 
to this approach gave no details of the precursor pyrrolinium salt, 





















At the time of writing this thesis, an SRI international
128
group has reported the synthesis of 4-alkyl-4-arylpiperidines by
a slight modification of the method described by these authors in
129
their original report (Scheme 17). Although preparation of the 
corresponding 3-methyl analogues was not reported, in this author's 
opinion the use of ethylpropionate in the first step of the 
reaction instead of ethylacetate could constitute a route to the 























In 1980, Zimmerman et al. demonstrated an important general
synthetic approach for the synthesis of morphinan-based 
130
analgesics. This approach was later utilized for the synthesis
131
of the 4-alkyl-4-arylpiperidines. The method consists of
treating the tetrahydropyridine (89) with n-butyllithium and the
appropriate alkylhalide, followed by catalytic hydrogenation of the
resultant enamine (90) to yield the desired 4-alkyl analogue
(Scheme 18; p.108).
This procedure was employed in the present work to secure
the 4-alkyl analogues, for a number of reasons. Firstly, the ease
of synthesis of the precursor tetrahydropyridine (89); secondly, it
avoids the use of diazomethane which is central to the pyrrolinium 
127
salt route; and, lastly, it is sufficiently flexible to be 
applicable for the synthesis of 3-methyl analogues through use of a 
Mannich condensation between the enamine (90), formaldehyde and 
dimethylamine, followed by catalytic hydrogenation of the Mannich 
base (91; see Scheme 18). Work by this author on such compounds 
commenced with attempted 4-methylation of the two dehydrated 
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2.3.2.1 The Synthesis of 1,3,4-trimethyl-4-phenylpiperidine
Original attempts to secure this compound concentrated on 
the chemical reactions expressed in Scheme 19.
A. Dehydration of i*-prodinol
Acid catalysed dehydration of a-prodinol (68) was
132
accomplished using concentrated HC1 and glacial acetic acid, and 
yielded a mixture of the two isomers (71) and (72). This 
dehydration is considered to proceed via a two step mechanism as 
outlined in Scheme 20. Isomer separation was achieved by fractional 
































Spectral data obtained for the two dehydrated compounds were 
consistent with the assigned structures, and differentiation was 
readily achieved by means of NMR spectroscopy. Thus, the 
spectrum of (71) displayed an olefinic multiplet at 5.80 ppm due 
to C5-H and a doublet at 0.77 ppm due to C3-CHg, while the 
spectrum of (72) displayed a singlet at 1.62 ppm due to C3-CHg and 
was devoid of olefinic proton resonance.
B. Mstaloalkylation of (71)
Alkylation of (71) with n-butyllithium and dimethylsulphate 
was expected to proceed as outlined in Scheme 19, p 92 . However,
this reaction afforded a mixture of (73; in about 2% yield) and the 
corresponding quaternary ammonium salt (74; in about 8% yield; see 
p.221 ). Separation of the two compounds was achieved by























A probable mechanism for this alkylation is outlined in 
Scheme 22.
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Characterisation of compound (73) was based on H and C 
NMR spectral data, both of which were consistent with structure. A 
notable feature of the *H NMR spectrum was the two olefinic 
doublets centred at 4.34 and 5.98 ppm due to C3-H and C2-H 
respectively. Also of significance was the C4-CH^ singlet at 
1.46 ppm.
The characteristic feature of the NMR spectrum of the
quaternary ammonium salt (74) was the down field chemical shifts of 
♦
N-Me^t which appeared as two sharp signals at 3.78 and 3.81 ppm,
which are assigned, respectively, as axial CH^ and equatorial 
133
CHg. Two olefinic signals at 5.83 and 6.46 ppm were also
observed due to C3-H and C2-H respectively, as well as a C4-CHg
♦ 13
singlet at 1.58 ppm. N-Me^ C chemical shifts at 42.27 and
42.91 ppm, due to axial CH^ and equatorial CH^ respectively, were
C. Catalytic hydrogenation of the enamine (73)
Catalytic hydrogenation of (73; Scheme 21) using palladium on
charcoal, in ethanol as solvent, yielded one single isomer (75) as
1 13
judged by H and C NMR data.
The NMR spectrum of the reduced product (75) clearly
demonstrated the disappearance of the olefinic doublet. A full
discussion of the stereochemical features of this compound is
presented in Section 2.3.3; p. 156 .
The mechanism of catalytic hydrogenation is complex and
still controversial. The generally accepted current theory suggests
the adsorption of the substrate to the metallic catalyst surface,
forming a chemisorption c o m p l e x . W i l l s t a t t e r * ^  and 
138
Ingold envisaged that electrons are being transferred from the 
surface of the chemisorption complex to the substrate.
D. The synthesis of 1 ,3,4-trimethyl-4-phenylpiperidine by N- 
demethylation of the quaternary ammonium salt (74)
N-Demethylation of compound (74) was achieved by treatment 
with AgCl (MeSO^— ►Cl ; the quaternary chloride generated
subsequently displays more favourable solubility characteristics),
139
and then refluxing with sodium thiophenate in 2-butanone. This 
reaction is of the simple S^2 type, and consists of attack by the 
thiophenoxide anion on the N-methyl group, as outlined in 
Scheme 23.
1 13
The H and C NMR spectra of enamine (76) were consistent
with structure. Thus, the NMR spectrum displayed only one N-CH^
signal at the upfield position of 2.70 ppm, compared with two more 
♦
deshielded N-CH^ signals in the starting material. Olefinic
resonances at 4.35 and 6.00 ppm, assigned respectively to C3-H and
C2-H, were also observed in the NMR spectrum.
Treatment of compound (76) with ethereal-HCl afforded the
corresponding enamine salt (77; Scheme 23). The characteristic
feature of the ^N HMR spectrum of this compound was the down field
N
II
chemical shift of C2-H at 8.95 ppm, typical of the CH function.
♦
The low field chemical shift for N-CH^ at 3.80 ppm, compared with 
the corresponding group in starting material at 2.70 ppm, was also 
observed.
Reduction of the enamine salt (77) with NaBH,, afforded
4
compound (75; Scheme 23).
Spectral analysis of the reduced product indicated 
disappearance of the olefinic signal. This compound was identical 






























Following the successful synthesis of (75) using the 5-Me 
isomer, the attempted synthesis of (73) in an effort to secure this 
distereoisomer by utilizing the 3-Me compound (72) was 
unsuccessful, mainly because the reaction is associated with steric 
hindrance, and returned unconverted starting material, in addition 
to the corresponding quaternary methosulphate salt, at the 
alkylation stage.
The synthesis of compound (75) by the route described was 
unsatisfactory in that the overall yields were very low, due to 
quaternisation of the key intermediate (73). Therefore, in an 
effort to increase the yield of the 4-methyl derivative, the use of 
l-benzyl-3-methyl-4-piperidone (78), instead of the N-methyl 
derivative, was undertaken, as the quaternary ammonium salt (79), 
likely to be formed, should readily undergo catalytic 
N-debenzylation to give the desired 4-aryl-l,3,4-trimethyl- 
































2.3.2.2 The attempted synthesis of-4-(3-methoxyphenyl)-l,3,4-
trimethylpiperidine using l-benzyl-3-methyl-4-piperidone
The proposed route of synthesis for this compound by this
particular method is outlined in Scheme 24.
In view of the difficulties generally experienced in
preparing l-benzyl-3-methylpiperidone (78) by the acrylate
41
condensation method, application of the synthetic procedure
140
described by Mistryukove et al. for the synthesis of 
N-alkylpiperidines was undertaken. This procedure is based on an 
exchange reaction between the methiodide of an N-alkylpiperidone 
and a primary amine.
The probable mechanism is shown in Scheme 25 and it may be 
viewed as a facile"double Hofmann elimination reaction," facilitated 
by the JJ-placed carbonyl group, followed by Michael addition 




















The C NMR spectrum of compound (78) displayed four CH^ 
lines in the aliphatic region, compared with three CH^ lines in the 
starting material. The spectrum also displayed the appropriate 
aromatic signals in accord with the assigned structure.
The characteristic feature of the NMR spectrum was the
Ar-CH^ protons which appeared as a singlet at 3.58 ppm, and the 
♦
absence of N-fCHg)^ resonances at 3.27 ppm and 3.53 ppm.
Condensation of the ketone (78; Scheme 24) with 3-anisyl 
lithium (derived from 3-bromoanisole and sec. butyl lithium) 
afforded an oil which, by t.l.c. analysis, was seen to be a mixture 
of two compounds,neither of which corresponded to the starting 
ketone. Sec. butyl lithium was employed in this synthesis, as a 
lower yield was obtained when n-butyl lithium was used as the 
metalating agent. The IR spectrum of this oil indicated 
disappearance of carbonyl absorption and the appearance of OH 
absorption.
Purification of this isomeric mixture (83) was not 
attempted, since acid-catalysed dehydration using concentrated HC1 
and glacial acetic acid affords the desired 5-Me isomer (84) as the 
major product, as well as the minor 3-Me isomer (85; see Scheme 
24). Separation of the 5-Me isomer was achieved by fractional 
crystallisation of the hydrochloride salts.
Spectral data obtained for this alkenic isomer were 
consistent with its structure. A characteristic feature of the 
NMR spectrum was the olefinic multiplet at 5.85 ppm due to C3-H.
An attempted synthesis of (79) by treatment of (84) with 
n-butyl lithium and 2.5 mole equivalents of dimethylsulphate
resulted in the formation of a mixture of the quaternary 
methosulphate salts of starting material and the desired product. 
All attempts to separate this mixture were unsuccessful. 
Spectroscopic data relating to these salts are presented on p.253 .
At this stage in the work, the synthetic approach expressed 
in Schemes 19 and 24 was abandoned.
2.3.2.3 The synthesis of 4-alkyl-4-arylpiperidines using
4-aryl-l,2,5,6-tetrahydro-l-methylpyridine as a precursor
In view of the difficulties reported in the last section,
application of the synthetic procedure described by Zimmerman 
130 131
et al. * for the synthesis of 4-alkyl-4-aryl-l-methyl- 
piperidine (Scheme 18; R = Me, n-Pr and iso-Bu; p. 108) was 
therefore undertaken, using 4-aryl-l,2,5,6-tetrahydro-l-methyl- 
piperidine (89; Scheme 18) as a precursor.
A. The synthesis of 4-hydroxy-4-(3-methoxyphenyl)- 
1-methylpiperidine
Treatment of the ketone (92; p.108)with the Grignard reagent 
derived from 3-bromoanisole and sec-butyllithium afforded the
13
alcohol (93). Characterisation of this alcohol was achieved by C 
NMR and IR spectra, one notable feature being the absence of 
carbonyl absorption (a characteristic of starting ketone).
B. The synthesis of 1,2,5,6-tetrahydro-4-(3-methoxyphenyl)-1- 
methylpyridine
In this work compound (89), a key intermediate in the 
synthesis of the whole series of 4-alkyl analogues, was prepared by 
acid-catalyzed dehydration of the alcohol (93) using concentrated 




R= i-Bu . n-Pr and Me 
Ar= m -O M e . C6 H4
























Confirmation of this olefinic product was provided by the
detection of additional resonances at 111.54 and 144.0 ppm, due to
13
C3 and C4 respectively, in the C NMR spectrum. The C3-H olefinic 
multiplet at 6.01 ppm was also observed in the NMR spectrum.
Because the 4-isobutyl, 4-n-propyl and 4-methyl analogues 
were produced by a similar procedure, only the synthesis of the 
4-isobutyl analogues will be described in detail and remarks 
concerning derivatives of the other two analogues, particularly the 
4-methyl derivatives, will be made when necessary.
C. The synthesis of 1,4,5,6-tetrahydro-4-(3-methoxyphenyl)-l- 
methyl-4-(2-methylprop-l-yl)pyridine
This compound (90a) was prepared by metalloenamine 
alkylation of the dehydrated derivative (89) using n-butyl lithium 
and l-bromo-2-methylpropane. Purification of the crude product was 
achieved by slurrying it in a mixture of hexane : ethyl acetate and 
silica gel.
n-Propylbromide and dimethylsulphate respectively were 
utilized as alkylating agents for the synthesis of the 4-n-propyl 
and the 4-methyl analogues.
This reaction proceeded smoothly to yield (90a) and (90b) in 
good yields. However, the yield of the C4-methyl analogue was low 
(39%) due to the formation of the by-product (94). This arises from 
partial C4-methylation; but the piperidine basic centre seems to 
show a preference for the highly reactive dimethylsulphate, forming 
the quaternary ammonium salt, a finding experienced in the
C4-methylation of (71; p. 95 ).
Attempts to increase the yield of the C4-methyl analogue by 
using only a slight excess of dimethylsulphate or utilizing methyl 
iodide as alkylating agent proved unsuccessful, generating a 
mixture of the desired product and more of the corresponding 
quaternary ammonium salt. This result was expected as methyl 




The C and H NMR spectra of the C4-isobutyl compound (90a)
13
were consistent with the assigned structure. Thus, the C NMR 
spectrum displayed carbon signals for the 4-isobutyl group, and C2 
and C3 chemical shifts at 136.32 and 111.80 ppm, respectively, 
were noted.
The characteristic feature of the NMR spectrum was the 
two olefinic signals at 5.40 and 4.81 ppm, which are assigned, 






D. The synthesis of 4-(3-methoxyphenyl )-l-methyl-4-(2-methyl-
prop-l-yl)piperidine and its corresponding free phenol
Catalytic hydrogenation of the enamine (90a) with palladium 
on charcoal, in ethanol as solvent, yielded compound (55z).
the disappearance of the olefinic signals.
O-Demethylation of the reduced product (55z) with HBr (48%) 
yielded the corresponding phenolic analogue. This O-demethylation 
is of the nucleophilic category and it is considered to proceed as 
shown in Scheme 26.


















The C and H NMR spectra of this compound were consistent 
with structure, the notable feature being absence of the signal for
o-ch3.
E. The synthesis of 1,4,5,6-tetrahydro-4-(3-methoxyphenyl)-l-
methyl-3-dimethylamino methyl-4-(2-methylprop-l-yl)pyridine 
via.the Mannich reaction
The reaction of ammonia or a primary amine or secondary 
amine (usually as the hydrochloride), formaldehyde and a compound 
containing at least one hydrogen atom of pronounced activity is 
known as the Mannich reaction.
This reaction is an extremely useful synthetic reaction of 
extraordinary wide and varied application, and appears in various 
modifications in numerous syntheses of nitrogen containing 
compounds, both acyclic and cyclic.
This general reaction was successfully employed in the 
present work to secure compound (91a), using (90a) as the sulphate 
salt, formaldehyde and dimethylamine. The pH of the solution was 
adjusted to approximately 3.0-4.0 using sulphuric acid.
The reaction is believed to proceed mechanistically as 
outlined in Scheme 27. Initial attack by the unshared electron pair 
of nitrogen on the carbonyl atom is followed by protonation and 
elimination of water to yield the ion (95), which is resonance 
stabilized. Attack by the carbanion from the enamine (96) on the 
positive carbon atom of (95) yields (97) which is followed by loss 
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Characterisation of the oily Mannich base (91a) was based on 
1 13
H and C NMR spectral data, both of which were consistent with 
structure.
The NMR spectrum displayed only one olefinic signal at
6.11 ppm, due to C2-H, compared with two olefinic signals in the 
starting material. A notable feature of this spectrum was the 
C3-CH2N(CH3 )2 ) signal at 2.20 ppm (6H).
Following the success of this reaction using the N-methyl 
derivatives, the attempted synthesis of the Mannich base of the
1-benzyl derivative (98; Scheme 28, p. 116) proved unsuccessful, and 
yielded a mixture, which was impossible to purify. The benzyl group 
was used again as a protecting group in the attempted synthesis of 






















F. The synthesis of <*- and B-4-(3-methoxyphenyl)-l,3-dimethyl- 
4-(2-methylprop-l-yl)piperidine and the corresponding free 
phenols
Catalytic hydrogenation of the Mannich base (91a) with 
palladium on calcium carbonate, in triethylamine as solvent, 
yielded an isomeric mixture of (54j ; R* * Me) and (54k; R* = Me), 





R=Me;* Pr; . Bu
(54)
This reaction actually occurs in two steps. Initially, the 
exo C-N bond is hydrogenolyzed to generate the 3-methyltetrahydro- 
pyridine and then the 2,3-double bond in the tetrahydropyridine 
ring is reduced to afford the desired diastereoisomer.
Basic conditions are preferred in this reaction, in order to 
increase the quantity of the a-isomer according to the Lilly
131 1
patent. The H NMR spectrum of the reduced product indicated 
disappearance of the olefinic resonance.
The major a_-isomer (54k) was separated by fractional 
crystallisation of the hydrochloride salt, while the minor _3-isomer 
(54j), which separated along with a trace of the major isomer, was 
later purified and characterised as the corresponding phenol (see 
Scheme 29).
Treatment of (54k; R2 = Me) with HBr (48%) afforded the
13 1
corresponding phenol. The C and H NMR of this compound indicated 
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fractional crystallisation 
of the HC1 salt
HBr
(pure B-)
The major 4-Pr(c-3-Me/4-Ar) was 
separated as the oxalate salt, 
while the minor isomer 




The major 4-Me (c-3-Me/4-Ar) 
and the minor 4-Me (t-3-Me/4-Ar) 
were separated as the HC1 salts.
Scheme 29
G. The synthesis of some of the methiodide salts of the
4-alkyl-4-arylpiperidines
The general procedure utilized in quaternisation of the 
basic piperidine was carried out by using methyl iodide and acetone 
as solvent.
The methiodide salts of compounds (55h; Ar = m.OMeCgH^ and
54b; R2 = Me) were prepared as model compounds to aid in
configurational assignments of the corresponding N-methyl 
133
analogues (see p. 156).
2.3.2.4 Miscellaneous syntheses
The synthesis of the ketobemidone derivative (99) and the
propionate reversed ester of pethidine (42; p. 125) was carried out
in order to complete a conformational equilibrium study of












A. The synthesis of 4-cyano-l-phenethyl-4-phenylpiperldine
The synthesis of this compound (100; Scheme 30) was achieved 
by direct alkylation of the secondary amine (101) with phenethyl 
bromide. This alkylation is of the nucleophilic category proceeding 













Characterisation of this compound was based on the spectral 
13 1
data obtained. The C and H NMR spectra were consistent with the
13
assigned structure and, notably, the C spectrum displayed the 
correct carbon signals for the N-phenethyl group.
B. The synthesis of l-phenethyl-4-phenyl-4-propionylpiperidine
The ketobemidone derivative (99; Scheme 30) was obtained by
treatment of the nitrile (100) with a Grignard reagent prepared
from magnesium and iodoethane. The probable mechanism of this
reaction involves an initial addition of the Grignard reagent to
the cyano group to form an imine salt (102), followed by
protonation of the imine salt to yield the corresponding imine,
which undergoes rapid hydrolysis to the desired corresponding
ketone (99), as illustrated in Scheme 32.
13
The IR and C NMR spectra of the ketone were consistent
with the assigned structure. Thus, the IR spectrum showed a strong
-icarbonyl absorption at 1720 cm . Ketone -C- chemical shift at
13
211.31 ppm was also observed in the C NMR spectrum, compared
in
with -C- chemical shift at 121.73 ppm in the starting material.
li)
III J
P h .  X
R
(100)










R = — CH 2 CH2 Ph
Scheme 32
C. The synthesis of l-methyl-4-phenyl-4-propionoxypiperidine
An initial attempt to secure compound (42) by treatment of 
the alcohol (104) with propionyl chloride proved unsuccessful, the 
dehydrated alcohol (107) being the major product.
Esterification of this alcohol was successfully effected 













The IR spectrum of this compound (42) displayed a strong
-1 13absorption at 1740 cm , characteristic of ester carbonyl. The C
NMR spectrum displayed the correct number of carbon signals
consistent with structure, characteristic ester carbonyl carbon
being noted at 175.57 ppm. The downfield chemical shift of C4 at
13
77.91 ppm was another characteristic feature of the C NMR 
spectrum of this compound.
2.3.3 Stereochemical (conformational and configurational) 
assignments to 4-alkyl—4-arylpiperidines by analysis of
1 13their H and C NMR spectra
Evidence of the stereochemistry of the 4-alkyl-4-aryl- 
piperidines was sought from NMR data. The NMR spectra of some 
3,4-dialkylisomeric analogues of this series displayed complex 
resonances which precluded any direct stereochemical deductions to
be made. Thus, the bulk of the stereochemical information was
13 1
derived from the C NMR data and supported with H NMR studies.
13
The most general method for C assignments is by the aid of
chemical shift correlation with spectra of closely related
compounds of established stereochemistry. The main principle behind 
13
the use of C NMR data for stereochemical assignments is based on 
the fact that the effects of a substituent (C3-Me in the present 
work) on the chemical shift of the parent compound depends not only 
on the nature of the substituent but also on its spatial 
orientation in relation to other carbons in the molecule. These 
substituent effects are significantly noticeable on the immediate 
a-carbon, as well as on distant carbon atoms in the molecules, 
especially the ^-carbon. Thus, as a starting point for this study, 
attention will be given first to the stereochemical assignments of 
the des C3-methyl analogues (parent compounds).
It is reasonable to assume that conclusions about the 
stereochemistry of the m-methoxyphenyl derivatives discussed here 
are equally relevant to their O-demethylated (free phenol) 
analogues, i.e. the forms in which they will be pharmacologically 
evaluated.
2.3.3.1 Des C3-Methyl Analogues
In these analogues, the problem to be solved is one of 
conformational equilibria, that is, whether the axial 4-aryl chair 
(55A) or equatorial 4-aryl chair (55B) is the preferred 
conformation (see Scheme 34)
R = Me ! « Pr , ; Bu 




Me \ N Ar
(55A) (55B)
Scheme 34
However, the question of special interest is that of protonated 
salts as solutes in water (or deuterium oxide).
In bases, because ring inversion and nitrogen inversion 
rates are rapid, the NMR data reflect that of an averaged 
conformation.
On the other hand, in salts the proton exchange rates at 
nitrogen are slow on the NMR time scale and as a result signals due 
to separate protonated epimers may be resolvable if the two species 
are significantly populated. In such cases chair-chair intercon­













(Epimer equilibrium by assuming the base conformation 55A to be 
preferred)
Such proved to be the case for the hydrochloride salt of 
derivative (55h) examined as solute in D^O, and so it was possible 
to compare the NMR parameters of the two epimers.
The following factors were utilised in making assignments for 
the conformational features of the epimers.
13
1. The aromatic Cq-1' C resonance
In the axial 4-aryl conformer (55A) the Cq-1' is higher
field than that of the equatorial conformer (55C) because it is the
more sterically compressed of the two carbons and hence subject to







2. The 4-R C chemical shift (especially for R=Me)
80
Independent work on 3-aryl-3-methylpiperidine derivatives 
has established chemical shift ranges for axial/equatorial methyl









eq 3-Ar chair axial 3-Ar chair
The range 23.2-25.8 ppm is associated with axial 3-Me and 
30.5-31.8 ppm with equatorial 3-Me for hydrochloride salts in CDCl^ 
and D^O (values will be a few ppm to lower field in corresponding 
bases, due to the removal of the N-protonated effect which is 
generally a shielding influence).
3. Various NMR parameters as will be discussed individually 
for the 4-Me, n-Pr and iso-Bu compounds.
Table 9. 13C MMR of So m  4^1lgrl-4HUTlplp«ridinMa
R O
C Chemical Shirts In ppm from TMS
Compound/Solvent R* R^ C-(2,6) C-(3,5) C-4 4-R1 N-Me OMe Cq-1* Cq-3'
a-Snd/9 -C Me (Me)
2 (Ar) (Ar)








55L; baa# In 
CDCI3
a 0




or 52 Me: 14.5 45.7 - 147.1 157.8

















(43.7) Me2: 24.1 
(23.0)
42.6 (42.1) 55.0 143.6 159.3
55c; HC1 in D20 CH2CH(Me)2 H 51.0 (53.7) 33.0 (32.1) 38.7 (36.8) °-CH2:; 50.1 (43.6) Me2: 24.06 42.7 (42.1) - 143.3 156.0
B-CH: 23.5 (23.0) (23.8) (148.4) (155.5)
55*; base in 
CDC13




Me2: 24.9 45.7 148 157.2
a. Data in parentheses refer to the minor epimer.




R2 R1 H (2 ,6 ) H (3 ,5 ) N-Me 4-R1
o-CH^; 0-CH2 (CH) M e;(M e)2
OMe Ar-H
55h, HC1 H Me eq: 3 .3 6  b rd ; 13 eq: 2 .5 6  brd; 14.1 2 .6 7 b . Me: 1 .19s —, 5 '-H :  7 .3 1  t ;  7 .8 ,
in  D Oc (3 .4 3  b rd ; 1 3 .0 ) (2 .1 2  b rd , 14) (2 .8 8 s ) (1 .3 2  s) 2 ' , 4 '  and 6 '-H
ax: 2 .8 0  d t ;  13; ax: 1 .8 9  d t ;  14
1 3 .5 ; 1 .5 14, 3
(3 .2 7  d t ;  13, (2 .0 3  d t ;  1 3 .6 ,
13 , 3) 1 3 .6 , 4 )
a B
5 5 t ,  HC1 H CH CH Me e q : 3 .3 5  b rd ; eq: 2 .4 8  b rd , 14 .8 2 .63a o -CH : 1 .3 3  m( 1.62m) Me: 0 .5 3  t ;  7 .7 - 5 '-H :  7 .1 9  t ;  7 .7 ,7 .7
In  D_0 C  C 1 2 .5 K (7 .1 0  t ;  8 .8 )
C. (3 .4 2  b rd ; 1 2 .5 ) (2 .1 8  b rd . 15) (2 .8 9 s ) B~CH : 0 .8  m (0 .6 1  t ,  7 .7 )
ax: 2 .6 9  b r t ; ax: 1 .81 d t ; C. 2 * , 4 1, 6 1-H : 6 .7 3 - 6 .8m
(3 .2 4  b r t ;  13, 13) 1 4 .3 , 1 4 .3 , 2 .5 4 '-H :  (6 .7  dd; 8 .2 )
a B
55s; HC1 Me CH_CH(Me)„ eq: 3 .4 3  b rd ;1 2 .5 eq: 2 .5 6  brd; 14 .6 2 .71a e-CH : 1 .42  d; 4 .9 Me : 0 .4 9  d; 6 .4 3 .76s 5 ' -H : 7 .2 9  t ;  7 .9 ,
in  D-0 2 2 (2 .2 6  brd; 1 4 .5 ) (2 .9 6 s ) (1 .7 1  brm) (0756 brd ) (3 .7 0 s ) 7 .9  (7 .1 5  b r t )
€. ax: 2 .7 8  b r t ; ax: 1 .9 5  b r t ;  1 4 .4 , fl-CH: 1 .2 9  m 6 * -Hr 6 .9 2  d; 7 .6 ;
1 2 .5 , 1 2 .5 1 4 .4 2 '-H :  6 .8 8  brs
(3 .4 3  b r t ;  1 2 .5 , (2 .0 4  b r t ) 4 '-H :  6 .8 2  d;
1 2 .5 ) 7 .9  (6 .6 8  b rd )
55s, HC1 H CH„CH(Me) eq: 3 .3 7  b rd ;1 2 .5 eq: 2 .5 3  brd; 14 .6 2 .6 75 o-CH : 1 .3 8  d; 5 .5 Me : 0 .4 9  d; 6 .7 _ 5 '-H :  7 .1 9  t ;  7 .9 ,7 .9
in  D.O 2 2 (3 .4 3  brd; 1 2 .5 ) (2 .2 1  brd; 1 4 .9 ) (2 .9 1 s ) ( 1 . 68d; 5 .5 ) (0754 d , 6 .7 ) (7 .1 0  t ;  7 .9 .T .9 )
£ ax: 2 .7 5  b r t ; ax: 1 .8 8  d t ;  1 4 .2 , 0-CH: 1 .2 0  m 2 '-H :  6 .8 3  brs
1 2 .5 , 1 2 .5 1 4 .2 , 4 ) 4 ' , 6 * -H : 6 .8 0 -6 .7 5  m
(3 .2 6  b r t ; (1 .9 1  d t ;  1 4 .2 , 4 ' -H : (6 .6 8  b rd )
1 2 .5 , 1 2 .5 ) 1 4 .2 , 4 )
a . C h es lca l s h i f t s  In  pps from TMS (e x te rn a l TMS In  DgO) fo llo w e d  by m u l t ip l ic i t y  and l in e  se p ara tio n s  o f  s ig n a l (J In  H z); d a ta  in  parentheses 
r e fe r  to  the minor e p ls e r . A b b re v ia tio n s : a , s in g le t ;  d , d o u b le t; t ,  t r i p l e t ;  m, m u lt lp le t ;  p lus com binations such as d t ,  do u b le t o f
t r i p l e t s ;  b r ,  broad; n r ,  n e ar; eq , e q u a to r ia l;  ax , a x ia l .
b . M ajor and minor s ig n a ls  o v erlap  c . E p ls er r a t io  2 .2 :1  d . Eplmer r a t io  2 .8 5 :1  e . Eplmer r a t io  3 .2 6 : 1
A• 4-Aryl-l,4-dimethylpiperidine
Both and spectra of (55h; Ar=m-OH(OMe) .C_H)HC1
— o 4
displayed duplicated signals typical of an epimeric mixture. The
13
higher field Cq-1' C chemical shift had the greater intensity, 
evidence that epimer (I; Scheme 36) predominates over the 















This conclusion was supported by the 4-Me C chemical shifts: the 
more intense lower field signal ( 32.3 ppm) assigned to 4-Me of
(I), which receives a major contribution from an equatorial 4-Me 
conformer (la), and the less intense higher field resonance ( 23.8
ppm) to the more sterically polarized axial methyl of epimer (II).
Details of duplication of NMR signals of (55h;
Ar=m-OH.C^Hil; HC1 in D_0) are shown in Table 10. The major epimer 
—  6 4 2
had the higher field N-methyl resonance [moved upfield by the
contribution from the axial N-methyl conformer lb], axial 2,6-H
signals (these protons are subject to aromatic shielding in
conformation la), and axial 3,5-H signals (protons deshielded by
144 145
axial 4-Me in epimer II). ’ Similar NMR results were found for
the HC1 of the OMe derivative with the addition of duplicate OMe
proton signals ( 3.81 and 3.80 ppm). These results agree with the
93
computations of Froimowicz. The epimeric ratio is judged to be 
about v2.2:1 in favour of the axial 4-aryl chair from integration 
of the 1H N-Me and 4-Me signals.
B . 4-Aryl-l—me thy 1-4-n-propylpi peri dine
1 13
H and C NMR spectra of (55t; HC1 in D^O) gave evidence of 
the presence of epimeric conjugate acids, which was indicated by 
duplication of signals. The epimeric ratio was calculated to be 
2.85:1 from integration of N-Me signals.
Following a similar procedure to that employed to deduce the 
conformation of the 4-Me derivative, evidence that axial 4-Ar chair 
of (55€; I; Scheme 37) predominates over the minor equatorial 4-Ar
chair epimer (II) was obtained by examining the Cq-1' and a-CH^ (of
13 13
















This conclusion was supported by analysis of the *H chemical shifts 
of N-Me, axial 2,6-H and axial 3,5-H (see Table 10).
C. 4-Aryl-l-methyl-4-(2-methylprop-l-yl)piperidine
1 13Duplication of signals was observed in the H and C NMR
spectra of (55z; Ar=m-0Me(0H).C-H.) as the HC1 salt in Do0,
“ 6 4  2
evidence of the presence of an epimeric mixture. The epimeric ratio 
was about 3.26:1 as calculated before.
Likewise, the axial 4-aryl chair (I; Scheme 38) was deduced 





A r  *1
C H ,C H (M e), ^  h'
H so.o ppm <55z> (Me)t CH CH,
(50.1)
1 Scheme 38 43.7 ppm (43.7)
s ,,
CH 2CH(Me) 2 
Me ~
A r
Ar = m.0H(0Me).C»H4 | Cq-1' 148.4 ppm
H
II
N-Me, axial 2,6-H and axial 3,5-H 1H resonances (see Table 
10 for details of signals duplication) supported this deduction.
2.3.3.2 The 3-Me series
In these analogues the major isomer with relative 
configuration c-3-Me/4-Ar is designated o_- and the minor component 
t-3-Me/4-Ar, with the exception of the 4-isoBu analogues, where 
the minor isomer was found to have a cis relationship and the meg or 
isomer a trans relationship.
N
Me
R = Me ; n P r;.-B u  
R = Me 
R2= Me . HR
(54)
Me Me
0 : t-3-Me/4-Ar a : C-3-Me/4-Ar
In the following discussion it will be useful to note that 
the numbering system being applied places emphasis on relative 
stereochemistry rather than whether the compound is the methyl
139.
ether or phenol. For example, the 4-methyl compound is designated 
(54a) in the B_-isomer, and (54b) in the o-isomer, and the specific 
agent (ether or phenol) under discussion will be highlighted in the 
relevant tables and sections of the text.
Problems of configuration and preferred conformation
Key NMR parameters for these stereochemical assignments are 
as follows:
13
1. The C chemical shift of Cq-1' (as discussed before)
2. The 13C chemical shift of 4-R Ql=4-Me; 4-CHgEt; 4-CHgCH(Me)^
Although the same arguments as discussed before obtain,
chemical shifts will also be influenced by the orientation of the
3-Me group. Appropriate reference data relate to isomeric
80
2,3-dimethyl-3-arylpiperidines. Isomeric pairs of such 
derivatives were all found to prefer an equatorial 4-aryl chair 













The range 27.2-28.1 ppm is associated with axial 3-Me and 17.0-20.3 
ppm with equatorial 3-Me (in the base). One example to illustrate 













Explanation of the 3-Me shift variations
The 3-Me chemical shift of the des 2-Me derivative is close 
to the previously quoted range (see p. 131 ) for axial Me. When
2-Me is axially oriented (a) and bears an anti-relationship to 
axial 3-Me, mutual deshielding obtains and the 3-Me chemical shift
79
moves to lower field. On the other hand, when 2-Me is equatorial 
(£) the two methyl groups sterically compress each other 






When comparisons are made amongst HC1 salts, allowance 
should be made for the overall shielding influence of protonated 
nitrogen.
13
3. The C-5 C chemical shift
Again (see p. 64 ) in a series such as (54a) and (54b), the 
C-5 chemical shift provides evidence of the orientation of 3-Me. 
Values for the des-methyl (55h) and equatorial 3-Me derivative 
(54a) should be similar, while that of the axial 3-Me member should
be distinctly to higher field of the previous two because of the
4. • j , • i o « 119,120st e n c  compression produced by axial 3-Me.
37.7 ppm
% Me
M e \  /Xy^ Ar
(54a)
4. Various 1H NMR parameters
Of most direct value will be knowledge of the multiplet 
separations of the 3-H resonance revealed after spin decoupling of 
the 3-Me proton. Thus, evidence from the vicinal coupling constant
3
( J) of the 3-H is necessary to confirm the stereochemistry of the
3-Me group.
In a six-membered ring chair system the order of magnitude
of diaxial (J ), axial-equatorial (J ) and diequatorial (J ) 
aa ae ee
coupling constants in the NMR spectrum can be predicted from the 
angular relationships of the protons by application of Karplus 
relationship.14^ Values are therefore largest when the vicinal 




less when they are cis-coplanar (0 = 0), and almost zero when the 
protons are at right angles. Thus, J values generally fall within
33
147
8-14 Hz, while vT and J ^ values fall within 1-6 Hz.’ ae ee
Other ^H NMR features will be advanced in evidence of 
stereochemistry later.
5. Existence of protonated epimeric pairs both of significant 
population
13 1
When this situation arises, duplication of C and H 
resonances will be observed.
Derivatives of configuration (54a) are expected to give the 
protonated species (I, Scheme 39) exclusively, since the 
alternative epimer (II) can only relieve non-bonded interaction of 
axial N-Me by conversion to an invertomer that carries two bulky 





















On the other hand, of the two possible epimers of derivative 
of configuration (54b) the equatorially protonated form may relieve 
diaxial methyl interactions by inversion to a conformer with a 













When the 4-R substituent is of a bulk greater than that of 
methyl, these arguments require modification (see p. 164)-




54b: c-3-Me/4-Ar (major) Me







in ppm from 
C3-Me
TMS
C4-Me N-Me Cq-l'(Ar) Cq-3'(Ar) OMe Other Ar carbons




















54b; Mel in 
CDCl.^DNSO-d.3 O









75; HC1 in 
D20 (At- C6H5)
- 56.6 36.2 36.7 26.9 50.9 14.0 25.9 43.5 147.8 - - 128.70;
125.4
; 126.4;
LY 109636 HC1 in 
D20 (At - C6H5)





Table 12 . IMR (6 scale in  ppa) C h a ra c te r is t ic s  o f  and 0 - 4 - A r y l - l , 3 ,4 , - t r ia e t h y lp ip e r id in e  and R e la ted  Compounds®
54a: t-3 -M e /4 -A r  






s o lv e n t
R2 2-H 3-H 5-H 6-H 3-Me 4-Me N-Me O ther protons
5 4 b (a ) , base 
in  CDC13
Me m m eq: 1 .6  brd m 0 .7 9d ; 7 .1 1 .30s 2 .2 7s OCH : 
6 '-R :  
2 '-H :  
OCH :
3 .7 8 s ; 5 '-H :  7 .2 2 t ;  
6 .9 d t ;
6 . 8 5 t ; 4 '-H :  6 .7dd  
3 .78s
5 6 b (a ) , HC1
in  lT  CDClg
Me m e q : 2 .3  m° m m 1.25d , 7 1 .45s 2 .9 d ; 2xCH : 3 .8 s ;  2xNH: 1 1 .5  
and 1 2 .4
(a x : 2 .7m )d ( 1 .05 d ) (1 .4 2 ) (2 .7 ) A r-H *
2 . D20 m m eq: 1 .74b rd ; 14 m 0 .6 5 d , 7 .3 1 .26s 0CH3 : 3 .63s
54b (a ) Mel 
in  CDC1- and 
DMSO-d.o





3 .3 9 5 ; 5 ’ -H : 6 .8 8 t ;  
6 . 52dd;
6 .4 3 t ;  4 '-H :  6 .39dd
5 4 b (o ); HC1
in  D~0
H m 2.35m®1 eq: 1 .9 b rd ; 15 m 0 .6 9 d ; 7 .3 1 .3 4s
(1 .3 1 )
2 .8 5s
(2 .7 s )
5 '-H :
2 '-H :
7 . 2 4 t ; 6 ' -H : 6 .8 7 b rd :  
6 .7 9 t ;  4 '-H :  6 .73dd
5 4 b (a ); base 
in  CDC1-
H m 2.00m m m 0.7 9 d ; 7 .1 1 .31s 2 .2 8s 5 '-H :
6 .7 8 ;
7 .1 3 t ;  6 ' - 2 ' /H :  
4 '-H :  6 .6 5 d t




3 .0 1 t ;  1 2 .6 ;1 2 .6  
3 .1 6 - 3 .45m
m 2 .4 2 h eq: 1 .6 6 d t; 1 5 ;2 ;2  
ax: 2 .0 8 d t;1 5 ;1 5 ;6
ax: 3 . 2 0 t ; 
1 3 ,1 3 ,3
0 . 59d; 6 .7 1 .29s 2.8 8s 5 '-H :
2 '- H :
7 . 2 6 t ; 6 '-H :  7 .0 b rd  
6 .9 3 t ;  4 '-H :  6 .77dd
54a ( ^ ) ; base 
in  CDC13J
Me m m eq: 1 .4 2 d t  
( 1 .5 2 )
m 0 .5 1 d ;
(0 .7 1 d
6 .7
; 7 )
1 . 165s 
(1 .2 7 )
2 .2 4 s  5 '-H :  7 .1 5 t ; 6 ’ -H : 6 .9 5 b rd ;
( 6 .8 2 ) ;  2 '-H :  6 .9 2 t  
( 2 .1 9 s ) ( 6 .7 6 ) ;  4 ’ -H :
6 .6 5 d d (6 .6 3 )
LY 109836; 




3 .4 8 - 3 .6m 
3 .2 8 - 3 .4m
2 . 4 - 2 . 52mk eq: 1 .9 9b rd ; 1 4 .5  
ax: 2 .4 - 2 .52m
ax:
eq:
3 .4 8 -3 .6m 
3 .2 8 -3 .4m
0 .7 1 d ; '




(1 .3 8 )
2 .8 8
(2 .7 8 )
A r-H : 7 .2 5 - 7 .55m
75; HC1 in  
°20
(A r-C 6H )
~ ax:
eq:
3 .4 5 - 3 .6m 
3 .2 5 - 3 .4m
2 .3 5 - 2 .5m eq: 1 .99b rd ; 1 4 .7 ax:
eq:
3 .4 5 - 3 .6m 
3 .2 5 -3 .4m
0 .7 3 d ; 7 .3 1 .41
(1 .3 7 )
2 .9 1  A r-H : 
(2 .7 5 3 )
7 .2 5 - 7 .55m
Footnotes to Table 12
a. Footnote a from Table 10 (p.133 ) applies
b. Approximate resonances for Ar-2',4' and 6'-H
c. Identified by 20.COSY plot and resolved into broad singlet when irradiated the C3-Me doublet at 1.05 ppm.
d. Identified by 2D.COSY plot and resolved into broad singlet when irradiated the C3-Me doublet at 1.25 ppm.
e. In addition to Ar-H signals for the minor epimer.
f. 2 proton multiplet. Forms a broad singlet when irradiated the C3-Me doublet at 0.73 ppm.
g. 2 proton multiplet. Forms a broad singlet when irradiated the C3-Me doublet at 0.69 ppm.
h. Identified by 20.COSY plot and forms a dd when irradiated the C3-Me doublet at 0.59 ppm.
j. A spectrum of mainly the minor isomer with a trace of the major isomer; data in parenthesis refer to the major isomer
(less intense than those of the minor isomer).
k. Identified by 20.COSY plot and resolved into broad singlet when irradiated the C3-Me doublet at 0.71 ppm.
a. Unresolved signal.
Separation of isomers of 3-methyl-4-alkylpiperidines prepared
The major isomers (4-R=Me and iso-Bu) were separated by 
fractional crystallisation of the hydrochloride salts, while the 
minor isomers, which were separated along with a trace of major 
isomer, were later purified and characterised as the corresponding 
free phenols (see Scheme 29; p.119 ). Similarly, major 4-n-Pr was 
separated from the isomeric mixture as the oxalate salt, while the 
minor isomer was purified and characterised as the corresponding 
free phenol (HC1).




The C NMR chemical shifts of Cq-1' of all derivatives
2 2 
(major: R =OMe(H); minor: R =H; free bases) fell in the range
149-149.7 ppm, an indication of a common equatorial 4-Ar chair
conformation (the range 147.4-150.6 ppm is associated with
equatorial Ar chair; see p. 138).
2. 4-Me
The 4-Me chemical shifts of major derivatives (bases and HC1 
salts) fell in the range 25.4-27.3 ppm, lower field than that of
4-Me of the minor phenolic HC1 value of 14.0 ppm. These results 
support a 3,4-diaxial methyl relationship of the major, and a 
3-equatorial/4-axial one for the minor isomeric series.
150.
3. C5
Further evidence for the orientation of 3-Me was provided by
the C-5 chemical shift. The upfield C-5 chemical shift of the major
2 2 
derivative (R = Me: 29.9 ppm; R = H: 26.7 ppm) compared to
2
downfield (R =H: 37.7 ppm) in the minor, gave evidence that the
3-Me group is axially oriented in the major and equatorially in the 
minor (diastereoisomers).
NMR Analysis
Proof that the C3-Me group has an axial orientation in the 
major isomer and an equatorial orientation in the minor isomer was 
provided by examination of the C3-H resonance after spin decoupling
the C3-Me doublet.
1 2 
The H NMR spectrum of (54b; R =Me; HC1 in CDCl^), unlike
that in D^O, was characteristic of an epimeric mixture. Spin
decoupling of the C3-Me doublets of the major isomer at 1.05 ppm
(R^=H; HC1 in CDCl^) and 0.69 ppm (R^=H; HC1 in D^O) resolved the
C3-H resonances into broad singlets. Therefore, the C3-H is
equatorially oriented and hence the C3-Me must be axial. On the
other hand, spin decoupling of the C3-Me doublet of the minor
2
isomer which gave one protonated epimer (54a; R =H; HC1 in D^O) at
0.59 ppm resolved the C3-H resonance into a doublet of doublets
2 2 
with J = 3.5 and 13.6 Hz. These two J values are typically those
of an axial-equatorial and an axial-axial coupled proton
respectively. Thus, the C3-H is axially oriented and hence the
C3-Me is equatorial.
Further Hi NMR evidence
1. 3-Me/4-Me shifts
The down field resonances of both 3-Me and 4-Me (of both HC1 
salt and free base) in the major isomer relative to the 
corresponding signals of the minor isomer support the 





2. Ring protons of phenolic isomeric pair (HC1)
Each isomer possesses seven ring protons. The NMR 
spectrum of the major isomer displayed 3 groups of 2 protons and 
one resolved one proton signal, identified as 4 doublets, two 
triplets and one multiplet. That of the minor isomer displayed one 
overlapping group of 2 protons and 5 resolved one proton signals, 
identified as 3 doublets, 3 triplets and one multiplet (see 54b and 
54a) in support of the stereochemistry already made. Differences 
between the 2-H resonances are of steric significance; the major 
resonance appeared as a broad doublet within multiplet at
3.4-3.55 ppm (or 3.2-3.35 ppm), while that of the minor isomer
appeared as a triplet at 3.2 ppm (13, 13, 3 Hz). A triplet for
axial 2-H may only arise if the stereochemistry is as shown (54a)
2
because the axial 2-H proton is subject to two large couplings ( J 
3
to eq 2-H) and ( J to ax 3-H)). In the major isomer the axial 2-H
2
signal is subject only to one large coupling ( J to eq 2-H) and is
lower field than ax 2-H in the minor isomer because it is
148













It is of interest and may be of stereochemical significance 
that the aromatic signals of the major isomer (54b) are higher 
field than the corresponding signals of the minor isomer (54a; see 
Table 13 and Fig. 5).
These differences might arise as a result of the different 
influence of axial and equatorial 3-Me on the preferred 
orientations of the piperidine and 4-aryl rings (see also p. 162).











2't (narrow) *4'dd 
L H L H
54b, base 7.22 6.88 6.83 6.71
in CDC13
(major) (8.8 Hz) (7.8 Hz) (2.3, 2.3 Hz) (8.2 Hz)




(minor) (7.9; 7.9 Hz) (7.9, 7.9 Hz) (2.4, 2.4 Hz) (^1.8, 7.9 Hz)
a. A spectrum of mainly the minor isomer with a trace of the major.

















T— I— I— I— I— J— |— I— I— I I | I I • 1 | * 1 1 1 I 1 : 1 ‘ | 1 1 1 1 I
7 . 2  7.1 7 . 0  6 . 9  6 . 3  6.7 6 . 6
Fig. 5. Partial 1H NMR spectrum (at 270 MHz) of the minor isomer (54a) with
a trace of the major isomer (54b) to illustrate the aromatic chemical 




The H NMR spectra of the major isomer (54b; R =Me as the
2
HC1 in CDClg and R =H; HC1 in D^O) indicated the presence of 
epimeric pairs, with both members of significant population (epimer 
ratio 2:3 in CDCl^, but much greater in D^O) evidence that one 
epimer prefers an axial, and the other an equatorial-3-methyl
conformation (see p. 143 ).
1 2 
The H NMR spectrum of the minor isomer (54a; R =H; HC1 in
D^O) indicated the presence of only a single protonated epimer in
support of the configuration already deduced.
The stereochemistry of l,3,4-trimethyl-4-phenylpiperidine
Only one isomer of (75) was Isolated. Its NMR features were 
similar to those of a single isomer form of LY 109836 provided by
Cq-1', 4-Me and C-5 that these materials had the same configuration 
as in the major 4-aryl-3,4-dimethyl analogues (see Tables 11 and 12
The stereochemistry of the nethiodide salt of (54b)
The methiodide of the major 3-methyl isomer (54b) was also 
1 13
examined. Its H and C NMR spectra provided support for the cis 
3-Me/4-Ar configuration (la) but indicated that the axial 4-aryl 
chair (lb) was the preferred conformation.
13
Dr Dennis Zimmerman. It was deduced from C chemical shifts of







The evidence is as follows:
13
1. The Cq-1' C chemical shift at 143.5 ppm is diagnostic of
an axially placed A r group. A good reference is the Cq-1' chemical
shift of the methiodide of a-promedol, which was found to prefer an
133





2. The C-5 C chemical shift at 31.7 ppm is close to values
found for C-5 in the des-3-methyl methiodide (30.1 ppm). Thus, C-5 
is not subject to steric polarization by 3-Me which implies that 
the latter is equatorially oriented.
3. The N-Me signals (3.12; 3.05 ppm) have chemical shifts
close to values observed for des 3-methyl analogues. For example,
N-Me signals of the des-3-Me (4Me) analogue resonate at 63.20 and 3.02 
ppm, and those of the des 3-Me (4-isoBu) at 3.18 and 3.02 ppm.
These results indicate that the N-Me protons of the methiodide salt 
of (54b) are little influenced by the 3-Me substituent. If 3-Me 
were axial, then the two N-Me shifts would be closely placed, as
158.
found for the methiodide of B-prodinol, shown to prefer an











54c: t-3-Me/4-Ar (minor) I
“ Me
13C Chemical shifts in ppm from TMS
Compound/
Solvent




N-Me OMe Cq-1’ (Ar) Cq-3’(Ar)
54d; base 
in CDClg






































54c; base Me 59.2 38.9 42.0 32.7 51.96 14.6 c 16.4 13.7 46.2 54.8 148.1 159.3 128.6; 119.5;
in CDCljh 113.7; 109.9
a. Data in parenthesis refer to the minor epimer.
b. A s p e c t r u m  of m a i n l y  t h e  m i n o r  i B o m e r  w i t h  a  t r a c e  of t h e  m a j o r  i s o m e r .
c. Unresolved.
Table 15. *H M R  (I scale in ppa) of a- and £-4-Aryl-1,3-dimethy1-4-n-propylpiperidine*
CHpHjMe 


































Me d d d d 0.79d;
7
d d 0.9brt 2.27 3.78s 5'-H: 7.15t; 6'-H: 6.95brd 
(6.82brd)




H d d d d d d d 2.83s - d
54d; base 
in CDClg
H d 1.95m® d d 0.67d;
7





















a. Footnote a from Table 10 (p.133 ) applied.
b. Forms a broad singlet when irradiated the C3-CH^ doublet at 0.73 ppm
c. Footnote b from Table 14 applied.
d. Unresolved signals.
e. Formta broad singlet when irradiated the C3-Me doublet at 0.67 ppm.
f. Unresolved multiplet (1.06-1.22)
II. 4-Aryl-113-dimethy1-4-n-propy1 seri es
Although difficulty was experienced in assigning all NMR 
signals (e.g. a-CH^ of 4-n-Pr and 4-iso-Bu substituents), useful 
stereochemical information was gained.
Utilization of the principles outlined in Section I (p.149) 
in analysis of the stereochemistry of the 4-n-Pr isomeric analogues 
provided conclusive evidence supporting the molecular geometry of 
these isomers.
NMR resonances of stereochemical significance are presented 




' C chemical shifts (ppm) of the major isomer
and the minor isomer (54c)
Compound Free base HC1 salt
Major (OMe) 149.7 d
Minor (OMe)a 148.1 d
Major (OH) 149.1 147.3
Minor (OH) d 147.6 (146.l)b
146.4C (144.9)
a. A spectrum of mainly the minor isomer with a trace of the major 
isomer
b Data in parenthesis refer to the minor epimer
c. Data from a second run
d. Not recorded
It may be concluded that both isomers prefer a common 
equatorial 4-Ar chair conformation (with the possible exception of 
one of the epimers of the minor diastereoisomer).
13Table 17. C-5 C Chemical Shifts (ppm) of the Major Isomer (54d) 
and the Minor Isomer (54c)*
Compound Free base HC1 salt
Des 3-Me 34.8 32.3 (31.3)b
Major (OMe) 26.4 d
Minor3 (OMe) 32.7 d
Maj or (O H ) 26.3 23.0
Minor (OH) d 31.0 (27.0 or
28.5° (27.9)
* Footnotes a, b, c and d from Table 16 apply.
These data provide evidence that 3-Me is axially orientated 
in the major isomer and equatorially oriented in the minor isomer.
NMR Analysis
Ar-Pattern
The free base of the major isomer displayed a pattern 
characteristic of conformation (54d) while that of the minor isomer 
was of type (54c), as presented in Table 18.
Table 18. Characteristic Si NMR (8 scale in ppm) Ar-pattem of the Major isomer (54d) and the minor isomer (54c) 
































a. A spectrum of mainly the minor Isomer with a trace of the major isomer







Evidence so far presented supports the stereochemistry (54d) 
for the major, and (54c) for the minor, 4-propyl derivatives as 
bases.
When NMR spectra of HC1 salts were examined, it was 
surprising that only the spectrum of the minor isomer showed the 
presence of a pair of significantly populated epimers (cf. p. 143). 
In the previous argument in regard to epimer populations, only the 
case of 4-methyl derivatives was considered. It is known from study 
of des 3-methyl analogues that preference for chairs with 
equatorial 4-alkyl substituents rises with increasing size of the
4-substituent. Epimer formation in 3-methyl-4-alkylpiperidines 
where 4R = propyl and isobutyl will now be considered.
In derivatives with axial 3-Me, axially protonated epimers 
(I; obtained exclusively; Scheme 41) are highly preferred due to an 
absence of 3-Me/4-R interactions and the unfavourable interactions 
that obtain in the equatorially protonated epimer (II; Scheme 41). 
Conformer (Ila) is unfavoured by the N-Me/3-Me syn diaxial 
interactions and its invertomer (lib) by 3-Me/4-R interactions which 
will be significantly greater than the 3-Me/4-Me interactions of the 















On the other hand, the equatorially protonated epimer of 
type (I, Scheme 42) may invert to a chair in which the 4-R group 







_  .OR1 
Ar
"  "  i n
Thus, it may be anticipated that epimers (I/II and III; 
Scheme 42) will both be significantly populated when the equatorial
3-Me base is protonated, providing a bulky substituent (>Me) is 
attached to C-4.
Protonated epimers
1 2 The H NMR spectra of the major 4-n-Pr isomer (54d; R =Me as
2
the oxalate and R =H as the HC1) indicated the presence of only one
2
N-protonated epimer, while that of the minor isomer (54c; R =H;
HC1) indicated the presence of two significantly populated epimers, 
evidence in support of equatorial 3-Me (54c).
In the NMR spectrum of the minor diastereoisomeric salt, 
duplication of N-methyl, 3-methyl and 4-CH^CH^Me resonances was 
clear. Relative intensities indicated an epimer ratio of about 1:1. 
The lower field N-Me chemical shift (2.89 ppm) was close to that of 
the major diastereoisomeric salt (N-Me; 2.87 ppm), both values 






The N-methyl shift of the second epimer (B; 2.66 ppm) is 
evidence that this arises from an equatorially protonated base 

















Of the dual 4-CH^CH^Me triplets (0.98, 0.64 ppm),that at
higher field is assigned to epimer (B) and that at lower field to
epimer (A). Likewise the lower field 3-Me doublet (1.24 ppm) is
assigned to (B) and the doublet at 0.70 ppm to eq 3-Me of (A).
Reasons for these assignments are explained in relation to
analogous 4-isobutyl epimers (p. 177 ).
13
Duplicated C NMR signals may also be assigned in terms of
13
the epimers (A) and (B). Cq-1' C shift (146.4 ppm) is assigned to
epimer (A), while that at 144.9 ppm is assigned to epimer (B). The 
13
C-5 C shift at 31.0 ppm is assigned to epimer (A) and that at
26.5 (27.0) ppm is assigned to epimer (B), at higher field because 
it is sterically compressed by axial 3-methyl.
The a-CH^ signals at 42.4 and 27.0 (26.5) ppm are assigned 
to epimer (B) and (A) respectively and both are sterically 
compressed by 3-Me (cf, des 3-methyl HC1 epimers, 55f.t p. 135).








*2C Chealcal shifts In ppa froa TKS
Coapound/
Solvent
R2 C-2 C-3 C-4 C-5 C-6 C3-Me 4-isobutyl
ch2 ch n.2
N-Me OMe Cq-1*(Ar) Cq-3'(Ar)
54k; base 
In CDC13
Me 59.6 b 42.6 31.9 52.1 14.7 c 23.6 24.9;
24.8











































































H 56.3 39.0 41.3 26.4 51.0 16.2 45.8 24.3 25.2;
24.6




H 56.2 37.3 40.0 23.35 50.6 13.65 44.3 23.7 23.8 43.2 - 147.5 155.3 129.2; 118.5; 
113.3; 112.6
a. Data In paranthasia rafar to the ainor aplaar.
b. Broad atpal at 36.7 ppa or overlapped with N-Me algnal at 46.4 ppa.
e. unresolved overlapped algnal at 31.0 ppa.
e. A apectrua of aainly the alnor laoaer with a trace of the aajor 
laoaer
f. Data In parentheala refer to the aajor laoaer froa the alxture 
described In footnote e (leaa Intense than those of the alnor 
laoaer).
d. Slpal at 22.0 ppa overlapped with that of £-£H at 22.8.
g. Signals overlap at 52.1 ppa.
Table 20. OaNBtariatlo hi M l  (| aoala la ppa) of g- and ^ -4-Aryl-l ,3-dlaethyl-4-(2-aethylpio|>-l-yl)piperldlne*
54k: t-3-Me/4-Ar 
(major)













He b 0.96d b b 0.71d; 6.6 2.19a 3.8 5'-Hs 7.21t; 6'-H: 6.98d; 
2'-H: 6.96brs; 4'-H: 6.72dd
54k; HC1 In 
D2°














5'-H: 7.30t (7.22); 6'-H» 6.98 





















2.32s - 5'-H: 7.lit; 6*-H: 6.74brd; 
2'-H: 6.68t; 4'-H: 6.60dd
64J; HC1 
In D20






2.85s - 5'-H; 7.24t; 6*-H: 6.89brd; 
2'-H: 6.80t; 4'-H: 6.74dd
a. Footnota a froa Table 10 (p.ill ) applied.
b. Unresolved signal.
o. Unreaolved duplicated Ar algnala 6.75-7.20 ppa.
d. Identified by a COSY plot and forms a broad singlet when Irradiated the 
C3-CHg doublet at 0.63 ppa.
e. Identified by a COSY plot and foraa a broad alnglet when irradiated 
the C3-€Hg doublet at 0.67 ppa.
,172.
III. 4-Aryl-l,3—dimethyl-4-isobutyl series
Characteristic stereochemical features are presented as 
before in Tables 21, 22 and 23; these features were utilized to 
deduce the stereochemistry of the isomeric pairs encountered in 
3-methyl-4-isobutyl derivatives. Difficulty in assigning all NMR 
signals was also met in this series.
13
Table 21. Cq-11 C chemical shifts (ppm) of the major isomer (54k) 
and the minor isomer (54j)
Compound Free base HC1 salt
Major (OMe) 148.1 144.4 (146.5)°
Minor3 (OMe) b d
Major (OH) 147.9 144.0 (146.5)
Minor (OH) 149.0 147.0
a. A spectrum of mainly the minor isomer with a trace of the major 
isomer.
b. Unresolved.
c. Data in parenthesis refer to the minor epimer.
d. Not recorded.
From these data, it is probable that both bases prefer 
equatorial 4-Ar chair conformations, as does the minor 




Table 22. C-5 C chemical shifts (ppm) of the major isomer (54k) 
and the minor isomer (54j)
Compound Free base HC1 salt
Major (OMe) 31.9 30.2 (27.4)b
Minor3 (OMe) 26.6 c
Major (OH) 31.6 27.5 (30.2)
Minor (OH) 26.4 23.4
a. A spectrum of mainly the minor isomer with a trace of the major 
isomer.
b. Data in parenthesis refer to the minor epimer.
c. Not recorded.
This evidence is in support of an equatorial 3-Me chair for 








1H NMR spectra of both isomers (HC1 salts, free base of the 
minor isomer and both epimers of the protonated major isomer) 
displayed duplicated signals with pronounced chemical shift 
differences for the terminal methyl groups of the 4-isobutyl 
substituent, evidence that protons of these two methyl groups are 








( 2 x 3  proton doublets)
1. 1H C3-H
In the minor isomer, irradiation of the C3-Me doublets
2
(R =H; free base at 0.63; HC1 at 0.67) resolved the C3-H multiplets
at 1.9 ppm and 2.3 ppm respectively into broad singlets. Therefore,
the C3-H has an equatorial orientation and the C3-CHg an axial
conformation in the minor series.
The C3-H resonances of the major isomer (free base and HC1
salt) were not resolved and appeared as a part of complex
2
multiplet. However, that of the major epimer (R =H, HC1) was 
identified as a multiplet at 2.8 ppm by a COSY experiment and 
subsequent spin decoupling of the corresponding 3-Me doublet caused 
this multiplet to reduce to broad singlet, evidence that the major 
epimer has an axially orientated 3-Me (see later).
2. 1H Ar-Pattern
The free base of the major isomer displayed a pattern 
characteristic of (54k), while that of the minor isomer was 
characteristic of (54j; free base) as outlined in Table 23.
Table 23. Characteristic ( 6 scale in ppm) Ar-pattem of (54k) and (54j)
Compound/ 5' t 6 'brd 2 ’t (narrow) 4'dd
Solvent L H L H L H L H
Major (OH), 7.12 6 .86a 6.87a 6.63
base in
CDCl3(54k) (8 .2,8 .2 Hz) (7.0 Hz)
Minor (OH), 7.11 6.74 6 .68a 6.60
base in
CDC13 (54j ) 17.9,7.9 Hz) (8.2 Hz) (7.3 Hz)
a. Unresolved
From evidence already presented it may be deduced that the
major base has the stereochemistry (54k). The fact that NMR spectra
of HC1 salts were typical of epimeric mixtures (see Fig. 6 ) adds
further weight to this assignment (see arguments cf. p. 164 ).
Figure 6 clearly shows duplication of signals due to 3-methyl,
terminal methyls of 4-isobutyl (pairs of doublets due to
non-equivalent methyl in each epimer) and N-methyl. Assignments of
these signals were possible from COSY and spin decoupling
13 1
experiments. From differences between the C and H chemical 
shifts of corresponding epimeric signals, the following 





a. 13C-5 has C chemical shift (30.2 ppm) typical of equatorial
3-methyl derivatives.
b. ®-CH2 higher field (32.4 ppm) than a-CH^ of des 3-Me 
analogue (43.6) because compressed by eq 3-Me.
13
c. Sterically compressed by 4-isobutyl; therefore C chemical 
shift at higher field (11.5 ppm) than 3-Me of minor 
diastereoisomer HC1 (13.0 ppm).
d. 1H N-methyl signal (2.89 ppm) lower field than that of major 
epimer (2.62 ppm) and characteristic of equatorial N-Me.
e. 3-methyl (0.86 ppm) and CH^CH(Me)^ (0.58, 0.7 ppm)
signals higher and lower field respectively of major signals 




/  f Ar b
preferred
13a. C-5 C chemical shift (27.5 ppm) approaches value seen in 
minor diastereoisomeric salt (axial 3-Me).
179.
13
b. a-CHg C resonance moves to lower field (49.2 ppm) when it
has an equatorial placement.
13c. 3-Me C resonance (13.0 ppm) close to 3-Me of minor 
diastereoisomeric salt.
d. *H N-methyl signal higher field than that of minor epimer 
because of receipt of axial N-methyl contribution
(see p. 135 ).
e. resonances of 3-Me (1.21 ppm) and 3-H (2.30 ppm) are
lower field than corresponding signals of the minor epimer 
because they fall directly in the deshielding zone of the 
aryl ring when it is axial (see A).









In conformation (A), as the 4-isobutyl group rotates about 
the 04-0-0^ bond, the terminal methyls fall within the shielding 
zone of the aromatic ring and hence resonate at higher field 











Fig. 6. H NMR spectrum of major 4— (3—hydroxyphenyl—1,3—dimethyl—4— (2—methylprop—1—yl)piperidine 
hydrochloride (54k).
2.4 Pharmacological Evaluation and Concluding Remarks
Phenolic analogues of some 4-alkyl-l,3-dimethylpiperidines 
and corresponding des 3-methyl analogues (except the 4-methyl 
derivative) and the phencyclidine derivatives (±)- (69g; 0A8),
(69h; 0A14), (69j ; 0A13), (+)- (69g; 0AD7) and (-)- (69g; 0AL7), 
in addition to compound (99; 0A92), related to ketobemidone, 
have been synthesised and submitted (as the HC1 salts) for 
pharmacological evaluation (ij^  vivo and in vitro) as either narcotic 
agonists or antagonists. These tests were carried out in laboratories 
of Janssen Pharmaceutics (JP) and the National Institutes of Health 
(NIH), Bethesda, USA.
2.4.1 JP Data (In Vivo)
Agonist (morphine-like) activity was assessed in rats by
the tail withdrawal test (TWR). This procedure involves immersing
the end of the tail of a rat in warm water at 55°C. The response,
typically tail withdrawal, is timed before and after intravenous
(iv) administration of the test compound. The ED__ (mg/kg) of the
50
test compound can be determined as that dose which inhibits tail
149
withdrawal in 50% of the rats.
Antagonist (naloxone; nalorphine-like) activity was assessed 
in rats treated with fentanyl. Fentanyl is injected subcutaneously 
(sc) at the very high dose of 0.63 mg/kg which results in pronounced 
respiratory depression, loss of righting reflexes, lead pipe 
rigidity and blockade of the pinna and cornea reflexes. The
test compound is then given intravenously (over a range of dose
levels) and the dose needed to reverse the various effects of
149
fentanyl can be assessed.
2.4.1.1 Des 3-methyl derivatives

















2.5 3/3 positive 
0.63 0/3 positive
Estimated ED_- 1.25 
50




From these data it can be concluded that both 0A1-16 (4-Pr) 
and 0A1-35 (4-isoBu) are 2-3 times more potent than morphine in 
the TWR test.
Results from three independent sources quoted a similar
order of analgesic potency for the 4-Pr derivative (see below).




Loew et al. (1988) reported agonist E D „  (mg/kg) values —  ——  bU
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1.0 (0.5-2.1) 0.9 (0.5-1.6 ) writhing sc
3.0 (1.8-4.7) 2.8 (1.7-4.6 ) tail-flick sc
0.06 (0.03-0.15) 0.9 (0.4-2.1) tail-flick icv
In 1978 Zimmerman et al. reported that the 4-Pr derivative
88
was about two times as active as morphine in rats and in mice.
General agreement amongst the three sets of data on the
4-Pr derivative can be concluded.
b. Antagonist activities
Apart from one result for 0A1-16, the 4-Pr and 4-iso-Bu 
derivatives failed to reverse fentanyl induced effects in rats 





















ineffective at 2.5 mg/kg
ineffective at 10 mg/kg
ineffective at 2.5 
and 10 mg/kg
2.5 mg/kg 3/3 positive
0.63 mg/kg 0/3 positive
Estimated ED_rt 1.25 mg/kgbu
ineffective at 2.5 mg/kg
slight analgesia at 
10 mg/kg
Estimated ED 10 mg/kg
Activity values reported by Zimmerman et al. (see p. 40) 
for the isomeric 4-methyl and 4-propyl derivatives agree in general 
with the present findings.
b. Antagonist activities












Antagonist activities (reversal of 
fentanyl induced effects)
An effective antagonist of fentanyl
2.5 and 0.63 mg/kg. Reverses respiratory 
depression at even lower dose levels 
(0.16, 0.04 mg/kg). Approaches value of 
naloxone in regard to reversal of 
respiratory depression (see standard data 
below). Zimmerman reported the compound 
to possess 1/10 the activity of naloxone 
in rats and mice.
Some effect at 10 mg/kg in 2 out of 3 
rats, no respiratory depression, no loss 
of righting reflexes, no rigidity, but 
blockade of cornea and pinna reflexes 
unrelieved. Ineffective at 2.5 mg/kg. 
Zimmerman reported this isomer to be a 
very weak antagonist.
ineffective at 2.5 mg/kg.
ineffective at 2.5 mg/kg (positive 
response in one out of three rats on 
respiratory depression).
ineffective at 2.5 mg/kg.
cis 3-Me/4-isoBu
Standard Reference Data
Effective ED __ values (mg/kg, iv)
50
Effect Nalorphine Naloxone
respiration, depression — 0.04
loss of rigidity reflexes - 0.04
Rigidity 0.63 0.02
Pinna reflex 0.63 0.02
Cornea reflex 5.0 0.04
Analgesia 2.5 0.04
2.4.2 NIH Data
2.4.2.1 In Vitro Experiments
a. Binding Experiments
Aliquots of a membrane preparation from rat cerebellum were
3
incubated with H-etorphine in the presence of 150 mM NaCl and
different concentrations of the test agent. Specific binding was
determined as the difference obtained in the absence and presence
of excess of unlabelled etorphine. The potency is expressed as
that concentration required to display half the specific binding
of the radioligand (EC... in nM). The EC,.- of morphine is about
oU dU
3
23.6 nM when using 0.5 nM of H-etorphine.
b. Mouse Vas Deferens (MVD)
This procedure involves treatment of an isolated, electrically
stimulated mouse vas deferens with different concentrations of the
test compound. The EC__ (nM) can be determined as that concentration
50
which produces 50% inhibition of twitches. The EC_. can also be
50
determined in the presence of a selective delta receptor antagonist
(an ICI peptide), a non-selective opiate antagonist (e.g. naltrexone)
or a di-antagonist (e.g. $-furaltrexamine: 0 -FNA). The EC__ for
— — 50
_7
morphine is about 3.95 x 10 (395 nM).
In the case of antagonists, pA^ values were determined 
in some cases. The pA^ value is the negative logarithm of that 
dose of antagonist that converts the action of a double dose of 
agonist to that of a single dose.
189
Table 24. Binding (EC__, nM), MVD (EC„) andpA data of some
50 oU 2
4-alkyl-4-arylpiperidines
















Action blocked by naltrexone and
B-FNA, but not by the ICI compound.(ICI 174864,
5-antag )
This compound approaches the potency
of morphine as ay-agonist.
MVD: inactive as agonist and behaves
as antagonist
pA^: 6.91 (y) vs Sufentanil
5.92 (5) vs DSLET
6.43 (<) vs 50488H
MVD: inactive as agonist and behaved
as antagonist
pA2 : 6.14 (y)
6.47 (6)
5.52 U )
MVD EC__: 1.31 x 10”7 
bO
Has opioid action at a lower dose 
than morphine but lacks antagonist 
action
pA2 : 5.63 (y )
6.23 (6)
5.66 ( <)
contraction of the abdominal musculature accompanied by extension 
of the hind limbs). Mice are injected (sc) with the compound under 
test, and then phenylquinone is injected (ip) 20 minutes later. The
ED__ (mg/kg) to inhibit the writhing response in 50% of the test
50
sample cam hence be determined.
d. The Hot-Plate Test (MHP)
This test involves the placing of mice on a hot-plate
maintained at 57 ± 5°C. Signs of discomfort are shown by the mouse
sitting up on its hind legs and licking or blowing its front paws.






















11% at 1.0 













15% at 10.0 
17% at 1.0 





















The 4-Pr derivative 0A1-16 displayed 2-3 and 10 times the 
activity of morphine, respectively in the TWR and TFM tests,
gg^gj
results in general agreement with published work, although
the potency values of 0A1-16 in mice were higher. In the
writhing test the potency of this analogue fell below that of
morphine. The 4-iso-Bu analogue 0A1-35 and the major 4-isoBu
analogue 0A1-33B (t-3-Me/4-Ar) were as effective as 0A1-16
in the TWR test, although less so in the TFM procedure. The
minor 4-iso-Bu analogue 0A1-33T (c-3-Me/4-Ar) and all other
derivatives examined had low orders of antinociceptive activities.
The ijri vitro data complemented these findings. Although
insufficient minor 4-Pr (t-3-Me/4-Ar) was isolated for pharma-
88—91
cological evaluation, Zimmerman et al. found this
compound (Picenadrol) to be an agonist in rats (TF) and in 
mice (WR) with potencies about half those of morphine.
It appears significant that all potent 4-arylpiperidine 
analogues of this class exhibit a preference (50% or above) 
for axial 4-aryl chair conformations (558) when protonated, 
as established by NMR studies.
OH
(559)
These results support the view that 4-arylpiperidine opioid
ligands bind to the opioid receptor in a manner similar to that
of morphine and its congerers and mimic the geometry of the
156
4-arylpiperidine moiety of the polycyclic molecules. The
most direct analogy is with benzomorphan analgesics (13),
129
as pointed out by Loew et al.
(13)
Thus,several C-9 unsubstituted N-methyl derivatives of (13)
have been reported with lower alkyl substituents attached to
C-5. The 5-methyl derivative had a codeine-like potency but
5-ethyl, 5-n-Pr and 5-n-Bu analogues all had about one half
157 158the activity of morphine in mice by the MHP test. * The
low activity of a trans 5-butyl derivative (non-phenolic
however) may correlate with the weak antinociceptive properties
of the 4-butylpiperidine (110, 1/9 x morphine in the TFM,
129
1/6 x morphine in the WRM). Both 9-methyl-5-n-Pr diastereo- 
isomers of (13 ) were active (£: 10 x morphine, a: 0.5 x 







(13  ^ R= n-Pr
(13b) R= CH,
The active 4-arylpiperidines 0A1-8B (t-3-Me/4-Ar) and
0A1-33B (t-3-Me/4-Ar) closely mimic the geometry of £-
(13a) in one of their preferred solute conformations
(protonated state).
In benzomorphans such as metazocine (5, 9 -dimethyl; 13b)
and (13a), absolute chirality has a dominant influence upon 
159
activity. Thus most of the activity of (±)-(13b) resides
14
in the laevo isomer. It is of interest, therefore, that 
antipodal forms of picenadrol (0A1-8B; t-3-Me/4-Ar) differ
88—91
substantially in potency [(-) 0.1 x morphine, (+) = morphine], 
results which will have even greater import once the absolute 
configurations of the antipodes have been established.
The only compound found to display prominent activity as 
an opioid antagonist was the cis-diastereoisomer 0A1-10T, which 
reversed all actions of fentanyl in rats at dose levels of
2.5 and 0.63 mg/kg, and effectively countered respiratory 
depression at even lower dose levels (it approached the 
potency of naloxone in this respect). The compound was also
characterised as an antagonist in the MVD with a pA^ of 6.91 (p ).
The corresponding trans isomer 0A1-8B (54c) was a much.weaker
antagonist versus fentanyl in rats. Neither isomer behaved as
an agonist in the TWR test. Results for the cis-isomer 0A1-8T (54d)
confirm the earlier report of its antagonism of opioids in rats
88—91
and mice (vs morphine) . Both cis diastereoisomers of the
4-Pr and 4-iso-Bu analogues displayed weak antagonistic action 
in the MVD. However,the latter reversed fentanyl-induced 
respiratory depression in one out of three rats at a dose 
level of 2.5 mg/kg.
198.







a. Agonist Activity (TWR):
b. Antagonist Activity:
NIH Data
In vitro Experiments i.
ii.
iii.
ineffective at 2.5 mg/kg 
ineffective at 2.5 mg/kg 
in reversing fentanyl- 
induced effects in rats
EC__: 1399 nM (Binding)
DU
MVD: inactive at all
concentrations tested 
(10”9 - 3 x 10”4 nM)
Behaved as an antagonist 
pA2 : 7.09 (U)
6.39 (6 )
5.94 (k )



















0A-L7 : (-) - (69g)
inactive at 2.5
2.5 (1 out of 3 rats)
1.25
inactive at 2.5
Morphine 3.15 (1981 data)
200.
2. NIH Data
a. In Vitro Experiments
Compound Binding EC^^nM) MVD
OA-8 680 14.2 x 10~7 (99.2 ± 8
inhibition)
The action blocked by 
Naltrexone and 8_-FNA, but 
not by ICI compound
Pethidine 6000' inactive
_7
Morphine 23.6 3.95 x 10
OA-8 binds less well than morphine and far less effective on MVD.








0% at 1 .0 , 
14% at 10, 
34% at 30




at 1.0 ; 
10; & 20 
inactive 
at 30
PPQ Writhing HP 
1.2(0.5-3) 0% at 20
and 5
0.7(0.3-2.1) 16% at 20




The a-racemate (69g) is about three times more effective
than morphine and six times more effective than pethidine in
this test. Comparative TWR data for the 3-desmethyl analogue
113(62g, about 2 times the activity of morphine in MHP test) is
not available. The absolute configuration of the C-3 chiral 
centre has the same influence in the PCP derivative (69g) and 
a-prodine. Structure-activity relationships of the two series 
differ however in respect of 1 ) the relative activity of 
a- and B-diastereoisomers: £- the more active prodine, a- 
the more active PCP analogue and 2) the importance of 
O-acylation: vital for activity in the case of the prodines, 
a_-acetoxy ester less active than the a-4-piperidinol in the 
PCP derivatives.
NIH Data
The a-racemate (69g) was less effective in mice by TF 
and writhing test procedures than it was in rats by the TW 
assay. It was half as effective as pethidine in the TF 
test and equipotent in the writhing test, while compound 




^H-NMR spectra were recorded on a JEOL GX270 MHz Fourier 
Transform (FT) NMR Spectrometer unless otherwise stated. The 
following abbreviations are used to describe resonance appearance 
in the ^H-NMR spectra: singlet, s; doublet, d; triplet, t; quartet, 
q; multiplet, m, plus combinations such as dt, doublet of triplets;
dd, doublet of doublets; br, broad; eq, equatorial and ax, axial.
13
C-NMR spectra were recorded on a JEOL GX270 FT NMR 
Spectrometer operating at 67.8 MHz unless otherwise stated. The 
multiplicity of the resonances was obtained from DEPT 
(Distortionless Enhancement by Polarisation Transfer); when 135 
DEPT is applied, CH and CH^ carbons will give positive signals, CH^ 
carbons will be negative and quaternary carbons will be absent, 
while only CH carbons will give positive signals when the 90 DEPT 
is applied.
The Infra-red spectra (liquids as films, solids as KBr discs 
or Nujol mulls) were recorded on a Unicam SP1020 Spectrometer.
Mass spectra were measured on a VG Micromass 7070E Mass 
Spectrometer operating at 70 ev El.
Elemental analyses were carried out by Butterworth 
Laboratories Ltd., Middlesex and Department of Chemistry,
University of Bath.
Melting points were recorded on a Gallenkamp apparatus, and 
are uncorrected.
Optical rotation readings were recorded on an Optical 
Activity Ltd., AA-10 Polarimeter, at four different wavelengths 
including the sodium D line (see appropriate table).
3.2 PHENCYCLIDINE DERIVATIVES DERIVED FROM a— AND B-PRODINE
3.2.1 Methyl 3-methy 1 amIno-2-methylprop ionate (64)
A solution of methylmethacrylate (302 g) in absolute alcohol 
(180 ml) was added slowly with stirring to a cooled solution of 
methylamine (200 ml; 33% w/v in IMS) over a period of three hours. 
After standing for 3 days the ethanol and IMS were evaporated 
in vacuo and the product was fractionally distilled under reduced
pressure to give the title compound (150 g; 57%) as a colourless
118
mobile oil, b.p. 69-72°C/28 mm (Lit. b.p. 65-68°C/20 mm).
O
-l »
v : 1740 cm (-C- str)
max
6 (CDC10; free base):
n 3
1.17 (3H; d; CH-CH3 ), 2.40 (3H; s; HN-CH3); 2.60 - 2.80 (6H; m; 
CH-CH3 ; HN-CH2 ), 3.67 (3H; s, C00-CH3 ).
«c (CDC13 ; free base):
CH, - N
204.
3.2.2 3 [ N-methyl-N- (2-ethyloxycarbonylmethyl) amine ]propionate (65)
A mixture of methyl 3-methylamino-2-methy1 propionate (64;
148 g) and ethyl acrylate (114 g) was left for five days in the
dark. The resulting liquid was fractionally distilled under reduced
pressure to give the title compound (170 g; 78%) as a colourless
118
oil, b.p. 138-139°C/20 mm (Lit. b.p. 105-107/2.0 mm).
O o
l , H(-C-OMe str)-1 11v : 1725 cm (-C-0C.H_ str), 1740 cm 
max - 2 5
H ' 3 ’
1.06 (3H, d; CH-CH3 ), 1.21 (3H; t; -CH CHg), 2.18 (3H; s; N-CH3 )t 
2.21-2.62 (7H; m; -CHg-CH; N-CH2CH2 ), 3.59 (3H; s; -0CH3 ), 4.05 
(2H; q; -0CH2CH3 ).
(CD01o ; free base): 
n










170 g) was added dropwise to a stirred suspension of bird-shot
sodium [prepared from sodium (17 g) in dry xylene (396 ml)], and
heated gently to maintain the temperature at 60°C. When the initial
reaction had subsided, the mixture was refluxed for 3 hours, by
which time all the sodium had disappeared. The resulting dark
liquid was cooled and added with stirring to ice-water (570 ml).
The aqueous layer was separated, washed with ether (2 x 100 ml) and
acidified with conc. HC1. After refluxing for four hours the
initial vigorous evolution of CO^ became negligible. The product
was concentrated iji vacuo to small bulk, made alkaline with solid
KOH, the aqueous layer saturated with NaCl, and the dark oily layer
then extracted with ether (8 x 250 ml). The organic layer was dried
(MgSO^), evaporated under reduced pressure, and the product
fractionally distilled in vacuo to give the title compound (60 g;




v : 1750 cm (-C- Str) 
max —
6 (CDC1-; free base):n o
0.92 (3H, d; C3-CH3 ), 1.94-2.18 (3H; m; C3-H; C5-H), 2.24 (3H; s; 
N-CH3 ), 2.95-3.28 (4H; m; C2-H; C6-H)
206.







3.2.4 a- and &-lt3-Di»ethyl-4-phenyl-4-prop ionoxypiperidine
1 ,3-Dimethyl-4-piperidone (63; 60 g) was added dropwise to a 
stirred solution of phenyl lithium [prepared over one hour from 
lithium (12.2 g) in dry ether (500 ml) and bromobenzene (136 g)]. 
After stirring for 24 hours at room temperature, the mixture was 
added to a mixture of crushed-ice (1000 g) and glacial acetic acid
(105 ml). The aqueous layer was separated and washed with ether 
(3 x 100 ml; discarded), then basified with strong aqueous ammonia, 
extracted with ether (5 x 300 ml), dried (MgSO^) and evaporated 
in vacuo to give an oil. This oily isomeric mixture was diluted 
with petroleum ether (pet. ether b.p. 60-80°C) and the resultant 
solid was recrystallised from dry ether to give the pure a-isomer 
(68; 70 g; 72%). The pet. ether and ether filtrates were evaporated 
in vacuo to give an _a • J  mixture (1 :1.2 ; 16 g; overall recovery 
89%), as an oil.
Propionyl chloride (79 g) was added dropwise to a stirred 
solution of the a-isomer obtained above (70 g) in dry toluene (610 
ml) and the reaction mixture was refluxed for six hours. The 
product was cooled, filtered and washed with dry ether to give the 
a- isomer of the title compound as the hydrochloride (40; 75 g, 
86%), m.p. 217-219°C (ethanol-ether), (Lit.^7 m.p. 220-221°C ).
O
v : 1752 cm (-C- Str). 
max —
6 : see Table 8 . p. 61 
n
see Table 7. p. 59
The same procedure described for the esterification of the 
a_-isomer was repeated on the a, _3-isomer mixture (16 g) obtained 
above, in dry toluene (135 ml) using propionyl chloride (18 g) to 
give the title product as the hydrochloride (21.3 g; 91%). 
Fractional recrystallisation of the hydrochloride salt from
ethanol-ether gave pure a-isomer (6.0 g; 26%). The filtrate was 
evaporated in vacuo and recrystallised again from ethanol-ether to 
give a mixture of a- and £-isomers (3.2 g). Finally, the filtrate 
was evaporated in vacuo and recrystallised from ethanol-ether to 




v : 1750 cm (-C- Str.). 
max —
5 : see Table 8 . , page 61.
H
6 : see Table 7.* page 59
3.2.5 o-4-Hydroxy-3-methyl-4-phenylpiperidine (69c)
A suspension of a-1,3-dimethyl-4-phenyl-4-propionoxy- 
piperidine (40; 20 g), 2,2,2-trichloroethylchloroformate (26 g) and 
K^COg (5.5 g) in dry toluene (250 ml) was refluxed for 2 hours, and 
then stirred at room temperature for 24 hours. The reaction mixture 
was diluted with CHCl^ (500 ml), washed with NaOH (2N; 2 x 50 ml), 
water (2 x 50 ml), HC1 (2N; 2 x 30 ml) and finally water 
(2 x 100 ml). The organic layer was dried (MgSO^) and evaporated in 
vacuo to yield a-3-methyl-4-phenyl-4-propionoxy-l-(2,2,2-trichloro- 
ethylcarbonyl) piperidine (69 ; 25 g; 78%), as sin oil. The oil was 
diluted with pet. ether (b.p. 60-80°C), and the solid that settled 
recrystallised from the same solvent to give the product as a 
colourless solid, m.p. 158°C.
209.
-1 I' -1 11
v : 1740 cm (-C- Str.), 1770 cm (N-C- Str.). 
max — —
Zinc dust (12.5 g) was added portionwise to a stirred 
solution of (69 ; 25 g) in glacial acetic acid (400 ml; 99%). The 
reaction mixture was refluxed for two hours, and then stirred at 
room temperature for 10-12 hours. The solid was filtered off and 
washed with methanol. The organic solvents were evaporated in 
vacuo, and the oily residue dissolved in dichloromethane (DCM;
400 ml). This was washed with NaOH (2N; 3 x 50 ml), water (2 x 
70 ml) dried (MgSO^) and evaporated dji vacuo to give a-4-hydroxy- 
3-methyl-4-phenyl-l-propanoylpiperidine (69a; 5.9 g; 39%), as an 
oil, which was diluted with ether and the resultant solid 
recrystallised from the same solvent to give the product as a 
colourless solid, m.p. 154-155°C.
-1 11
v : 1640 cm (-C- Str.). 
max —
6 : see Table 8 . p. 61 
H
6 : see Table 7. p. 59
m/z: Mf 247 (85%), 205 (21%), 190 (84%), 105 (89%), 99 (80%), 57
(100%), see Scheme 6 ; p. 69 •
Found: C, 72.56; H, 8.84; N, 5.62%
C1c.Ho1N0- requires: C, 72.84; H, 8.56; N, 5.66% 
lb d.
KOH (5 g) was added portionwise to a stirred solution of the
a-amide (69a; 5 g) in isopropanol (60 ml), and the reaction mixture
refluxed for 48 hours. The resulting solution was cooled and the
isopropanol evaporated iji vacuo. DCM (50 ml) was added to the oily
residue and the liberated inorganic salt filtered off and washed
with DCM (50 ml). The combined organic layer was extracted with HC1
(2N; 2 x 20 ml), and the aqueous layer basified with strong aqueous
ammonia, extracted with CHCl^ (3 x 40 ml), dried (MgSO^) and
evaporated dji vacuo, to give the title compound (2g; 51%) as an
oil. The oil was diluted with pet.ether (b.p. 60-80°C), and the
resultant solid recrystallised from the same solvent to give the
154
title compound as a colourless solid, m.p. 130-131°C (Lit. m.p. 
125-126°C).
5 : see Table 8 . P« 61.
H
*5^,: see Table 7. p. 59.
m/z: Mf 191 (100%), 173 (70%), 149 (72%).
Found: C, 63.10; H, 7.88; N, 6.12%.
C12H18N0C1 re^uires: c * 63.30; H, 7.97; N, 6.15%.
3.2.6 a-1- (1-Cyanocyclohexyl) -4-hydroxy-3-methyl-4-phenyl-
piperidine (69e)
To a solution of o-4-hydroxy-3-methyl-4-phenylpiperidine 
(69c; 4 g) hydrochloride in water (30 ml) was added a few drops of 
dilute hydrochloric acid. Cyclohexanone (2 ml) was added and, while 
stirring vigorously, sufficient alcohol (1 ml, 95%) was added to 
give a homogeneous solution. A solution of KCN (1.8 g) in water 
(10 ml) was added dropwise, and vigorous stirring continued at room 
temperature for 72 hours. The resulting mixture was basified with 
NaOH (5N) and extracted with CHClg (4 x 50 ml). The organic layer 
was dried (MgSO^) and evaporated in vacuo to give the title 
compound (3.5 g, 67%) as an oil. The oil was triturated with pet. 
ether (b.p. 60-80°C) and the resultant solid was recrystallised 
from the same solvent to give the product as a colourless solid, 
m.p. 138°C.
$H : see Table 8 . p. 61.
6C : see Table 7. p. 59.
m/z: Mf 298 (28%), 271 (100%), 255 (85%), 105 (52%), 27 (31%).
Found: C, 65.58; H, 8.72; N, 9.00%.
C17H27N20C1 recluires: c » 55.68; H, 8.75; N, 9.01%.
3.2.7 a-4-Hydroxy-3-methyl-l- (1-phenylcyclohexyl) -4-phenyl-
piperidine (69g)
A solution a-l-(l-cyanocyclohexyl)-4-hydroxy-3-methyl-4- 
phenyl-piperidine (69e; 2.5 g) in dry THF (15 ml) was added 
dropwise to phenyl .magnesium bromide [prepared from Mg (1.8 g) and 
bromobenzene (11 g) in dry THF (100 ml) ]. The reaction mixture was 
refluxed for 2 hours, and then stirred at room temperature for 24 
hours. The resulting mixture was diluted with ether (200 ml) and 
added to a mixture of crushed ice (100 g) glacial acetic acid 
(15 ml). The organic layer was separated and washed with NaOH (3N;
3 x 30 ml), dried (MgSO^) and evaporated in vacuo to give the title 
compound (2.3 g, 76%) as an oil. Treatment of the oil with 
ethereal-HC1 gave the hydrochloride m.p. 230-231°C (methanol).
6 : see Table 8. p. 61.
H
6^: see Table 7. P» 59.
m/z: Mf 349 (49%), 306 (100%), 160 (22%), 91 (47%), 42
(11%), see scheme 11; p. 77 .
Found: C, 73.12; H, 8.15; N, 3.40%.
C24H32N0C1*^H2° recluires: c 73*02; H » 8 *17; N » 3.55%.
3.2.8 a-4-Acetoxy-3-methyl-l- (1-phenylcyclohexyl) -4-phenyl- 
piperidine (69J)
Acetyl chloride (15 ml) was added dropwise to a stirred 
solution of a-4-hydroxy-3-methyl-l-(1-phenylcyclohexyl)-4-phenyl- 
piperidine (69g; 0.5 g) in dry THF (10 ml), and the reaction 
mixture was refluxed for 12 hours. The resulting solution was 
cooled and the excess acetyl chloride and THF were evaporated 
in vacuo to give the title compound as the hydrochloride salt (0.3 
g; 60%), m.p. 210-213°C (ethanol-ether).
O
-1 H
« : 1760 cm (-C- Str.).
max —
5 : see Table 8. p. 61.
H
see Table 7. p. 59. 
m/z: 391 (54%), 348 (100%), 91 (93%).
Found: C, 71.10; H, 7.82; N, 3.15%.
C . N 0 _ C 1  • /£H_0 requires: C, 71.45; H, 7.83; N, 3.20%.
cO 04 4 d.
3.2.9 The Synthesis of j*-4—Hydroxy—3-methy1-1-(1-phenylcyclohexyl) 
-4-phenylpiperidine (69h)
The same synthetic procedures previously described for the 
synthesis of the a-isomer were employed for the synthesis of 
jj-4-hydroxy-3-methyl-l-( 1-phenylcyclohexyl )-4-phenylpiperidine. For 
results see Table 25 and for NMR results see Tables 7 and 8.
3.2.10 Resolution of (±)-Ji-4-hy droxy-1,3-dimethyl-4-phenyl-
piperidine (68)
Racemic a-prodinol (68; 20 g) was dissolved in acetone 
(240 ml) and mixed with (+)-tartaric acid (14.72 g) in methanol 
(228 ml). Sufficient acetone was added to make a total volume of 
(800 ml) and the mixture was left for three days at room 
temperature. The (+)-base, (+)-tartarate salt (16.8 g; 98%) was 
isolated and recrystallised twice from methanol. The resultant 
solid had m.p. 163-164°C and [a] + 13.5° (C = 1.0 H20) (Lit.69
m.p. 162-163°C with + 13.5° (C = 1.0, H20) . The (+)-base was
regenerated from an aqueous solution of the salt with excess NH^OH, 
extracted with ether (3 x 60 ml), dried (MgSO^) and evaporated in 
vacuo. The remaining solid was recrystallised from petroleum spirit 
(b.p. 60-80°C) to give (+)-a-4-hydroxy-l,3- dimethyl-4-phenyl- 
piperidine (5.64 g) , m.p. 89-90°C, [a] 25 + 11.5° (C = 1.0, Me2C0) 
[Lit.69 m.p. 90-91°C [a]25 + 11.8° (C = 1.0, Me2C0)].
Partially resolved (-)- a - 4 -hydroxy-1,3-dimethyl-4-phenyl- 
piperidine was recovered from the resolution mother liquor by 
addition of base (NH^OH) and extraction with ether (3 x 50 ml). 
Solvent was removed in vacuo to give crude (-)-a-4-hydroxy-l,3- 
dimethyl-4-phenylpiperidine (9.4 g). This base was added to a 
solution of (-)-tartaric acid (9.62 g) in acetone (1404 ml) and 
methanol (105 ml), and the mixture was left for thirty days at room 
temperature. The (-)-base (-)-tartarate salt (12.8 g; 65%) was 
isolated and recrystallised twice from methanol to yield a solid
215.
with m.p. 161-162°C; [a]25 -13.0°C (C = 1.0, H20) [Lit.69 m.p.
163-164°C; [a]26 - 12.9° (C = 1.0, H20)] . The (-)-free base was
regenerated as described for the (+)-isomer, to afford (-)-a-4-
r i 25hydroxy — 1,3-dimethyl-4-phenylpiperidine, m.p. 88-89°C; L<*J D -
12.5 (C = 1.0, Me2C0). [Lit.69 m.p. 89-90°; [a ]  2D5 - 12.0° (C = 1; 
Me2C0) ] (See Table 2 8) for full range of optical rotation 
readings).
3.2.11 The Synthesis of (-)-js and (+)-a-4-hydroxy-3-methyl-1- 
(1-phenylcyclohexyl)-4-phenylpiperidine
The synthetic procedures previously described for the 
synthesis of the a isomer were repeated in order to prepare ( + ) 
(69g) and (-) (69g) derivatives. For results see Table 27, p.218 
and Table 28, p.219 respectively. The NMR and m/z spectroscopic 
results of these derivatives were obtained, but are not presented 
in the thesis, since they are identical to those of the (i)-a- 
derivatives.
Table 25. The Synthesis of the B-analogues of PCP.
R  < 6 9 >
No Compound R R1 m.p.(Lit.) Yield m/z Formula Required % Found %






c o o c h2c c i3 c o c2h 5 












43 247 (92%) C15H21N02 72.84 8.56 5.66 72.59 8.52 5.58
54 191 (82%) C,-H oN0Cl.)£Ho0 61.00 7.66 5.92 61.28 7.82 6.14lo d
73 298 (76%) C ^ H ^ N ^ C l . ^ 0  63.84 8.51 8.76 63.80 8.76 8.82
76 349 (100%) C H N0C1 ./£Ho0 73.02 8.17 3.55 73.40 8.27 3.52
24 32 2
s Of the hydrochloride salt 
b Of the free base 216
Table 2 d. Specific Rotation [a] of (+)-a-4-Hydroxy-l,3-Dimethyl-4- 
Phenylp iperidine-(+)-Tartarate and (-)-a-4-Hydroxy-l# 3- 
Dimethyl-4-Phenylpiperidine- ( -) -Tartarate
salt3 Wavelength (nm) r ,25 
1 ° D
(+)-a-4-Hydroxy-l,3-dimethyl-4- 589 + 13.5°
phenylp iperidine-(♦)-tartarate 546 + 14.0°
436 + 19.5°
365 + 25.5°
(-)-a-4-Hydroxy-l,3-dimethyl-4- 589 - 13.0°
phenylpiperidine-(-)-tartarate 546 - 15.5°
436 - 19.0°
365 - 24.0°
a. Concentration = 1% w/v; Solvent H^O




No Compound R R* m.p.(Lit.) Yield Formula Required % Found %
°C % C H N C H N
8 69
1 40a CH* C0CoH_ 214-215 (194-196) 88
o 2 b
2 69m C00CH-CC1. C0CoHc 81
2 o 2 b
3 69a COC-H. H 162-163 40 C1cHo,N0o 72.84 8.56 5.66 72.38 8.44 5.46
2 b lb 21 2
4 69c H H 134-135b 60 C^H.^NOCl 63.30 7.97 6.15 62.96 7.78 6.00
12 18
o .b5 69e L J H 144-145 71 C„,JUJU>C1.33U> 63.84 8.51 8.76 64.08 8.89 8.8817 27 2----  2
o6 69g | | H 238-239® 72 C2AH32 N0C1 74.73 8.37 3.64 74.65 8.31 3.75
8 Of the hydrochloride salt 
b Of the free base
fOM
00
Table 26. The Synthesis of the (-)-a-analogues of PCP.
P h ^ O R 1
»*w*‘Meo
(69)












2 69m COOCH CCl- C0C2H5 82
3 69a c°c 2h 5 H 171-172 42 C15H21N02
72.84 8.56 5.66 72.58 8.47 5.41
4 69c H
X ™





65.68 9.01 8.75 65.42 8.92 8.76
6 69g £J H 236-237® 75 C24H32N0C1 74.73 8.37 3.64 74.85 8.21 3.57
s Of the hydrochloride salt 
d Of the free base
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3.3 THE SYNTHESIS OF 4-ALKYL-4-ARYLPIPERIDINES
3.3.1 Dehydration of o-4-hydroxy-l13-dimethyl-4-phenylpiperidine
A mixture of a-4-hydroxy-l,3-dimethyl-4-phenylpiperidine 
(68; 10 g), concentrated hydrochloric acid (83 ml) and glacial 
acetic acid (155 ml) was refluxed for six h. The mixture was 
concentrated in vacuo, diluted with H^O (70 ml), basified with 
strong ammonia, extracted with ether (3 x 80 ml), dried (MgSO^) and 
evaporated in vacuo to yield a mixture of 1 ,2,5,6-tetrahydro-l,3- 
dimethyl-4-phenylpyridine and 1 ,2,5,6-tetrahydro-l,5-dimethyl-
4-phenylpyridine (7.6 g; 82%) as sin oil. Treatment of the oily
residue with ethereal-HCl and subsequent fractional crystallisation
from ethanol-ether afforded the 5-Me isomer (71) as the
13?
hydrochloride (3,3 g; 36%), m.p. 193° (Lit. 196°C).
The filtrate was evaporated in vacuo and recrystallised from 
the same solvent, yielding an additional crop (1.9 g; overall 
recovery: 56%) of the pure 5-Me compound. Finally, the filtrate was 
evaporated in vacuo and recrystallised from isopropanol-ether to 
give mainly the 3-Me isomer with a trace of the 5-Me isomer, which
was recrystallised from ethanol-ether to yield the pure 3-Me isomer
132
(72; 0.5 g; 6%), m.p. 191°C (Lit. 189-190°C). The isomers (71) 
sind (72) were readily differentiated by means of NMR 
spectroscopy.
5-Me isomer (71)
5 (CDC1_; free base):
H o
221.
2.88-3.10 (4H; m; C6-H, C2-H), 5.80 (1H, m, C3-H), 7.15-7.29 (5H, 
m, Ar-H).
5 (CDC1 , free base):
L o
18.38 (C5-CH3 ), 31.66 (C-5), 45.48 (N-CHg), 55.01 (C-6), 59.76 
(C-2), 121.89 (C-3), 125.65 (Ar-Cm), 126.29 (Ar-Cp), 127.75 
(Ar-Co), 140.40 (C-4), 140.50 (Ar-Cq).
3-Me isomer (72)
5 (CD1_; free base):
H o
1.62 (3H; s, C3-CH3 ), 2.82 (3H, s f N-CH3 ), 1.62 (2H, brs, C5-H), 
3.21 (2H, m, C6-H), 3.48 (2H, brs, C2-H), 7.15-7.38 (5H, m, Ar-H).
(CDC13 ; free base):
17.48 (C3-CH3 ), 28.8 (C-5), 43.16 (N-CH3 ), 51.00 (C-6), 56.34 
(C-2), 122.90 (C-3), 127.11 (Ar-Cm), 128.10 (Ar-Cp), 128.30 
(Ar-Co), 130.94 (C-4), 140.30 (Ar-Cq).
3.3.2 lf4 t5,6-Tetrahydro-lf4,5-trimethyl-4-phenylpyridine (73)
To a solution of 1,2,5,6-tetrahydro-l,5-dimethyl-4- 
phenylpyridine (71; 5 g; 0.027 mole) in dry tetrahydrofuran (50 ml) 
under at -10°C was added n-butyl lithium (24 ml; 0.034 mole;
1.4 M in hexane) at such a rate that the temperature was maintained 
at less than -5°C. The resulting deep red solution was stirred for 
15 minutes at -5°C and then cooled to -30°C. Dimethylsulphate 
(3.4 g; 0.027 mole) in dry tetrahydrofuran (50 ml) at -40°C was 
added dropwise such that the temperature was maintained at less
222.
than -30°C. The final solution was warmed to -10°C, stirred for 30 
minutes at this temperature, and the residual n-butyllithium 
quenched by the addition of H^O (20 ml). The organic layer was 
separated, washed with H^O (10 ml) and then saturated NaCl (10 ml), 
dried (MgSO^) and evaporated in vacuo to yield a mixture (0.56 g) 
of the title compound and the corresponding quaternary ammonium 
salt as an oil.The oily residue was diluted with dry ether and the 
resultant solid was filtered to yield the quaternary ammonium salt 
of the title compound (74; 0.4 g), m.p. 157-158°C. The filtrate was 
evaporated jm vacuo to give the title compound (0.1 g) as an oil. 
Quaternary ammonium salt (74)
SH (V ):
0.66 (3H, d, C5-CH3 ), 1.58 (3H, s, C4-CH3 ), 2.36 (1H, dq, C5-H), 
3.02 (1H, t, C6-Hax), 3.66 (1H, brs, C6-Heq), 3.78 (3H, s,
N-CH3ax), 3.81 (3H, s, N-CH3eq), 5.83 (1H, m, C3-H), 6.46 (1H, d, 
C2-H), 7.22-7.42 (5H, m, Ar-H).
V D20):
11.73 (C5-CH3 ), 27.82 (C4-CH3 ), 37.30 (C-4), 40.45 (C-5), 42.27 
(N-CH3 , ax), 42.91 (N-CHg, eq), 49.82 (C-6), 131.64 (C-3), 113.64 
(C-3), 131.20(C-2), 145.00 (Ar-Cq), 115.00-119.55 (Other Ar-C).
Found: C, 58.62; H, 7.62; N, 4.22%
C. £.H__N0 .S requires: C, 58.69; H, 7.70; N, 4.28%. 
lb 2b 4
Free base (73)
6 (CDC10 ; free base):
H o
223.
0.58 (3H, d, C5-CH3 ), 1.46 (3H, s, C4-CH3 ), 1.93 (1H, m, C5-H),
2.53 (2H, m, C6-H), 2.69 (3H, s, N-C^), 4.34 (1H, d, C3-H), 5.98 
(1H, d, C2-H), 7.17-7.47 (5H, m, Ar-H)
6 (CDC13 ; free base): 14.95 (C5-CH3 ), 28.00 (04-CHg), 38.73 (C-5),
40.06 (C-4), 42.46 (N-CH3 ), 52.71 (C-6), 106.16 (C-3), 125.50 
(Ar-Cm), 126.11 (Ar-Cp), 128.73 (Ar-Co), 133.26 (C-2), 146.20 
(Ar-Cq).
Attempts were then made to secure (73) by N-demethylation of the 
quaternary salt (74) by the following method:
The N-methyl quaternary salt (74; 0.38 g) in methanol 
(20 ml) was stirred with dry, freshly prepared silver chloride 
(6 g) for four hours. The resultant solid was filtered off and 
washed with methanol (15 ml). The washings were combined with the 
original filtrate and evaporated in vacuo to give an oil, which was 
dissolved in ethanol (20 ml) and treated with a solution of sodium 
thiophenate (1.4 g) in ethanol (60 ml). After the mixture had been 
stirred for 30 minutes, the sodium chloride which separated was 
filtered off and washed with ethanol (20 ml). The filtrate was 
evaporated in vacuo, and the oily residue was dissolved in ethyl 
methyl ketone (100 ml) and refluxed gently under for 20 hours. 
The solvent was evaporated in vacuo and the residue was treated 
with ether (100 ml), followed by extraction with HC1 (2N: 2 x 
10 ml). The combined aqueous extracts were basified with strong 
aqueous ammonia, extracted with ether (3 x 10 ml), and the ether 
dried (MgSO^) and evaporated in vacuo to yield the crude title 
product (0.07 g; 35%) as an oil. Treatment of this oil with 
ethereal-HCl afforded the enamine salt (77) as an oil.
The enamine salt (77)
{H tD20):
0.83 (3H, d, C5-CH3 ), 1.42 (3H, s, C4-CH3 ), 2.54 (1H, q, C5-H), 
3.38-3.42 (2H, m, C3-H), 3.80 (3H, s, N-CH3 ), 3.88-4.04 (2H, m, 
C6-H), 7.25-7.42 (5H, m, Ar-H), 8.95 (1H, s, C2-H)
fiC (D2°):
14.00 (05-CHg), 28.41 (C4-CH3 ), 36.60 (C-5), 38.73 (C-4), 39.20 
(C-3), 49.53 (N-CH3 ), 56.90 (C-6), 126.70 (Ar-Cm), 129.64 (Ar-Cp),
133.34 (Ar-Co), 144.31 (Ar-Cq), 179.66 (C-2).
3.3.3 The synthesis of l p3 f4-Trimethyl-4-phenylpiperidine (75)
A. 1,4,5,6-Tetrahydro-l,4,5-trimethyl-4-phenylpiperidine (73;
0.08 g) in ethanol (30 ml) was hydrogenated at room temperature 
over palladium (5%:, Pd on C; 0.1 g) at 60 p.s.i., in a rocking 
Parr apparatus for 12 h. The catalyst was filtered off and the 
filtrate evaporated in vacuo to yield the crude title compound 
(0.05 g; 62%) as an oil. Treatment of this oil with ethereal-HC1 
afforded the hydrochloride salt m.p. 193-194°C (ethanol-ether). 
(Sample supplied by D. Zimmerman, m.p. 188-189°C; Mix m.p. 
184-188°C). This compound is a pure, single isomer (see p.167 ).
fi : see Table 12, p. 147.
H
5 : see Table 11, p.146.
w
B. Sodium borohydride (0.06 g) was added to a stirred solution 
of the enamine salt (77) obtained in section 3.3.2B in ethanol 
(2 ml). The resulting mixture was stirred for 3 h at room 
temperature. The excess of sodium borohydride was destroyed by the 
addition of HC1 (2 N; 1 ml), followed by water (10 ml), which was 
then basified with concentrated aqueous ammonia and extracted with 
ether (3 x 5 ml). The combined organic extract was washed with H^O 
( 2 x 4  ml), dried (MgSO^) and finally evaporated iji vacuo to yield 
the crude title compound (0.035 g; 69%) as an oil. Treatment of 
this oil with ethereal-HCl afforded the hydrochloride salt, m.p. 
189-191°C (ethanol-ether). Thin layer chromatography (TLC) and 
NMR analysis have shown this compound to be identical with the 
material obtained above (Section A).
3.3.4 l,3-Dimethyl-4-piperidone methiodide (80)
Methyl iodide (35 g) was added dropwise to a stirred
solution of 1 ,3-dimethyl-4-piperidone (63; 30 g) in acetone
(250 ml). The reaction mixture was stirred for two hours. The solid
produced was filtered off and washed with dry ether to give the
155
title compound (60 g; 40%), m.p. 170-172°C (Lit. 184-185°C) as a 




\> : 1740 cm (-C-)
max
3.3.5 l-Benzyl-3-methyl-4—piperidone (78)
1 ,3-Dimethyl-4-piperidone methiodide (80; 50 g), benzylamine
(21 g) and water (19 ml) were combined, and the resulting mixture 
was warmed to give a clear solution. The reaction mixture was left 
overnight at room temperature. The oily layer which separated was 
extracted with ether (6 x 100 ml), dried (MgSO^) and then 
evaporated in vacuo to give a dark oil, which was distilled under 
vacuum to give the title product (15 g; 33%), b.p.
100-110°C/0.2 mm. (Lit.41, b.p. 110-115°C/0.3 mm).
O
-1 II
v : 1755 cm (-C- str) 
max
$ (CDC1_; free base):
r i  o
0.97 (3H, d, C3-CH3 ), 3.60 (2H, s, Ar-CH2 ), 7.25-7.37 (5H, m,
Ar-H).
3.3.6 a- and ^-1-Benzyl—4-hydroxy-4— ( 3—methoxyphenyl) -3- 
methylpiperidine (83)
Sec-Butyl lithium (86 ml; 0.12 mole; 1.4 M in hexane) was 
added dropwise to a stirred solution of m-bromoanisole (22 g; 0.12 
mole) in dry tetrahydrofuran (60 ml) under N2 at -55°C. The 
resulting suspension was stirred at this temperature for 1 h and 
this was followed by the addition of l-benzyl-3-methyl-4-piperidone 
(78; 15 g; 0.08 mole) in dry tetrahydrofuran (100 ml) at a rate 
such that the temperature was maintained below -40°C. When the 
addition was complete, the temperature was allowed to rise to 
approximately -20°C over about 1 h and then to room temperature 
over a further 1 h period. Residual sec-butyl lithium was quenched 
by the addition of saturated NaCl (50 ml), followed by the addition
227.
of H^O (50 ml). The organic layer was separated, washed with NaOH 
(2N; 100 ml), H^O (2 x 50 ml), dried (MgSO^) and evaporated 
in vacuo to yield a mixture of the title compound (22.2 g; 72%) as 
an oil, which was employed in the next synthetic step.
v : 3060-3300 cm 1 (0-H str.). 
max
3.3.7 Dehydration of a- and ji-l-benzyl-4—hydroxy-4-(3—methoxy- 
phen 1)-3—methylpiperidine
The isomeric mixture (83) obtained in Section 3.3.6 (12 g) 
was treated with concentrated HC1 (100 ml) and glacial acetic acid 
(190 ml) by the same procedure described in Section 3.3.1 to yield 
a mixture (10 g; 88%) of 1-benzyl-l,2,5,6-tetrahydro-4- 
(3-methoxyphenyl)-5-methylpyridine (84) and the corresponding
3-methyl isomer (85). Treatment of the oily residue with 
ethereal-HC1, and subsequent fractional crystallisation from
ethanol-ether, afforded the 5-Me isomer (7 g; 61.1%), m.p. 227°C
13?
(ethanol). (Lit. , 225-226°C).
The 5-Me isomer (84)
6 (CDC1-; free base): 1.01 (3H, d, C5-CH.), 2.44-2.59 (2H, m, 
ri o “-o
C6-Hax, C2-Hax), 3.03-3.23 (2H, m, C2-Heq, C6-Heq), 3.56 (2H, s, 
-CH2Ph), 3.76 (3H, s, OCHg), 5.85 (1H, dt, C3-H), 6.73-7.39 (9H, m, 
Ar-H).
228.
$£ (CDC13 ; free base):
18.64 (C5-CH3 ), 32.41 (C-5), 53.80 (C-6), 55.04 (OMe), 57.21 (C-2),
111.96 (C-3), 138.59 (Ar-Cq), 141.02 (C-4), 142.35 (Ar-l')t 159.51 
(Ar-3'), 114.01-129.06 (other aromatic carbons).
3.3.8 l-Benzyl-4-hydroxy-4-phenylpiperidine (108)
l-Benzyl-4-piperidone (30 g) was treated with phenyl lithium 
[prepared from lithium (5 g) and bromobenzene (58 g) in dry ether 
(300 ml)] by the same procedure described in Section 3.2.4 to yield 
the title compound (40 g; 94%) as an oil.
v : 3460 cm * (0-H str.). 
max
6 (CDC1_; free base):
n o
1.64 (2H, dd, C3/5-Heq), 2.08 (2H, dt, C3/5-Hax), 2.43 (2H, dt, 
C2/C6-Hax), 2.70 (2H, brd, C2/6-Heq), 3.51 (2H, s, CH2-Ph), 
7.16-7.47 (10H, m, Ar-H).
6^ , (CDClgj free base):
38.14 (C-5/3), 49.10 (C-2/6), 69.98 (CHg-Ph), 70.93 (C-4),
CHg-Ar-Cq (138.04), C4-Ar-Cq.(148.39), other aromatic carbons 
(124.45-129.10).
3.3.9 l-Benzyl-l,2f5,6-tetrahydro-4-phenylpyridine (109)
l-Benzyl-4-hydroxy-4-phenylpiperidine (108; 15 g) was 
treated with concentrated HC1 (120 ml) and glacial acetic acid 
(225 ml) by the same procedure described in Section 3.3.1 to yield
229.
the crude title product as an oil. This oil was diluted with 
petroleum ether (b.p. 40-60°C), the resultant solid (starting 
material) was filtered off and the filtrate was evaporated dji vacuo 
to yield the title compound (11.5 g; 82%) as an oil.
5 (CDC1 *, free base):
H 3
2.55 (2H, m, C5-H), 2.69-3.16 (4H, m, C2-H, C6-H), 3.62 (2H, s, 
-CH2-Ph), 6.05 (1H, m, C3-H), 7.16-7.37 (10 H, m, Ar-H).
6 (CDC1*; free base):
v O
27.86 (C-5), 49.78 (C-6), 53.16 (C-2), 62.53 (CH2-Ph), 121.72 
(C-3), 134.73 (C-4), 138.10 (CH2-Ph-Cq), 140.67 (4-Ph-Cq), other 
aromatic carbons (124.71-129.03).
3•3.10 1-Benzyl—1,4,5,6-tetrahydro-4-methy1-4-phenylpyridine (106)
1-Benzyl-l,2,5,6-tetrahydro-4-phenylpyridine (109; 10 g;
0.04 mole) in dry tetrahydrofuran (100 ml) was treated with n-butyl 
lithium (32 ml; 0.045 mole; 1.4 M in hexane) and then with 
dimethylsulphate (5.1 g, 0.04 mole) by the same procedure described 
in Section 3.3.2, to yield the crude product (6.4 g; 60%) as an 
oil. An attempt to distill this mobile oil under vacuum failed and 
therefore it was employed in the next synthetic step without any 
further purification.
6^ (CDClgj free base):
1.40 (3H, s, C4-CH3 ), 1.81-1.97 (2H, m, C5-H), 2.51-2.78 (2H, m, 
C6-H), 3.96 (2H, s, CH^Ph), 4.48 (1H, dxd, C3-H), 6.14 (1H, d,
230.
C2-H), 7.09-7.41 (10 H, m, Ar-H).
3.3.11 4-Hydroxy-4-(3-methoxyphenyl)-1-methylpiperidine (93)
Sec-Butyl lithium (221 ml; 0.31 mole; 1.4 M in hexane) was
added dropwise to a stirred solution of m-bromoanisole (45.9 g;
0.25 mole) in dry tetrahydrofuran (110 ml) under at -55°C. The
resulting suspension was stirred at -50°C for 1 h. and this was
followed by the addition of l-methyl-4-piperidone (92; 80 g; 0.27
mole) in dry tetrahydrofuran (100 ml) at a rate such that the
temperature was maintained below -40°C. When the addition was
complete, the temperature was allowed to rise to approximately
-20°C over about 1 h., and then to room temperature over a further
1 h. period. Residual sec-butyl lithium was quenched by the
addition of saturated NaCl (100 ml), followed by the addition of
H^O (100 ml). The organic layer was separated, washed with NaOH
(2N; 100 ml), H^O (2 x 50 ml), dried (MgSO^) and evaporated
in vacuo to give the crude title product as an oil. This was
diluted with hexane (150 ml) and the resultant solid was filtered.
The isolated crystalline product was dried in a vacuum oven to
53
provide the pure product (50.6 g; 87%), m.p. 112-113°C (Lit. , m.p. 
112-113°C).
6 (0DClo ; free base):
H o
1.68 (2H, d, eq C3/5-Heq), 2.11 (2H, td, C3/5-Hax), 2.24 (3H, s, 
N-CH3 ), 2.44 (2H, dt, C2/6-Hax), 2.57 (2H, d, C2/6-Heq), 3.76 (3H, 
s, 0CH3 ), 6.74-7.26 (4H, m, Ar-H)
231.
6C (CDClgj free base):
38.11 (C-3/5), 46.10 (N-CH3 ), 51.41 (C-2/6), 54.10 (0CH3 ), 70.02 
(C-4), 110.60 (Ar-2'), 112.00 (Ar-4'), 116.83 (Ar-6'), 129.10 
(Ar-51), 150.50 (Cq-1'), 159.45 (Cq-3').
3.3.12 1,2,5,6-Tetrahydro-4-(3—methoxyphenyl)-1-methylpyridine (89)
A mixture of 4-hydroxy-4-(3-methoxyphenyl)-1-methyl­
piperidine (93; 24 g), concentrated HC1 (250 ml) and glacial acetic 
acid (470 ml) was refluxed for 12 hours, and then concentrated in 
vacuo. The oily residue was diluted with H^O (300 ml), basified 
with strong aqueous ammonia, extracted with ether (4 x 100 ml), 
dried (MgSO^) and evaporated in vacuo to yield the crude title 
product (23 g; 82%), as a dark oil. The oily residue was diluted 
with petroleum ether (b.p. 40-60°C) and the resultant solid was 
filtered off. The filtrate was evaporated in vacuo to give the 
title compound (20.50 g; 73%), as an oil.
$ (CDC1 *, free base):
H o
2.52 (2H, m, C5-H), 2.60 (2H, m, C6/2-Hax), 2.33 (3H, s, N-CH3 ),
3.03 (2H, d, C6/2-Heq), 3.70 (3H, s, 0CH3 ), 6.01 (1H, dt, C3-H),
6.70-7.35 (4H, m, Ar-H).
$ (CDC1_; free base):
U O
27.57 (C-5), 45.10 (N-CHg), 51.64 (C-6), 54.32 (C-2), 54.36 (0CH3 ),
110.34 (Ar-2'), 111.54 (C-3), 116.86 (Ar-4‘), 121.37 (Ar-6')»
128.57 (Ar-5'), 141.81 (Cq-l')f 144.00 (C-4), 159.06 (Cq-3').
3.3.13 1,4,5,6-Tetrahydro-4- ( 3-methoxyphenyl) -1-nethy1-4-
(2-methylprop-l-yl)pyridine (90a)
To a solution of 1,2,5,6-tetrahydro-4-(3-methoxyphenyl)- 
1-methylpyridine (89; 6 g; 0.03 mole) in dry tetrahydrofuran 
(84 ml) under at -10°C was added n-butyl lithium (15 ml; 0.047 
mole; 2.5 M in hexane) at such a rate that the temperature was 
maintained at less than -5°C. The resulting deep red solution was 
stirred for 15 minutes at -5°C and l-bromo-2-methylpropane (5.1 g; 
0.037 mole) in dry tetrahydrofuran (70 ml) added dropwise at such a 
rate that the temperature was maintained at less than -5°C. The 
reaction mixture was stirred for 10 minutes at -5°C, and the 
residual n-butyl lithium : quenched by the addition of H^O (40 ml).
The organic layer was separated, washed with H^O (20 ml) and then 
saturated NaCl (20 ml), dried (MgSO^) and evaporated in vacuo to 
give the crude title product (6.8 g; 92%), which was purified 
according to the following procedure. To a solution of the crude 
product obtained above (6.8 g) in hexane : ethyl acetate (68 ml, 
44:24) was added silica gel (6.8 g) to produce a slurry, which was 
stirred for 2 hours at room temperature. The slurry was filtered 
off and washed with hexane : ethyl .acetate (73 ml; 48:25). 
Evaporation of the solvent mixture dri vacuo gave 1,4,5,6-tetrahydro 
-4-(3-methoxyphenyl)-l-methyl-4-(2-methylprop-l-yl)pyridine (5.2 g ; 
70%) as an oil.
6 : see Table 31, p. 235.
H
6 : see Table 3 0, p. 234.
v







At  = C_H -OMe (m) 
6 4 —




A. Results for the 4-iso-Bu derivative in this table and 
subsequent tables are presented for comparative reasons.
B. n-Propylbroraide was employed as alkylhalide
C. See Section 3.3.20 for full experimental conditions.
D. Of of the purified 4-alkyl compound from the corresponding
4-aryl-l,4,5,6-tetrahydro-l-methylpyridine (89).
Table 30. 13c MB of Somm 4-Alkyl-4-®UTrl-l ,4,5,O-tetrafaydro-l-uethylpyrldlnea.“
Ar5 Ar.rg.OMo. C»H»
(90)
*3C Chealcal ahifta (ppa; TNS lntarnal standard)
Coopound R C-2 C-3 C-4 C-5 C-6 N-Ma 4-R
a- and 0-£ *•; "•2
ONe Cq-1' Cq-J' Other Ar-C
• hi2 ?h (m«)2 136.23 103.14 40.31 37.50 b 42.13 a-CH2s c if2:25.04; 54.81 152.00 159.00 128.41; 119.62;
CH 2 3
0-CH2: 24.60 25.00 114.10; 109.63
b
a
CH2 136.32 103.00 40.02 37.01 46.30 42.18 a-CHgS 45.9 
0-CHg! 17.16
Me: 14.60 54.80 151.60 159.10 128.51; 119.43; 
114.0; 109.92
c No 135.61 105.41 nr30.70 38.50 46.32 42.23 — Me: 30.60 54.71 152.70 159.03 128.54; 118.91; 
113.26; 109.92
a. Bu«i in CDCl^
b. Signala overlap at 146.20 pp« 
e. Unreaolved.




Compound R N-Me C2-H C3-H C5-H C6-H OMe Other protons
a -$H2& ( N c2) 2.64, e 6.93, d 4.64, d c ax:eq: 2.53-2.70, a 3.00,■ Ar-H: 6.64-7.21, a
-CH2CH: 16.2, a 
-CHgCH: 1.22, a 
-CH(Me)2: 0.74, d 
and 0.91, d
a I
b -CH2CH2CH3 2.54, a 6.40, d 4.81,dxd d ax/eq: 2.44-2.74, a 3.75,a Ar-H: 6.70-7.22,a
-CHg-CHgS 1.26-1.31, a
~CH2~CH2_CH3: 0,81' t 
-CH2-CH2: 1.52-1.82, a
c Ha 2.57, a 6.7, d 5.92, d b ax/aq: 2.43-2.73, a 3.80,a Ar-H: 6.70-7.22, a
C4-Ma: 1.38, a
a. Baa—  in CDCl^
b. Signala overlap (1.60-1.73 a) 
e. Bignala overlap (1.73 - 2.01 a)
d. Signala overlap ( 1.81 - 2.10 a)
0
3.3.14 1,4,5,6-tetrahydro-4-( 3-methoxyphenyl )-l-«ne thy 1-3-
dime thylaminome thy 1-4-(2-methylprop-l-yl )pyridine (91a)
To a solution of aqueous formaldehyde (1.5 g; 37%) and 
aqueous dimethylamine (2.1 g; 40%) in H^O (15 ml) was added enough 
concentrated to adjust the pH of the reaction mixture to 3-4.
A solution of 1,4,5,6-tetrahydro-4-(3-methoxyphenyl)-l-methyl-4-(2- 
methylprop-l-yl)pyridine sulphate [prepared by the extraction of 
(90a, 5 g) with H^SO^ (2.5 M; 2 x 8 ml) from a solution in hexane 
(10 ml) ] was added, and the pH adjusted to 3-3.5 by the addition of 
H^SO^ or dimethylamine. The mixture was stirred at approximately 
60-70°C for 2 h. while maintaining the pH of the reaction mixture 
between 3-3.5. The solution was cooled to room temperature and 
added to NaOH (25%; 30 ml). The resulting suspension was extracted 
with hexane (4 x 25 ml). The combined organic extracts were washed 
with H^O (5 x 15 ml), dried (MgSO^) and evaporated in vacuo to 
yield the title product (2.27 g; 74%) as an oil.
6 : see Table 34, p. 239.
H
: see Table 33, p. 238.






Ar = C.H.-OMe(m) 
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A. Of the crude Mannich base from the corresponding 4-alkyl-4- 
aryl-1,4,5,6-tetrahydro-l-methylpyridine (90).
O'








shifts (ppa; TMS internal standard) 
C3-CH2N(Me)2 4-R 
CH2 Me2 a - and 0 -£ Me; (Me)2
ONe Cq-1* Cq-3' Other Ar-C and C-C




«v : 26.5 
26.4



















a. Base* in CDCl^
b. Signala ovarlap at 46.30 ppa 
e. Unraaolvad
Table 34. Si ( * seal* la ppa) of d-Allqrl-d-aryl— S-dl— tbylaalno— thyl-1,4.5.6-tetrahydro-l-aethylpyrldlnes.*
A r R








2.62. a 6.10, a d c 2.44, d 2.20, a 3.80,a Ar-H: 6.70-7.21, a 
•-CH2: d; 8-CH: d
CH(Me)2: 0.79, d; 1.04, d
b -c h2ch2ch3 2.67. a 6.11. a d ax/eq: 2.42-2.71, a 2.23, a 2.20, a 3.80,a Ar-H: 6.70-7.30, a 
e-CHgj d; B-CHgj d
-CH -CH_: 0.94, t 2 ~3
c Me 2.62. a 6.00, a b ax/eq: 2.64-2.90, a 2.40, d 2.11, 8 3.80,a Ar-H: 6.70-7.30, a 
C4-Me: 1.52, a
a. Bases in CDCl^
b. Msjor signals overlap (1.83-2.10 ppa)
e. Signals overlap (2.70-2.80)
d. Unresolved algnal
3.3.15 a- and B-4- (3-methoxyphenyl) -1,3-dime thy 1-4- ( 2-methylprop- 
l-yl) piperidine
The Mannich base Ola; 4 g) in triethylamine (80 ml) was
hydrogenated over palladium (5%; Pd on CaCO^; 2 g) at 60 p.s.i., in
a rocking Parr apparatus at 50°C for 24 hours. The catalyst was
filtered off and the filtrate evaporated in vacuo to yield the
crude title product (2.73g,80%) as an oil. Treatment of the oily
residue with ethereal-HCl, and subsequent fractional crystal-
2
lisation from methsmol-ether yielded the major isomer (54k R = Me;
1.1 g), m.p. 187-188°C. The filtrate was evaporated in vacuo and 
recrystallised from ethanol-ether to yield mainly the minor-isomer 
(54j; R2 = Me; 0.4 g) with a trace of the major isomer. All
attempts to obtain the pure minor isomer failed and therefore it
was decided to purify the corresponding phenols.
: see Table 20, p. 171 .
6^  : see Table 19, p. 170.
Microanalysis : see Table 36, p. 247.
3.3.16 Major 4-(3-Hydroxyphenyl) 1 , 3-dimethyl-4-(2-methylprop-l-yl) 
piperidine (54k, R^ = H)
Ma j or 4- (3-Me thoxyphenyl) 1,3-dime thy 1-4- (2-methylprop-l-yl)
2
piperidine (54k; R = Me; 0.9 g) was treated with aqueous HBr (4.5 
ml; 48%) and the solution refluxed for 6 hours. The mixture was 
cooled, diluted with H^O (10 ml), neutralised to pH 8 with
concentrated aqueous ammonia, and extracted with ether (4 x 15 ml), 
which was dried (MgSO^) and evaporated iji vacuo to yield the crude 
title product (0,64g,75%) as a yellowish solid. Treatment of this 
solid with ethereal-HCl afforded the hydrochloride salt, m.p. 
256-258°C (methanol-ether).
: see Table 20. p. 171.
ri
; see Table 19. p. 170.
Microanalysis : see Table 37, p. 248.
3.3.17 Minor 4-(3-Hydroxyphenyl)-1,3-dimethyl-4-(2-methylprop-l-yl) 
piperidine (54k; B? - H)
The diastereoisomeric mixture (minor with a trace of major) 
obtained in Section 3.3.15 (0.6 g) was treated with HBr (3.5 ml; 
48%) by the same procedure described in Section 3.3.16 to yield a 
mixture (0.44 g; 76%) mainly of the minor isomer with a trace of 
the major isomer as a yellowish oil. Treatment of this oil with 
ethereal-HCl, and subsequent fractional crystallisation from
p
methanol ether, yielded the minor-isomer (54j; R = H; 0.32 g), 
m.p. 220-222°C.
$ : see Table 20. P« 171.
H
^  : see Table 19. P* 170.
Microanalysis : see Table 3 7, p. 248.
3 • 3 • 18 4- (3-Methoxyphenyl) -1-methy 1-4- (2-methylprop-l-yl) piperidine 
(55z; Ar = nt-OMe.C^Hj
1,4,5,6-Tetrahydro-4- (3-methoxyphenyl) -l-methyl-4- 
(2-methylprop-l-yl)piperidine (90a; 3 g) in ethanol (60 ml) was 
hydrogenated at room temperature over palladium (5% Pd on C; 1 g) 
at 80 p.s.i., in a rocking Parr apparatus, for 12 h. The catalyst 
was filtered off and the filtrate evaporated in vacuo to yield the 
crude title compound (2.42g,82%), as an oil. Treatment of the oil 
with ethereal-HCl afforded the hydrochloride salt, m.p. 192-193°C 
(ethanol-ether).
6 : see Table 10. p. 133.
H
& : see Table 9. p. 132.
v
Microanalysis : see Table 35, p. 246.
3.3.19 4-(3-Hydroxyphenyl)-1-methyl-4-(2-methylprop-l-yl)piperidine
(55*. Ar = m-0H.C_H.)
— 0 4
4- (3-Me thoxyphenyl) -1,3-dimethyl-4- (2-methylprop-l-yl) 
piperidine (2 g) was treated with aqueous HBr (8 ml; 48%) by the 
same procedure described in Section 3.3.16 to yield the title 
compound (1.4 g; 74%), as a yellowish solid. Treatment of this 
solid with ethereal-HCl afforded the hydrochloride salt m.p. 
181-182°C (ethanol-ether).
; see Table 10. , p. 133.
H
5 C ; see Table 9., p. 132.
Microanalysis: see Table 33, p. 2 46.
3.3.20 1,4,5,6-Tetrahydro-4- ( 3-methoxyphenyl) -1,4-dime thy lpyr idine
(90c)
To a solution of 1,2,5,6-tetrahydro-4-(3-methoxyphenyl)-l- 
methylpyridine (89; 10 g; 0.05 mole) in dry tetrahydrofuran 
(140 ml) under at -10°C was added n-butyl lithium (24.9 ml;
0.078 mole; 2.5 M in hexane) at such a rate that the temperature 
was maintained at less than -5°C. The resulting deep red solution 
was stirred for 15 minutes at -5°C and then cooled to -30°C. 
Dimethylsulphate (6.25 g; 0.05 mole) in dry tetrahydrofuran (90 ml) 
at -40°C was added dropwise such that the temperature was 
maintained at less than -30°C. The final solution was warmed to 
-10°C, stirred for 30 minutes at this temperature, and then worked 
up by the same procedure described in Section 3.3.13, to give an
oil. The oily residue was treated with dry ether and the resultant 
quaternary ammonium salt filtered off. The filtrate was evaporated 
in vacuo to give the crude product, which was purified by the same 
procedure described in Section 3.3.13, to yield the title compound 
(4.2 g; 29%), as an oil.
6 ; see Table 31 - p. 235. 
H
6 ; see Table 30. p. 234.
0
The same synthetic procedures previously described for the 
synthesis of the a_- and B-4-iso-Bu and the corresponding
3-desmethylanalogues were employed for:
3.3.21 The synthesis of 4-n-propyl analogues
a. a -4-(3-Hydroxyphenyl)-l,3-dimethyl-4-n-propylpiperidine 
(54d)
For results, see Table 37 .p. 248.
For NMR results, see Table 14;15.
b . B.-4-(3-Hydroxyphenyl)-1,3-dimethyl-4-n-propylpiperidine 
(54c)
For results, see Table 3 7. p. 248.
For NMR results, see Table 14; 15 ,
c. 4-(3-Hydroxyphenyl)-l-methyl-4-n-propylpiperidine (55ii)
For results, see Table 35.
For NMR results, see Table 9; 10.
3.3.22 The synthesis of 4-methyl analogues
a. Major 4-(3-Hydroxyphenyl)-l,3,4-trimethylpiperidine (54b) 
For results, see Table 37*
For NMR results, see Table 11; 12 .
b. Minor 4-(3-Hydroxyphenyl)-1,3,4-trimethylpiperidine (54a) 
For results, see Table 3 7.
For NMR results, see Table 11; 12.
c. 4-(3-Hydroxyphenyl)-l,4-dimethylpiperidine (55h)
For results, see Table 35.
For NMR results, see Table 9; 10.
3.3.23 4— (3-Methoxyphenyl)-1,4-dimethylpiperidine methiodide
4-(3-Methoxyphenyl)1,4-dimethylpiperidine (55h; 0.05 g) in 
acetone (3 ml) was treated with iodomethane (0.1 g) by the same 
procedure described in Section 3.3.5 to yield the corresponding
methiodide salt, m.p. 235-236°C. See page 156 for discussion of NMR
results.
3.3.24 Major 4-(3-Methoxyphenyl)-1,3,4-trimethylpiperidine 
methiodide
Major 4-(3-Methoxyphenyl)-1,3,4-trimethylpiperidine (54b; 
0.15 g) in acetone (4 ml) was treated with iodomethane by the same 
procedure described in Section 3.3.5 to yield the title compound 
(0.18 g; 75%), as a colourless solid, m.p. 205-207°C (methanol).
6 see Table 12. p. 147. n
6 see Table 11. p. 146.
L
Found: C, 50.98; H, 6.89; N, 3.65%.
C-iCH0 N0I requires: C, 51.21; H, 6.98; N, 3.73%. lb do














55z iso-Bu C.H -OMe(m) 6 4 —
192-193 EtOH/EtgO 82 C17H28N0C1 68.55
9.47 4.70 68.40 9.42 4.65
55t n-Pr C.Hil-OMe(m)A 85
6 4 -
55h Me C.H ..-OMe(m) 
6 4 — 166-168
Et0H/Et20 78
55z iso-Bu C-H ..-OH(m) 6 4 — 181-182 EtOH/EtgO 76 c 16h 26n°c i 67.71 9.23 4.94 67.62 9.10 4.92
551 n-Pr C6H4-0H(m) 178-179(187-190)86 EtOH/EtgO 74 C15H24N0C1 66.77 8.97 5.19 66.58 8.87 5.10
55h Me C^H ,-OH(m)B 
6 4 — 200-201(214-215)86 69
A. The hydrochloride salt of this compound could not be recrystalliseditherefore,characterisation of this compound was 
based on the free phenol.
B. Attempts to purify this compound were unsuccessful.

















Methanol-ether 187-188 C18H3ON0C1 69.34 9.69













66.77 8.97 5.19 67.1 9.11 5.00
A. Yield for isomeric mixtures obtained from hydrogenation of the precursor Mannich base. Purification and 
characterisation of the minor isomer in each case was achieved on the free phenols (see Table 30).
B. This compound was initially separated from the isomeric mixture as the oxalate salt and had m.p. 191-193 (methanol), 
then the free base was liberated and converted to the hydrochloride salt for characterisation.








m.p. (°C) Formula Required %





(major) 75 Methanol-ether 256-258 C17H28N0C1 68.55 9.42 4.70 68.2 9.63 4.55
54j (minor) 76 Methanol-ether 220-221
C17H28N0CX
68.55 9.42 4.70 68.4 9.71 4.63
54d
n-Pr
(major) 74 Ethanol-ether 260-261 C16H26N0C1 67.71 9.23 4.93 67.37 9.15 4.80
54c (minor) 72 Methanol-ether 230-232 C16H26»°C1 67.71 9.23 4.93 67.42 9.12 4.78
54b
Me
(major) 72 Methanol-ether 190-191 C14H22N0CX 65.74 8.67 5.48 65.40 8.74 5.22
54a (minor) 73 Ethanol-ether 182-183 C14H22N0CX‘!iH20 63.51 8.37 5.29 63.31 8.32 5.28
A. Yield from O-demethylation of precursor methoxyphenylpiperidines. The major isomers came from pure 
methoxyphenylpiperidines and the minor isomers from impure methoxyphenylpiperidines (containing a 
trace of major).







R* M* A B C D E F G H Other
1 54k a— Me 66 25 100 - 80 30 25 43 43
♦ •
N = CH_; 33* 
1 2 
Me
2 54k a— H 16 51 100 43 34 21 25 49 49 {CH2 = CH2J+"; 34*
3 54J 0- H 41 100 - 26 20 - 44 44 CH2 - ft - CH2; 33*
a. Ion types





B C D E F G
1 55b a Me 30 100 30 - 30 25 -
2 55b a H 43 100 33 - 34 26 -
3 55a ft H 62 100 46 38 32 46
4 75(Ar«Ph) 49 89 - 100 62 50 97
a. Ion types
A.





















R* M* A B
Ion type® 
C D E F G
1 54d A Me 100 - - 72 100 26 - 34
2 54d A H 21 21 - - 90 53 48 100
3 54c A H 28 - 100 - 100 34 67 -
a. Ion types






D from Table 38< applied
E. E from Table 38 applied F. G from Table 38 ■ applied G. H from Table 38 applied
Table 41 ■ Percent Abundance of Diagnostic Fragment Ions of Sons 4-Alkyl—4-aryl-l-methylpiperidinea.
No Compound R R1 M* M+1 A
Ion type® 
B C D E F
1 55h Me Me 34 - - 93 100 21 43 -
2 55b Ch2CH2CH3 H 36 - 38 57 100 23 42 -
3 55z CH2CH(He)2 Me b 100 75 67 100 - - 34














ch2=n=ch2 H from Table 38'* a p p lie d
b. M* not seen in 70 eV E.I. spectrum; M+* observed in iso-BUT Cl spectrum
253.
3.3.25 Attempted Synthesis of:
a. 1,4,5,6-Tetrahydro-l,3,4-trimethyl-4-phenylpyridine (105) 
from 1,2,5,6-tetrahydro-l,3-dimethyl-4-phenylpiperidine
1,2,5,6-tetrahydro-l,3-dimethyl-4-phenylpyridine (72; 2.5 g; 
0.013 mole) in dry tetrahydrofuran (25 ml) was treated with 
n-butyllithium (12 ml, 0.017 mole) and then with dimethylsulphate 
(1.7 g; 0.013 mole) in dry tetrahydrofuran (10 ml) by the same 
procedure described in Section 3.3.2. This procedure yielded a 
mixture of unconverted starting material and the corresponding 
quaternary methosulphate.
b . 1-Benzyl-l,4,5,6-tetrahydro-4-(3-methoxyphenyl)-1,4,5- 
dimethylpyridine methylmethosulphate (79)
1-Benzyl-l,2,5,6-tetrahydro-4-(3-methoxyphenyl)-5-methylpyrid 
ine (84; 4 g; 0.014 mole), was treated with n-butyllithium (14 ml; 
0.02 mole, 1.4 M in hexane) and then with dimethylsulphate (4.5 g; 
0.035 g) in dry tetrahydrofuran (50 ml), by the same procedure 
described in Section 3.3.2. This procedure yielded a mixture of the 
quaternary methosulphate salts of the starting material and 
required product which could not be separated by the author.
SH (D20):
0.58 and 0.82 (2xd; C5-CH3 ), 1.92 (s; C4-CH3 ), 3.68 and 3.78 (2xs, 




The crude 1-benzyl-l,2,5,6-tetrahydro-4-methyl-4- 
phenylpyridine (106; 5.0 g) was treated with aqueous formaldehyde 
(1.5 g; 37%) sind aqueous dimethylamine (2.75 g; 40%) by the same 
procedure described in Section 3.3.14 to yield a mixture which 
proved impossible to purify.
3.4 MISCELLANEOUS SUBSTANCES
3.4.1 4-Cyano-l-phenethyl-4-phenylplperidine (100)
Phenethylbromide (3 g) was added dropwise to a stirred 
suspension of 4-cyano-4-phenylpiperidine (101; 2.8 g) and K2C03 
(6 g) In absolute alcohol (60 ml). The resulting mixture was 
refluxed for 48 hours. The ethanol was evaporated to vacuo to give 
an oil, which was dissolved In HC1 (20 ml; 2N), and then washed 
with ether ( 3 x 5  ml; discarded). The aqueous layer was baslfled 
with concentrated aqueous ammonia, extracted with ether (4 x 10 
ml), dried (MgSO^) and finally evaporated In vacuo to yield the 
title compound (3.5 g; 79%) as an oil, which was employed in the 
next synthetic step.
(CDC13 ; free base):
2.09 (4H, m, C3/5-H ), 2.54 (2H, m, C2/6-Hax), 2.68 (2H, m, 
C2/6-Heq), 2.82 (2H, dt, CHg-Ph), 3.06 (2H, dt, N-CH2 ) 7.20-7.50






To the Grignard reagent [prepared from magnesium (1.3 g) and 
iodoethane (7.8 g) in dry ether (60 ml)] was added 4-cyano-l- 
phenethyl-4-phenylpiperidine (100; 3.4 g) in dry toluene (40 ml). 
The ether was immediately evaporated in vacuo and the reaction 
mixture was refluxed for 1 h. After cooling, ammonium chloride 
(4 g) in H^O (20 ml) was added. The organic layer was separated, 
and the aqueous layer washed with toluene (3 x 5 ml). The combined 
organic washings were added to the original organic layer and the 
whole refluxed with HC1 (60 ml; 2N) for 30 min. The aqueous layer 
was separated, washed with toluene (2 x 15 ml; discarded), basified 
with potassium hydroxide pellets, extracted with ether (3 x 50 ml), 
dried (MgSO^) and evaporated in vacuo to yield l-phenethyl-4- 
phenyl-4-propionylpiperidine (3.1 g, 82%) as an oil. Treatment of 




v : 1720 cm (-C- str.) max
6 _ _  _ 
„ : see Table 42 , p.259. 
H





m/z : M+1 322 (61%), 230 (100%).
Found: C, 73.70; H, 7.90; N, 3.87%.
C22H28N0C1 re<*uires: c » *73.83; H, 7.88; N, 3.91%.
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3.4.3 l-Methyl-4-phenyl-4-propionoxypiperidine (42)
4-Dlmethylaminopyridine (0.18 g) was added to a stirred 
solution of 4-hydroxy-l-methyl-4-phenylpiperidine (104; 0.25g)and 
propionic anhydride (10 ml), and the reaction mixture was stirred 
for 48 hours at room temperature. The resulting solution was poured 
Into acetic acid (50 ml; 50%). The aqueous solution was washed with 
ether (4 x 50 ml; discarded), baslfled with Na^CO^ and extracted 
with ether (4 x 50 ml). The combined organic extracts were washed 
with water (10 x 15 ml), dried (MgSO^) and finally evaporated 
In vacuo to yield the crude title product (0.21 g; 70%) as an oil. 
Treatment of this oil with ethereal-HC1 afforded the hydrochloride, 
m.p. 196-197°C (ethanol-ether).(Lit.4^ m.p. 183-184°C.)
5 : 1740 cm”* (C=0 str.).max
; see Table 42. p. 259.
H
Found: C, 63.60; H, 7.71; N, 4.92%.






Table *2. H NMR Characteristics of reversed ester of pethidine and related compound (HC1 in D^O)




























2.48,q,7.5 1.06,t ,7.5 
(0.99t)
7.35-7.45,m
a. Chemical shifts in ppm from external TMS, followed by multiplicity and line separations of signals; data for minor epimers in 
parentheses.
b. Signal of 4-C0CoH_ or 0C0CoH_
d b d b
c. Major signal overlaps eq. 3,5(H), ax. 2,6(H) and Ph-CH2
d. Epimer ratio in this compound is about (1:1).
*
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